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The MDM2 protein regulates the tumour suppressor protein p53, acting as its chaperone, 
regulating its translation and targeting p53 for degradation by the 26s proteasome via its E3 
ligase activity. The E3 ligase activity of MDM2 is dependent on its C-terminal RING 
domain. E3 ligases containing a RING domain are traditionally thought to catalyse the 
transfer of ubiquitin from their conjugating enzyme (E2) partner to the target protein, in the 
final step of the ubiquitination cascade. Various E2 enzymes have been shown to interact 
with their partner E3 ligases, yet evidence for the interaction between MDM2 and its partner 
E2, UbcH5α has not yet been shown. It has been reported that the reason for this lack of 
evidence is that the interaction between the two is highly unstable. 
 
Here I show that MDM2 forms a stable isolatable interaction with UbcH5α, the C-terminal 
tail of MDM2 is not necessary for this interaction. Although RING E3 ligases were not 
previously thought to interact with ubiquitin, preliminary evidence is emerging that suggests 
that this interaction is possible indeed I show that MDM2 and ubiquitin form a stable 
complex. I demonstrate that UbcH5α and ubiquitin both interact with the RING of MDM2, 
specifically the 20 most C-terminal amino acids of MDM2. My results show that both these 
proteins can bind this region of the RING simultaneously. I also highlight specific residues 
including tyrosine 489 and arginine 479 important for UbcH5α and ubiquitin binding 
respectively and the negative affect that these mutations have on the E3 ligase activity of 
MDM2 towards p53. Furthermore I show by limited proteolysis and hydrogen deuterium 
exchange that UbcH5α can be allosterically activated by MDM2. A novel peptide phage 
display technique linked to next generation sequencing was developed to further confirm an 
allosteric change and demonstrates that UbcH5α has different binding specificity for peptides 
when in a free or ligand bound conformation. 
 
MDM2 is a popular target for cancer therapeutics due to its dysregulation throughout many 
cancer types, including 30% of soft tissue sarcomas. Dissecting the mechanism of MDM2 
function is an important step in identifying specific drugable interfaces on MDM2 and its 





APS   Ammonium persulphate 
ATP   Adenosine triphosphate 
BLAST  Basic local alignment search tool 
BME   β-mercaptoethanol 
bp   Base pair 
BSA   Bovine serum albumin 
CDK   Cyclin dependant kinase 
CHIP   C terminus HSC70 interacting protein 
CK    Creatine phosphokinase 
CP   Creatine phosphate 
CPSA   Constant current chronopotentiometric stripping analysis  
ΔT   Delta tail 
DMSO  Dimethyl sulphoxide 
DNA   Deoxyribonucleic acid 
DTT   Dithiothreitol 
DUB   Deubiquitinating enzyme 
ECL   Enhanced chemiluminescence 
E1   Ubiquitin activating enzyme 
E2   Ubiquitin conjugating enzyme 
EDTA   Ethylenediaminetetraacetic acid 
ELISA   Enzyme linked immunosorbent assay 
FL   Full length 
GST   Glutathione S-transferase 
HD   Hydrogen-deuterium 
HDME  Hanging drop mercury electrode 
HECT   Homologous to E6AP carboxyl terminus  
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His   Histidine 
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
IMAC   Immobilised metal ion affinity chromatography 
LB   Luria-Bertani 
V 
 
MAb   Monoclonal antibody 
MDM2  Mouse double minute 2 
MOPS   3-(N-morpholino)propanesulfonic acid 
MS   Mass spectrometry 
NGS   Next generation sequencing 
NMR    Nuclear magnetic resonance 
OD   Optical density 
p53   Tumour suppressor protein 53 
PAGE   Polyacrylamide gel electrophoresis 
PBS     Phosphate buffered saline 
PCNA   Proliferating cell nuclear antigen 
PCR    Polymerase chain reaction 
pRB   Retinoblastoma protein 
RbR   Ring between ring 
RECAMO  Regional centre for applied molecular oncology 
RFU   Relative fluorescent units 
RLU    Relative light units  
RING   Really interesting new gene 
RNA   Ribonucleic acid 
RNF4   Ring finger protein 4 
rpm   Revolutions per minute 
SDS   Sodium dodecyl sulphate 
SECMALS Size exclusion chromatography linked to multi angle light scattering 
SUMO Small ubiquitin like molecule 
TEMED  Tetramethylethylenediamine 
TFA   Trifluoroacetic acid 
TRIS   2-amino-2-hydroxymethyl-propane-1, 3 diol 
UbcH5α  Ubiquitin conjugating enzyme human 5α 
UBD   Ubiquitin binding domain 
Ube1   Ubiquitin activating enzyme 
UBL   Ubiquitin like 
U-BOX  UFD2 homology 
UPS   Ubiquitin proteasome system 
UV   Ultraviolet 
VI 
 





















Table of Contents 
Declaration          i 
Acknowledgements         ii  
Abstract          iii  
Abbreviations         iv 
Figures          xv 
Tables           xix  
 
1 Introduction         1 
1.1 Ubiquitination        1 
1.1.1 Introduction       1  
1.1.2 Ubiquitin       4 
1.1.3 Chain linkages      4 
1.1.4 Ubiquitination cascade     7 
1.2 E3 ligases        11 
1.2.1 RING E3 ligases      11 
1.2.2 U-box E3 ligases      12 
1.2.3 HECT E3 ligases      12 
1.2.4  Ring between ring E3 ligases     15 
1.2.5 E4s        15 
1.3 Ubiquitin binding proteins      17 
1.4 Deubiquitinating enzymes      18 
VIII 
 
1.5 Functions of ubiquitin       19 
1.5.1 Degradation       19 
1.5.2 Signalling for degradation by ubiquitin   20 
1.5.3 Protein-protein interactions     21 
  1.5.4 Cellular localisation      22 
 1.6 MDM2        24 
  1.6.1 Introduction       24 
  1.6.2 Structure       25 
  1.6.3 N-terminal domain      27 
  1.6.4 Acidic domain      28 
  1.6.5 Zinc finger       29 
  1.6.6 RING domain       30 
  1.6.7 Dimerisation of MDM2     33 
 1.7 Roles of MDM2, p53 dependant     36 
  1.7.1 p53        36 
  1.7.2 p53 pathway       36 
  1.7.3 Inhibition of p53 induced gene expression   39 
  1.7.4 Translation of p53      40 
  1.7.5 Chaperone for p53      41 
  1.7.6 E3 ligase activity      41 
  1.7.7 Positive feedback  loops     42 
   1.7.7.1 PTEN pathway     43 
   1.7.7.2 Retinoblastoma pathway    43 
IX 
 
   1.7.7.3 p14/19ARF pathway     43 
  1.7.8 Negative feedback loops     45 
   1.7.8.1 Siah-1 pathway     45 
   1.7.8.2 Cyclin G pathway     45 
   1.7.8.3 MDM2 feedback loop     45 
 1.8 Roles of MDM2, p53 independent     48 
  1.8.1 MDM4       48 
  1.8.2 DNA repair       49 
  1.8.3 Ribosomal proteins      51 
  1.8.4 NF-κβ        51 
  1.8.5 MDM2 binding proteins     51 
 1.9 Thesis objectives       52 
 
2 Materials and methods       53 
 2.1 Plasmids, chemicals and reagents     53 
 2.2 Microbiological techniques      54 
  2.2.1 Bacterial cultures      55 
  2.2.2 Glycerol stocks      56 
  2.2.3 Preparation of competent cells, heat shock method  56 
  2.2.4 Preparation of bacteria, heat shock method   56 
 2.3 Molecular biology methods      57 
  2.3.1 Plasmid DNA amplification     57 
  2.3.2 Agarose gel electrophoresis of DNA    57 
X 
 
  2.3.3 DNA sequencing      58 
  2.3.4 Cloning       58 
   2.3.4.1 Traditional cloning using restriction enzymes 58 
   2.3.4.2 PCR amplification     58 
   2.3.4.3 Restriction digests of vector and insert  61 
   2.3.4.4 Ligation of vector and insert    61 
 2.4 Biochemical techniques      65 
  2.4.1 Protein quantification      65 
  2.4.2 SDS PAGE       65 
  2.4.3 Precast gel protocol      66 
  2.4.4 Coomassie staining      66 
  2.4.5 Immuno blotting      67 
  2.4.6 Stripping nitrocellulose blots     68 
 2.5 Protein expression and purification     69 
  2.5.1 Purification of GST tagged proteins    69 
  2.5.2 GST tag cleavage using PreScission Protease  71 
  2.5.3 Purification of his-tagged proteins    71 
  2.5.4 Buffer exchange      73 
  2.5.5 HIS-tag cleavage using free thrombin   74 
  2.5.6 UbcH5α purification in preparation for hydrogen  
deuterium (HD) exchange     74 
 2.6 Biochemical assays       76 
  2.6.1 In vitro ubiquitination of p53     76 
XI 
 
  2.6.2 In vitro discharge assay     77 
  2.6.3 Protein binding ELISA     79 
  2.6.4 Peptide binding ELISA     79 
  2.6.5 Competition ELISA      80 
  2.6.6 Protein-peptide-protein ELISA    80 
  2.6.7  AlphaScreen®      81 
  2.6.8 Peptide phage display      82 
  2.6.9 Enzymatic protein digest     84 
 2.7 Biophysical assays       85 
  2.7.1 Gel filtration       85 
  2.7.2 In gel enzymatic digestion of protein samples for mass  
 spectrometry analysis     85 
  2.7.3 Peptide purification for mass spectrometry    86 
  2.7.4 Hydrogen deuterium exchange    87 
  2.7.5 Thermal denaturation      87 
 
3. Results         89 
 3.1 MDM2 binds to UbcH5α and ubiquitin    89 
  3.1.1 Introduction       89 
  3.1.2 Purification of recombinant MDM2    91 
  3.1.3 E3 ligase activity of MDM2     100 
  3.1.4 MDM2 binds to UbcH5α     107 
  3.1.5 MDM2 binds to ubiquitin     111 
XII 
 
  3.1.6 Ubch5α and ubiquitin bind to the same region of the  
 RING domain      113 
  3.1.7 Can the RING of MDM2, UbcH5α and ubiquitin form  
 a trimeric complex      116 
  3.1.8 Narrowing down residues important for UbcH5α and 
 ubiquitin binding      119 
  3.1.9 Specific residues within the RING domain of MDM2 are 
 important for UbcH5α and ubiquitin binding and for E3 
 ligase activity       123 
  3.1.10 Discussion       127 
3.1.10.1 Comparison of MDM2 RING and RNF 4 RING 133 
   binding to UbcH5α and ubiquitin 
3.1.10.2 Further dissecting UbcH5α and ubiquitin binding 
   to the RING of MDM2    136 
 
4. Results         140 
 4.1 Allosteric activation of UbcH5α by MDM2    140 
  4.1.1 Introduction       140 
  4.1.2 Peptide 8 can be used to study the interaction between  
UbcH5α and MDM2      142 
  4.1.3 Proteolysis of UbcH5α     144 
  4.1.4 Mass spectrometry of limited proteolysis   152 
  4.1.5 Hydrogen deuterium exchange    163 
XIII 
 
  4.1.6 Discussion       175 
 
5. Results         182 
 5.1 Peptide phage display       182 
  5.1.1 Introduction       182 
  5.1.2 Peptide phage display utilising NGS for a novel 
 application       185 
  5.1.3 Analysis of raw data      189 
  5.1.4 Discussion       219 
 
6. Results         224 
 6.1 Investigating the role of the tail in the dimerisation of MDM2 224 
  6.1.1 Introduction       224 
  6.1.2 Full length MDM2 dimerises in solution as detected by  
 SERS         226 
  6.1.3 Gel filtration chromatography    231 
  6.1.4 Size exclusion chromatography with multi angle light 
   scattering       236 
  6.1.5 Discussion       240 
   6.1.5.1 Exploring the ability of full length MDM2 and 
 the RING domain to dimerise   241 
   6.1.5.2 Previous studies on the role of the tail in  




7 Further work         245 
 7.1 Investigation of MDM2 and dimer formation   245 
 7.2 MDM2 and allosteric activation of UbcH5α    246 
 7.3 MDM2 and ubiquitin       247 
  7.3.1 Electrochemistry      248 
 7.4 MDM2 and gankyrin       251 
  7.4.1 Gankyrin binds to MDM2     252 
 
8 References         257 
9 Appendices         273 
 9.1 Appendix I – Mass Spectrometry data  
9.2 Appendix II – HD exchange peptide data     
 9.3 Appendix II- Nanosensing protein allostery using a bivalent 
  mouse double minute two (MDM2) assay       










1.1 Diversity of ubiquitination       3 
1.2 Structure of ubiquitin        5  
1.3 Ubiquitination cascade       10 
1.4 Mechanism of E3 ligase activity      14 
1.5 The role of ubiquitin in protein-protein interactions    23 
1.6 Schematic diagram of MDM2      26 
1.7 Solution structure of MDM2 RING (429-491) domain   32 
1.8 Comparison of MDM2 dimer organisation with other RING/U-box 
 dimers         34 
1.9 Crystal structure of the p53 tetramerisation domain    37 
1.10 Diagram showing the involvement of MDM2 in the p53 positive  
feedback loops        44  
1.11 Diagram showing the involvement of MDM2 in the p53 negative 
 feedback loops        47 
3.1 Schematic diagram showing the features of the original MDM2  
constructs         92  
3.2 Cell expression trials for full length MDM2     94 
3.3 Purification of FL MDM2 and MDM2 ΔT     96 
3.4 Expression and purification of MDM2 RING constructs   99 
3.5 Ubiquitination of p53 by MDM2      101 
3.6 Discharge of ubiquitin from UbcH5α by MDM2    103 
XVI 
 
3.7 FL MDM2 and MDM2 ΔT binding to BOX I and BOX V peptides. 105 
3.8 MDM2 binds to UbcH5α in solution      108 
3.9 MDM2 binds to UbcH5α in solution, alpha screen    110 
3.10 MDM2 binds to ubiquitin in solution      112  
3.11 UbcH5α and ubiquitin bind to RING peptides    114 
3.12 Can UbcH6α, ubiquitin and peptide 8 form a trimeric complex  117 
3.13 UbcH5α and ubiquitin bind to peptide 8 simultaneously   118 
3.14 UbcH5α and ubiquitin bind to the same region of the RING 
 simultaneously, what is the nature of this binding    120 
3.15 UbcH5α and ubiquitin binding to alanine scan peptides in comparison  
 to peptide 8         121 
3.16 Purification of RING domain proteins     124 
3.17 E3 ligase activity and UbcH5α and ubiquitin binding of all RING 
 domain constructs        126 
3.18 Structure of the MDM2/MDM4 RING domain heterodimer   128 
3.19 Predicted model of MDM2 RING:UbcH5α:ubiquitin complex  132 
3.20 MDM2/MDM4 heterodimer inserted into the RNF4  
RING:UbcH5α:ubiquitin complex      135 
4.1 Peptide 8 can mimic FL MDM2 in an activity assay    143 
4.2 Model of how peptide 8 could result in a conformational change  
and different digestion products of UbcH5α     145 
4.3 Trypsin and Arg-C digest of UbcH5α     146 
4.4 Model showing how peptide 8 binding to UbcH5α may affect its  
XVII 
 
digestion         148  
4.5 Glu-C digest of UbcH5α       149 
4.6 Controls for trypsin and Glu-C digests of UbcH5α     151  
4.7 The Orbitrap Elite MS analyser      153 
4.8 Proteolysis assay with Glu-C in preparation for MS analysis  155 
4.9 Comparing the crystal structures of UbcH5α and UbcH5c   156 
4.10 Stable core of UbcH5α       158 
4.11 Interaction of UbcH5α, peptide 8 and ubiquitin    159 
4.12 Interaction of UbcH5α, RING and ubiquitin     161  
4.13 RING contact point on UbcH5α       162 
4.14 HD exchange linked to mass spectrometry     164 
4.15 Screenshot showing the coverage of UbcH5α    166 
4.16 Model showing the level of HD exchange for free UbcH5α   167 
4.17 The sequence of UbcH5α showing the level of HD exchange for  
specific residues        168 
4.18 Screenshot showing UbcH5α peptides that display a change in HD 
 exchange when UbcH5α is in complex with peptide 8   171 
4.19 Screenshot showing UbcH5α peptides that display no change in HD  
exchange when UbcH5α is in complex with peptide 8   172 
4.20 The overlapping peptides that display a difference in HD exchange  
correspond to the N-terminal helix of UbcH5α    173 
4.21 Schematic diagram showing how a ‘closed conformation’ of the  
E2-ubiquitin conjugate upon RING binding contributes to the  
XVIII 
 
overall mechanism        179  
5.1 Schematic diagram showing simplistic phage display method  183 
5.2 The diversity of phage libraries      186 
5.3 PCR primers for peptide phage display     188 
5.4 Peptides that preferentially bind to free UbcH5α or ligand bound  
UbcH5α, in round two with slow wash method, analysed by MEME 214 
5.5 Top ten peptides that preferentially bind to free UbcH5α in varied  
conditions         215  
5.6 Top ten peptides that preferentially bind to UbcH5α in complex with  
peptide 8 in varied conditions       216 
5.7 BLAST of MEME consensus sites      223 
6.1 Schematic of proposed assemble of PSN through specific  
interactions between peptide 12.1 and MDM2    227  
6.2 SERS analysis of PSN aggregation      229 
6.3 Competitive inhibition of MDM2 binding to p53 derived BOX I peptide 
 by ligands         230 
6.4 Elution profiles of RING proteins as detected by ELISA   234 
6.5 Comparison of elution profiles of RING proteins as detected by ELISA 235 
6.6 SECMALS data for RING ΔT      238 
7.1 Electrochemistry data from free and ligand bound ubiquitin   249 
7.2 Gankyrin binds to MDM2       254 
7.4 Gankyrin binds to RING domain of MDM2     255 





2.1 Sequences of peptides used throughout PhD     53 
2.2 Primers used for traditional cloning      58 
2.3 Restriction enzymes used in traditional cloning    60 
2.4 Primers used in site directed mutagenesis     63 
2.5 Primary antibodies        69 
5.1 Peptides that preferentially bind to free UbcH5α compared to UbcH5α 
 in complex, in round one with the quick wash method   190 
5.2 Peptides that preferentially bind to free UbcH5α compared to UbcH5α  
in complex, in round one with the slow wash method   192 
5.3 Peptides that preferentially bind to free UbcH5α compared to UbcH5α  
in complex, in round two with the quick wash method   193 
5.4 Peptides that preferentially bind to free UbcH5α compared to UbcH5α 
 in complex, in round two with the slow wash method   199 
5.5 Peptides that preferentially bind to UbcH5α in complex compared to 
 free UbcH5α, in round one with the quick wash method   206 
5.6 Peptides that preferentially bind to UbcH5α in complex compared to 
 free UbcH5α, in round one with the slow wash method   207 
5.7 Peptides that preferentially bind to UbcH5α in complex compared to  
free UbcH5α, in round two with the quick wash method   208 
5.8 Peptides that preferentially bind to UbcH5α in complex compared 
XX 
 









    
1 
 






Ubiquitination is the ATP-dependant, covalent modification of a protein with 
ubiquitin. Ubiquitination is one of the most common post translational protein 
modifications but the nature of this modification is highly diverse. 
Discovered in 1980
1
 by virtue of the fact that proteins with polyubiquitin chains were 
observed that were subsequently targeted for degradation by the 26s proteasome
2
. 
Degradation of protein by the ubiquitin proteasome pathway (UPS) is the most 
prevalent method of protein degradation within the cell. Protein levels are dynamic 
and are kept stable by the strict relationship between protein synthesis and protein 
degradation, this tight level of control is critical for protein function and for rapid 
control during the response to cell stresses or environmental stimuli. In additional  the 
UPS is important for the removal of misfolded and aggregated proteins from the cell
3
. 
Ubiquitination as a signal for protein degradation is the most well studied function of 
ubiquitin modification, there are however may other functions that ubiquitin can 










The ubiquitin signalling pathway is more diverse and complex than initial 
observations suggested. A chain of at least four ubiquitins (polyubiquitination) is 
required to signal for degradation, but chains of up to three ubiquitin molecules can 
exist and signal non-proteolytic events.  Proteins can also be monoubiquitinated either 
at one site or multiple sites throughout the protein (multi-monoubiquitination) (figure 
1.1 i-iv).  
 
Ubiquitin is covalently linked to target proteins through its C-terminal glycine to a 
lysine residue on the substrate, though cases exist in which the N-terminal amino 





Ubiquitin itself contains 7 lysines that can be ubiquitinated in the formation of 
polyubiquitin chains. Chains can also form through the N-terminal methionine residue 
of ubiquitin, though this is less common.  The first identified and best characterised of 
these polyubiquitin linkages are K48 linked chains. K63 linked chains are also well 
characterised but less is known about the nature of the other linkages (K6, K11, K27, 
K29 and K33), they are all abundant in vivo and they are all required for a fully 




Ubiquitin does not only form homogeneous chains i.e. chains in which ubiquitin 
molecules are linked via the same lysine, ubiquitin can also form heterogeneous 
chains. These heterogeneous chains can also form branched chains, in which two 
ubiquitin molecules are linked through adjacent lysines e.g. K6 and K11 on to the 
preceding ubiquitin molecule (figure 1.1 vi-vii). Branched chains do not associate 




Post-translational modification of substrates with smaller molecules is not restricted to 
ubiquitination, a number of ubiquitin-like proteins (UBLs) have been identified 
including small ubiquitin-like modifier (SUMO), neuronal-precursor-cell-expressed 
developmentally down regulated protein 8 (NEDD8) and human leukocyte antigen F-
associated (FAT10). The UBLs all share a basic tertiary core structure and ubiquitin is 
able to form mixed chains with these UBLs
10
 (figure 1.1 viii).  
All these variable factors result in a large number of possible protein modifications by 
the UPS, and raises the question of how this complex system is controlled. Many 
advances in knowledge have been made yet still many methods of control remain a 
mystery.  
 
Considering the diversity of ubiquitination and the role it plays in a broad range of 
cellular processes it is no surprise that dysregulation of the UPS has been  implicated 
in a number of disease processes including Parkinson’s disease and other 
neurodegenerative diseases
11

















Figure 1.1: Diversity of ubiquitination. Ubiquitination is the addition of ubiquitin to a target protein, 
the nature of ubiquitination is diverse. Monoubiquitination is the addition of one ubiquitin molecule to 
a protein (i). Monoubiquitination can happen at multiple different sites on a target protein resulting in 
multi-monoubiquitination (ii). Chains of ubiquitin can be added to a target protein, these chains vary in 
length (iii), a chain of at least four ubiquitin molecule signals for degradation by the 26s proteasome 
(iv). Ubiquitin chains can be linked via the same lysine of ubiquitin (v) or linkage sites can be mixed 
throughout the chain (vi), mixed linkages can result in branched ubiquitin chains (vii). Ubiquitin can 
















Ubiquitin is a small protein of 76 amino acids in length. It is highly conserved across 
eukaryotes, only 3 of the 76 amino acids differ between yeast and human versions, its 
ubiquitous presence inspired its name. UBLs are also present throughout eukaryotes, 
some such as SUMO and NEDD8 are present across the board whereas other such as 




The structure of ubiquitin includes an α helix and mixed 5 strand β sheet, there is a 
hydrophobic core between the β sheet and α helix, The overall structure of ubiquitin is 
extremely compact and tightly hydrogen bonded with only limited residues displaying 
any flexibility to allow for protein-protein interactions. The C-terminal tail is exposed 
to facilitate covalent linkage to target proteins (figure 1.2). The seven lysines 




Ubiquitin has three hydrophobic patches, each being responsible for interactions with 
its various binding partners and the proteasome. The hydrophobic patch of Ile44, 
Leu8, Val70 and His68 is involved in the majority of ubiquitin interactions, including 
most ubiquitin binding proteins and the proteasome
14,15
. The hydrophobic patch of 
IIle36, Leu71 and Leu73 is important for recognition by some HECT E3 ligases
16
. 
The final hydrophobic patch of Gln2, Phe4 and Thr14 is recognised by ubiquitin 
specific protease and some deubiquitinating enzymes (DUBs)
17
.    
 
1.1.3 Chain linkages 
 
The 7 lysines of ubiquitin are integral to polyubiquitin chain formation; these chains 
also form a structure, and can be in a compact or open conformation. K6, K11 and 
K48 linked polyubiquitin chains tend to be compact with the distal and proximal 
ubiquitin moieties forming an intramolecular interface, on the other hand K63 linked 
polyubiquitin chains tend to be in an open conformation and the only point of contact 









Figure 1.2: Structure of ubiquitin. This model was made in PYMOL and is based on the published 
crystal structure of ubiquitin
13
. The blue residues indicate the exposed C-terminus, the residues 
coloured orange show the N-terminus, and the residue coloured pink is Ile 44, a residue important for 















The open conformation of K63 linkages gives these ubiquitin chains more flexibility 
and allows them to adjust their conformation despite the rigidity of ubiquitin. 
Polyubiquitin chains are highly dynamic and the opposite of the usual conformation 
state can also be seen. 
 
The cellular response to ubiquitination will vary depending on the lysine linkage 
point; it is becoming clearer that specific linkages signal for specific events. K48 
linked polyubiquitin chains are the best characterised of all the lysine link points and 
are believe to be the principle signal for targeting substrates for proteasomal 
degradation. K48 is the most abundant linkage in resting cells, the ratio of chain 
linkages however may change under stress conditions or during disease. 
Monoubiquitination is known to signal non-proteolytic events, K63 linked 
polyubiquitin chains also signal non-proteolytic events, these chains mark proteins 
that contribute to DNA repair in response to stress
8
 and are an important component 
of signalling cascades in the immune response. For example activation of the NF-κβ 
family of transcription factors occurs in response to numerous stimuli and is essential 
for cell transformation. In unstimulated cells NF-κβ is sequestered in the cytoplasm 
by its inhibitor Iκβ. Activation of NF-κβ is initiated by degradation of Iκβ which 
occurs primarily by the activation of the Iκβ kinase (IKK). NF-κβ is then free to enter 
the nucleus where it can act of a family of transcription factors. IKK phosphorylates 
Iκβ and this targets it for K48 linked polyubiquitination and its subsequent 
degradation by the 26S proteasome. In addition K63 linked polyubiquitination plays 
an important role in activating IKK. TRAF6 is an E3 ligase that facilitates the 
synthesis of K63 linked polyubiquitin chains and is an essential signalling protein in 
the immune and inflammatory pathways. TRAF6 mediates activation of the TAK1 
kinase complex via K63 linked polyubiquitination, this subsequently activates IKK by 
phosphorylating Iκβ, therefore facilitating the release of NFκβ to act on its nuclear 
transcription factors
19
.         
 
Little is known about the other linkages. K6 linked polyubiquitin chains have been 
associated with proteins involved in DNA repair
20
 whilst K27, K29 and K33 are the 
hardest to study as they are the least abundant linkages seen in resting cells
18
. K27 has 
been implicated in targeting proteins involved in mitochondrial biology
21
. 





. Specifically K11 linkages are found in a subset of proteins that 




With the exception of K63 linked chains, it is likely that each different linkage signals 
proteasomal degradation of its substrate, yet the different linkages are formed in 
response to different stresses and signals within the cell and a lack of high affinity 
specific reagents makes it difficult to study the more minor forms of ubiquitin linkage.  
Ubiquitin chain linkages are generated for a specific purpose and target proteins are 
ubiquitinated on a certain residue, this shows that the system needs to be controlled at 
multiple levels to ensure the correct modification with the correct length and linkage 
of chain, if just one area of control is deregulated then there is the potential for disease 
to develop.           
     
1.1.4 Ubiquitination cascade 
 
The post translational modification of a protein with ubiquitin is an ATP dependant 
reaction that requires not only ATP but a group of enzymes. The core ubiquitin 
pathway components comprise of an activating enzyme (E1), a conjugating enzyme 
(E2) and a ligase (E3). 
The first step in ubiquitin conjugation is to activate the C-terminus of ubiquitin, in 
eukaryotes this is a two-step reaction. The E1 has little affinity for ubiquitin by itself; 
MgATP binds to E1 before the two step reaction occurs in order to increase the 
affinity of E1 for ubiquitin. In the first step a ubiquitin-adenylate intermediate is 
formed, in the second step this intermediate reacts with the active cysteine on E1 to 
form a E1-ubiquitin thiol ester
23
.This first, two-step reaction, is the same for all UBL 
proteins, each UBL has its own dedicated E1, except in the case of Atg8 and Atg12 
which share a common E1
24
. The mechanism concerning the first part of this two-step 




The next step in the conjugation cascade is the transfer of ubiquitin from the E1 
cysteine to an E2 cysteine. The enzymes involved in the ubiquitination cascade are 
hierarchical in organisation; there is one E1, significantly more E2s, most likely 
because of the many downstream targets and a large number of E3s. This is slightly 
different for SUMO and NEDD8 they have one E1 and a few E3s but only one E2 
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each, Ubc12 for NEDD8 and Ubc9 for SUMO
10
. All E2 enzymes share a conserved 
globular domain of ~150 amino acids. The core domain consists of 4 standard α 
helices, a shortened α helix and a four stranded anti-parallel β sheet. The active site 
cysteine resides in a shallow cleft on the surface of the protein, residues surrounding 
this cysteine are highly conserved throughout the E2 family
26
. Free E2s bind very 
tightly to loaded E1s, the KD is subnanomolar
27
 but non covalent E2-ubiquitin binding 
affinities are very low
26
, this highlights the importance of E1 in this cascade.   
 
The final step in the conjugation cascade is the transfer of ubiquitin to the target 
substrate, this requires an E3 ligase.  Each E3 interacts with one, or possibly a few, 
E2s, E2s will interact with many E3s.  Each E3 recognises a specific substrate or set 
of substrates and substrate modification by ubiquitin is E3 dependant
28
. One of two 
events can happen in this final step. Either the E3 activates the E2 and ubiquitin is 
transferred directly to the target substrate from the E2 or the ubiquitin is transferred 
from the E2 to an active site cysteine on the E3 and then ubiquitin is transferred from 
the E3 to the target (figure 1.3). The ubiquitination conjugation pathway is 





The many E2 and E3 enzyme pairings along with the diverse nature of ubiquitin 
modification illustrate what a complex system the ubiquitination pathway is. The 
exact nature of regulation of all the components and how specificity is controlled is 
still elusive in parts. It would appear that the E3 is responsible for substrate 
recognition, and it is the pairing of the E3 with a certain E2 that specifies the length 
and linkage of the ubiquitin chain
30
. Some E3s can interact with multiple E2s, such as 
BRCA1/BARD1
31
. Some of these pairings result in monoubiquitination of a substrate, 
other pairing result in the formation of polyubiquitin chains. 
 
Substrate specific E3s may not apply to all UBLs; it may not be that all UBLs are 
conjugated to multiple downstream targets. SUMO however is conjugated to multiple 







E2s were originally proposed to bring E3 and substrate together
33
. In principle this is 
remains true, three groups of E3 ligases have been subsequently identified and whilst 
they all catalyse the transfer of ubiquitin to their target the mechanisms of catalysis 
differ. E3 ligases belong to either the Homologous to E6AP Carboxyl Terminus 





































Figure 1.3: Ubiquitination cascade. An overview of the ubiquitination cascade showing ubiquitin 
transfer from ubiquitin activating enzyme (E1) to ubiquitin conjugating enzyme (E2) to substrate, via 

















1.2 E3 ligases 
  
1.2.1 RING E3 ligases 
 
RING E3 ligases best fit the original proposed model of ubiquitin transfer. Originally 
RING E3 ligases were thought to act as a scaffold protein, binding their E2 and target 
substrate and catalysing the transfer of ubiquitin between the two
34,35
. To support this 







. Structures of E3s and E2s in complex show the E3 binding site 
is ~ 15Å  away from the active site cysteine of the E2
39
, this makes the proximity 
catalysis mechanism unlikely. Currently the mechanisms of how RING E3s catalyse 
the transfer of ubiquitin to the target is unclear, ideas regarding the allosteric 
activation of E2 have been proposed but not confirmed
35
. As to whether there is a 
universal mechanism of ubiquitin transfer for all RING E3s or mechanisms that are 
E3 and/or E2 specific remain to be seen. 
 
The first RING described contained the zinc coordination sequence: Cys-X2-Cys-X9-
36-Cys-X1-3-His-X2-3-Cys-X2-Cys-X4-40-Cys-X2-Cys (x is any amino acid)
40
. As other 
RING containing proteins have been identified there have been some variations on the 
sequence above with regards to cysteines and histidines, though all RING domains 
still coordinate two zinc ions. 
 
Two groups of RING E3s exist, those that act alone, such as MDM2 and c-Cbl and 
those that act as a component of a large multi protein complex, such as Rbx1/Roc1. 
There are further subgroups of multi protein complexes, the Skp1/Cullin/Fbox (SCF) 
group and the Anaphase Promoting Complex/Cyclosome (APC/C) group
41
. In these 
multi protein complexes the RING E3 subunit does not recognise the substrate; this is 
mediated by another subunit within the complex. Rbx1/Roc1 is an example of a RING 
E3 that can form an SCF, and other cullin RING ubiquitin ligase complexes with 








1.2.2 U-box E3 ligases 
 
A relatively small number of E3 ligases contain the U-box E2 binding domain. It was 
originally proposed that the U-box would adopt a RING domain like conformation. 
Instead of zinc coordination, electrostatic interactions were proposed as the method of 
structural organisation
44
. The actual structure displays a hydrophobic core with two 
internal interaction centres comprising of hydrogen bonds and salt bridges. The 
spacing of the residues involved in these interactions are remarkably similar to the 
spacing of zinc coordinating residues in the RING domain
45
. This structure implied 
that U-box domains could bind E2s and facilitate ubiquitin conjugation. A number of 




Relatively little is known about U-box E3s compared to RING E3s. The most well 
characterised U-box domain containing protein is Carboxyl-terminus of Hsc70 
Interacting Protein (CHIP), the recognition of CHIPs target substrates, generally 
unfolded protein, is dependent on the association of CHIP with Hsp70 or Hsp90
48
. 
More recently however CHIP has been shown to ubiquitinate native proteins, such as 
IRF1,  in an Hsp70- independent manner
49
. As with RING E3s the mechanism of 
ubiquitin transfer by U-box E3 ligases remains unclear. 
 
 
1.2.3 HECT E3 ligases 
 
The HECT E3s operate a different mechanism than RING and U-box E3s. They 
contain a conserved cysteine and this accepts ubiquitin from the E2 forming a thiol 




The first identified member of the HECT domain family of ligases was E6 Associated 
Protein (E6AP). When E6AP is bound to the E6 protein on an oncogenic human 





The HECT domain is 350 amino acids in length and all HECT domains exhibit 
similarity to that of E6AP. The HECT domain always resides at the C-terminus of a 
13 
 
protein; this is in contrast to RING domains which are found at differing points in 
proteins. Substrate specificity tends to be dictated by the N-terminus of the HECT 
domain containing proteins
52
. Modelling indicates that HECT domains have great 





































Figure 1.4: Mechanism of E3 ligase activity. Overview of the different mechanisms of activity that 
E3 ligases employ. RING E3 ligases catalyse the transfer of ubiquitin from the E3 to the substrate, the 
mechanism for this remains unknown. HECT E3 ligases accept ubiquitin from the E2, on to their active 










1.2.4 Ring between ring E3 ligases 
 
Ring Between Ring (RBR) E3s are a small sub class of RING E3 ligases, there are 
only thirteen in the human genome, they are few but are conserved across eukaryotes. 
This sub group of RING E3 blurs the boundaries between RING and HECT E3 
mechanisms of action. 
 
They were originally identified because they contain a standard RING domain but 
they also contain two additional domains. The RBRs contain a trio of closely spaced 
domains, a standard amino-terminal RING domain (RING1), an InBetween Ring 
domain (IBR) and a second RING domain (RING2). RING1 is comparable to other 
RING E3s; the zinc coordination site follows the same conserved sequence of 





The majority of RBRs are not yet well understood, their substrates and E2s are poorly 
defined. They have been implicated in regulation of translation
56
 and NF-κβ 
signalling
57
. The most well characterised RBR is parkin, because of its association 
with Parkinson’s disease
58
, its list of substrates continues to grow
59
 and the nature of 
the substrates suggest that parkin has a role in the degradation of misfolded or 
aggregated proteins. 
 
A cysteine in the RING2 domain, highly conserved throughout RBRs, functions like a 
HECT domain active site cysteine, it forms a thioester bond with ubiquitin before 
transferring it to the substrate. RING1 can bind E2s and the E2 binding site is very 
similar to that identified in other RING E3 domains such as BRCA1. As RBRs 
contain a RING E3 domain that binds to E2s and an active site cysteine with activity 
comparable to HECT E3s they are thought of as RING/HECT hybrids
55





As discussed a polyubiquitin chain consisting of at least four ubiquitin molecules can 
target a protein for degradation by the 26s proteasome system. It has been suggested 
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that ubiquitin chains are formed before addition to the substrate, this theory is 
supported by the presence of free, unanchored chains in the cell
60
. Conversely, in vitro 
experiments suggest that each ubiquitin is added sequentially to form polyubiquitin 
chains.  Multiple rounds of the ubiquitination cascade described above seems the most 
likely mechanism for ubiquitin chain formation. Major conformational changes in the 
enzyme complex would be required to move along the ubiquitin chain. The three 
enzymes described above are not always sufficient for the formation of a 
polyubiquitin chain. For some E3 ligases an additional conjugation factor may be 
required, these extra factors are known as E4s. 
 
UFD2, a protein found in yeast, was first identified as an E4
61
. Yeast UFD2 is 
implicated in cell survival under stress conditions and is essential for homoeostasis of 
unsaturated fatty acids. A mammalian E4 homologous to yeast UFD2  is required for 
the polyubiquitination of mammalian ataxin-3, ataxin-3 is responsible for 
spinocerebellar ataxia type 3, a neurodegenerative disorder
62
, this highlights the 
importance of E4s, polyubiquitination and subsequent degradation of proteins. The 
yeast and human homologous E4s shared a U-box domain and it was initially 
considered that the U-box facilitated an interaction with the ubiquitin conjugated 
targets and that the U-box was essential for E4 activity. 
 
E4s have since been identified that are not homologous to UFD2; CHIP is one such 
example, though it does still contain a U-box. CHIP is an E4 for parkin
63
, 
interestingly CHIP has its own intrinsic E3 activity. Further E4s have been identified 
that are not homologous to UBD2 nor do they contain a U-box domain, one such 
example is p300, an E4 for MDM2. Unlike CHIP p300 does not have intrinsic E3 





The term E4 encompasses a wide range of enzymes, as of yet they do not appear to 
share a common feature, they do not share a common U-box domain, nor do they 
need to have their own E3 ligase activity. The mechanism of how they work alongside 





1.3 Ubiquitin binding proteins  
 
Interaction of ubiquitin with the 26s proteasome is its most widely studied interaction, 
though this is only one of the many interacting partners of ubiquitin. Ubiquitin and 
ubiquitin chains can interact with a wide variety of proteins containing a ubiquitin 
binding domain (UBD). UBD is a general term for at least 16 very different domains 
that can interact with ubiquitin including Ubiquitin Interacting Motif (UIM), 
Ubiquitin Associated (UBA), and Zinc Finger Ubiquitin Binding domain (ZnF UBP). 
Different UBDs and/or different proteins containing UBDs can mediate distinct 
downstream cellular processes such as regulating the stability, function and 
localisation of the ubiquitin tagged proteins.  
 
UBDs differ greatly in size, between 30-150 residues, but the majority of UBDs are α 
helical
65
 and interact non covalently with one of two hydrophobic regions on the 
surface of ubiquitin
15
. Interaction with the hydrophobic patch including residues Leu 
8, Ile 44 and Val 70 is linked to signalling for degradation. Interaction with the 
hydrophobic patch that includes Phe 4 and Ile44 is linked to non-proteolytic 
signalling
14
. UBDs do exist that do not centre on Ile 44 and the hydrophobic regions 
on the surface of ubiquitin
66
  there is one such example in which the C-terminal di-




The majority of information for how each UBD distinguishes between different 
ubiquitin chain linkages is still unknown. Proteins containing repeats of the UIM can 
offer some insight. Two UIM motifs separated by different length spacers can 
recognise differently linked ubiquitin chains. For example, Rap80 contains two UIM’s 
separated by a long spacer, these domain recognise ubiquitin molecules in an 
extended conformation, as often seen in K63 linked chains. Conversely ataxin-3 has 
repeats of UIM separated by a much shorter spacer, these recognise ubiquitin 
molecules in a more compact conformation, as often seen in K48 linked chains
68







1.4 Deubiquitination enzymes 
 
Ubiquitination of proteins is a reversible process; the removal of ubiquitin from a 
substrate is carried out by a group of enzymes known as deubiquitinating enzymes 
(DUBs). There are approximately 100 DUBs and these fall into 5 families based on 
their catalytic domain, there are four cys protease families and one metalloprotease 
family
69
. Some DUBs recognise specific chain linkages, others are non-specific and 





The removal of ubiquitin is very important for the regulation and function of a 
number of cellular processes. An important function of DUBs is to recycle ubiquitin. 
They associate with the 26s proteasome and remove ubiquitin from its substrate 
before it itself is unfolded and degraded
71
. Keeping levels of ubiquitin high is 
important for a rapid response to cell stresses and stimuli. DUBs are quite often seen 
in complex with E3s and they can affect the rate of ubiquitination of a substrate. E3s 
are prone to autoubiquitination in the absence of their target substrate; DUBs remove 
the ubiquitin saving the E3 from degradation so that they are able to respond to 
substrate increases. DUBs are also important for the intracellular localisation of 
proteins. The endocytic pathway depends on the tight regulation of ubiquitination and 




DUBs are also involved in cell death. Apoptotic cell death is mediated by intrinsic 
and external pathways that result in the activation of Cys-dependant Aspartyl-Specific 
Proteases (caspases), the main regulators of cell death. Several E3 ligases are known 
to have an important role in signalling for this apoptotic response. The interplay 
between ubiquitination and deubiquitination sets the threshold for apoptotic 
signalling. Deregulation of DUBs can disrupt apoptotic signalling resulting in 




A20 is an example of a protein that has dual function as an E3 ligase and DUB. Its N-
terminal domain is a DUB for K63 linked polyubiquitin mediators of the NF-κβ 
signalling pathway, such as TRAF6. Its C-terminal domain is a ubiquitin ligase for 
19 
 
K48 linked degradation of the same substrates. Interestingly A20 is not a general 
DUB, it does not recognise specific chains, e.g. K63 linked polyubiquitin chains, it 
instead has specificity for particular polyubiquitinated substrates, e.g. TRAF6 and 
removes the polyubiquitin chain without disassembling it. This limited DUB activity 








As previously described, chains of at least four ubiquitin molecules can target a 
protein for degradation by the 26s proteasome. Longer chains can increase the affinity 
of the protein for the proteasome, increasing the likelihood of successful degradation. 
In the majority of cases ubiquitin chains are linked by K48 or K11, though less 
abundant linkages K6, K27, K29 and K33 can also target proteins for degradation by 
the 26s proteasome. 
 
Ubiquitin chains linked via K63 are regarded to signal for non-proteolytic events. 
Interestingly K63 and K48 linked chains bind to the 26s proteasome with similar 
affinity. Their structural differences account for how one linkage results in substrate 
degradation and the other does not. As outlined above K63 linked chains are in an 
open conformation, this open conformation increases the chains affinity for DUBs 
associated with the proteasome, and K63 linked chains are therefore disassembled 
quickly releasing the substrate before it reaches the proteasome. The decreased 
affinity that K48 has for the proteasome associated DUBs results in much slower 




There is the possibility that polyubiquitin chains may not always be sufficient for 
targeting the substrate to the proteasome. Some E3s can interact with the proteasome 
suggesting that they direct the substrate to the proteasome for efficient degradation
75
. 
While it is clear that some E3s can associate with the proteasome it is not clear 
whether association is necessary for substrate degradation. Studies in yeast have 
highlighted a role for polyubiquitin receptor proteins in the transport of 
20 
 
polyubiquitinated substrates to the proteasome
76
. The activity of these proteins 
associated with ubiquitin binding was facilitated by a variety of ubiquitin binding 
domains. For example UBA and UBL containing proteins RAD23 and Dsk1 
respectively have been implicated as potential binding factors that can bind 
polyubiquitin chains and the proteasome
77,78
. A study has suggested that pathways 
operating downstream of polyubiquitination to target proteins to the proteasome 
exhibits substrate specificity and selection
78,79
.   
 
In addition to the well-studied role of ubiquitin in proteasomal degradation of 
proteins, ubiquitin has also been shown to be involved in lysozyme degradation and 
autophagy. K63 chains were thought to not signal for proteolytic events as proteins 
tagged with K63 linked chains were not targeted for degradation by the 26 
proteasome. While they target proteins involved in the stress response, they may also 
signal for protein degradation, just not via the proteasome, K63 linked chains may 




Aggregated proteins are harmful to the cell but are often too large to be removed by 
the proteasome, the process of autophagy is important for the removal of these 
aggregates. Autophagy receptors have been identified that can bind to ubiquitin, 




1.5.2 Signalling for degradation by ubiquitin 
 
As described in detail above polyubiquitination is the main mechanism for protein 
degradation but what of the event prior to this, the event that signals for a protein to 
be degraded by the ubiquitination pathway. The ubiquitin proteasome system 
degrades a wide variety of proteins that contain specific degradation signals or 
degrons. Many types of degron signals exist, some better characterised then others, 
and some examples are outlined below. 
 
The N-end rule pathway polyubiquitinates proteins that contain specific degrons 
called N-degrons. The main determent of an N-degron is a destabilising N-terminal 
residue of a substrate protein. The N-end rule states that the N-terminal amino acid of 
a protein determines its half life
82
. Recognition components of the N-end rule 
21 
 
pathway, called N-recognins, are specific E3 ligases that can target N-degrons
83
. 
Regulated degradation of specific proteins by the N-end rule pathway mediates a 
number of functions including sensing of oxygen, elimination of misfolded proteins, 
signalling by G proteins and regulation of DNA repair, neurogenesis and fat 
metabolism, to name a few. 
 
The SFC family of E3 ligase contain an F-box domain. Degradation of most SFC 
substrates requires phosphorylation of specific Ser/Thr residues on the substrate, these 
short phosphorylated peptide motifs can bind to the F box, following binding to the F-
box subsequent ubiquitination of the substrate can take place. The best characterised 
phosphodegrons are those involved in the elimination of cyclins and cyclin dependent 
kinase (CDK) inhibitors by the ubiquitin system.  In the mammalian cell SCF 
complexes target phosphorylated forms of cyclin E and CDK inhibitor p27
KIP184,85
. 
The mechanisms by which phosphorylation drives substrate binding to SCF and 
subsequent ubiquitin conjugation are not fully understood. 
 
Chaperone proteins have roles in the pathway of substrate recognition, ubiquitination 
and degradation. In many cases the exact roles of the chaperones are not defined. In 
the case of the E3 ligase CHIP it uses Hsp70 or Hsp90 as substrate recognition 





The PEST sequence was identified in 1986 and is a peptide sequence rich in proline 
(P), glutamic acid (E), serine (S) and threonine (T). It is associated with proteins that 
have a short, less than 2 hours, half life
86
. Some PEST sequences appear to be 
constitutive proteolytic signals, others appear to be conditional signals and their 
mechanism of action varies
87
.      
 
1.5.3 Protein-protein interactions 
 
When ubiquitin is bound to a protein it can affect that proteins interaction with its 
binding partners, it can facilitate protein: protein interactions a number of ways. 
Ubiquitin can induce a conformation change in the protein that it is bound to; this 
structural change can alter the interaction of binding partners. Ubiquitin is able to 
22 
 
provide, or extend, the interface between two binding partners; free ubiquitin chains 
can also provide an interface for two interacting proteins
88
 (figure 1.5).  
 
1.5.6 Cellular localisation  
 
As discussed above ubiquitination of a substrate can affect the substrates interaction 
with its binding partners, a change in binding activity, either activating or inhibitory, 
can result in a change of localisation for the substrate. Ubiquitination can also affect 
localisation of a substrate by binding to and masking a signal important for 
localisation or, upon binding, mediate a conformation change resulting in the masking 
or unmasking of a localisation signal, e.g. nuclear export signal, or nucleolar 
localisation signal
89



















Figure 1.5: The role of ubiquitin on protein-protein interactions. Ubiquitination can result in the 
allosteric activation of the substrate, altering its binding to other proteins (i). Ubiquitin can provide or 
extend a binding interface between two binding partners (ii). Chains of ubiquitin can provide a binding 





















The Murine Double Minute 2 (MDM2) gene was first cloned as a gene amplified on 
double minute particles in a transformed murine cell line, hence its name
90
. At a 
similar time a protein identified as p90 co-purified with the tumour suppressor protein 
p53 in immunoprecipitation studies using cell extracts
91,92
. p90 was later identified as 
the MDM2 gene product. Following this MDM2 was studied as a gene amplified in 
many sarcomas
93
. MDM2 can act as a critical negative regulator of p53
94
, at least in 
early development, as MDM2 null mice were embryonic lethal but this could be 




MDM2 is 491 amino acids in length and contains an N-terminal p53 binding domain, 
an acidic domain, a zinc finger and a C-terminal RING domain (figure 1.6). The 
RING domain of MDM2 has features that set it apart from other RING domains but 
its presence confirmed that MDM2 was an E3 ligase, in fact the RING of MDM2 is 
critical for its activity as an E3 ligase, and it specifically targets p53, among others, 
for degradation
97
. Not only does MDM2 target p53 for degradation by the 26S 
proteasome via its E3 ligase activity, it has also been shown to act on the translation 
of p53
98




A homologue of MDM2, known as MDM4 or MDMX, was identified more recently. 
Although the domains of MDM4 are homologous to those of MDM2, MDM4 is not 
able to substitute for MDM2 in early development and interestingly MDM4 does not 
display intrinsic E3 ligase activity towards p53
100,101
. MDM2 can associate with 
MDM4 to form a heterodimer, indeed it has been suggested that dimerisation of 
MDM2, as either a homodimer or as a heterodimer with MDM4, may be essential for 




Amplification of MDM2 has been implicated in a wide variety of cancers, including 
30 % of soft tissue sarcomas and 7 % of all solid tumours
103
. In addition to MDM2 
gene amplification, recent years have seen the identification of alternative and 
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aberrantly spliced forms of MDM2 mRNA expressed in many tumour types, their 
expression is often associated with advanced levels of disease
104
. While it is true that 
gene amplification does lead to increased MDM2 protein levels and this is seen in 
various cancer, some tumours have been identified that contain elevated MDM2 
protein without an increase in copy number. This implies that just looking at gene 
amplification will underestimate the number of tumours in which overexpression of 
the MDM2 protein contributes to cancer
105
. MDM2 is involved in a wide network of 
signalling pathways that rely on tight regulation for the normal function of the cell, 
overexpression of MDM2 protein could completely deregulate the normal signalling 
of these pathways. This will be discussed I further detail in following sections.  
 
Despite being a popular research target, due to its dysregulation throughout many 
cancer types, there is still much that is not understood about the roles of MDM2 and 
also its mechanism of action in currently identified roles. Realistically our knowledge 




MDM2 is 491 amino acids in length. It contains an N-terminal p53 binding domain 
(aa 29-108), central acidic domain (aa 223-288), zinc finger (aa 289-331) and a C-
terminal RING domain (aa 438-491). It also contains several localisation motifs, a 
nuclear localisation signal (starting at aa 178), nuclear exclusion signal (starting at aa 
192) and a nucleolar localisation signal (aa 466, 478) (figure 1.6). The sequence of 
MDM2 is conserved throughout eukaryotes; the three major domains of MDM2 are 




Currently there is structural knowledge for only approximately 30 % of the MDM2 
protein. Compared to the structural knowledge we have on other RING E3 ligases this 
is surprising, a possible reason for this lack of information could be that MDM2 
contains large regions of intrinsic peptide disorder
107
. While there is no crystal 
structure for MDM2 in its entirety, there are crystal structures for the hydrophobic N-
terminal p53 binding domain and the C-terminal zinc finger and RING domain. The 









Figure 1.6: Schematic diagram of MDM2. This schematic shows the location of the domains and 























1.6.3 N-terminal domain 
 
The N-terminal domain of MDM2 is 93 amino acids in length (residues 16-109) and 
was the first domain of MDM2 identified to bind to the tumour suppressor protein 
p53
108
. The N-terminal domain of MDM2 interacts with the activation domain (Box-
1) in the N-terminal domain of p53
109





The N-terminal domain of p53 contains the Box-I motif, a domain defined using 
crystallographic studies. These crystal studies showed that the N-terminal domain of 
MDM2 contained a deep hydrophobic cleft in which the p53 Box-I peptide bound, in 
particular a triad of hydrophobic amino acids, Phe19, Trp23 and Leu26 insert deeply 
into this binding pocket. These amino acids are involved in the transactivation of 
p53
111
, MDM2 binding to the N-terminal transactivation domain of p53 can therefore 
block p53-dependent transcription through steric mechanisms
112,113
. MDM2 competes 
with p300, a co-activating protein that binds to p53 for binding to the transactivating 
domain of p53
114
. Small molecules such as Nutlin compete with p53 for the 
hydrophobic binding pocket of MDM2 and release p53 from MDM2 mediated 
transrepression. Although Nutlin disrupts the high affinity interaction between the 
hydrophobic pocket and Box-I domain it is not an E3 ligase inhibitor, in fact an 
increase in p53 ubiquitination is seen when nutlin is added to cells. The E3 activity of 
MDM2 is enhanced because nutlin binding to the hydrophobic pocket increases the 
stability of a low affinity complex between of the acidic domain of MDM2 and the 
ubiquitination signal within p53
115,116
, leading to ubiquitination. This allostery 
between domains will be discussed in further detail in following sections. 
 
The N-terminal domain of MDM2 is flexible and can adopt different conformations 
depending on the length of the peptide bound to the hydrophobic pocket
117
. The 
differing conformations of MDM2 could be important for its diverse functions and 
should be an important consideration for the designing of anticancer drugs targeting 
the MDM2 protein. 
 
In addition to residues 25-109 that form the p53 binding domain, the adjacent residues 
12-24 form a pseudo substrate motif or ‘lid’ that can regulate the conformation of the 
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hydrophobic pocket. This ‘lid’ is strictly conserved across mammals
118
. The 
identification of the lid is not the first instance in which a lid or flap adjacent to an 
active site has been discovered
119
. The phosphorylation state of a serine at position 17 
of the lid could be important for the interaction of MDM2 with different ligands. A 
phosphomimetic mutation, S17D, in the pseudo substrate motif directly affects the N-
terminal MDM2 domain conformation, it opens the hydrophobic pocket and stabilises 
the full length MDM2-p53 complex
120
. The phosphorylation state of the lid and nature 
of the ligand bound are clearly important for the conformation of the N-terminal 
domain of MDM2, conformation could greatly increase downstream functions, and 
this is a very important point to consider when designing therapeutics targeted at 
MDM2. 
 
1.6.4 Acidic domain 
 
Adjacent to the N-terminal domain of MDM2 is a central domain rich in acidic amino 
acids and therefore known as the acidic domain (residues 221-228); the acidic domain 
is intrinsically disordered with no known structure. 
 
The acidic domain of MDM2 binds to p14/19ARF. ARF is activated by inappropriate 




. ARF protein 
is nucleolar and by binding to MDM2 sequesters it in the nucleoli, inhibiting MDM2 
nuclear export. p53 levels are therefore stabilised in the nucleoplasm where it can 
activate a p53-dependent stress response. Loss of ARF results in a predisposition to 





MDM2 mutants in which the N-terminal domain was truncated still had E3 ligase 
activity towards p53; this suggested a secondary binding site between MDM2 and 
p53. Deletion of the acidic domain of MDM2 significantly reduced E3 activity 
suggesting that the secondary binding site lay within the acidic domain. Binding 
assays confirmed that the acidic domain of MDM2 could bind to p53
124
. NMR 
spectroscopy showed shifts within the Box-V domain of p53 upon MDM2 binding
116
 
and the acidic domain was subsequently shown to bind to the consensus sequence 






As previously mentioned ligand binding to the hydrophobic pocket of MDM2 
increased the stability of binding between the acidic domain of MDM2 and the Box-V 
domain of p53. The domains of MDM2 do not act independently of one another and 
the interaction between the hydrophobic pocket and acidic domain of MDM2, in the 
degradation of p53 is an excellent example of the allosteric control of MDM2 activity. 
There is an intrinsic conformational restraint to ubiquitination of the native p53 
tetramer; this restraint is released when the binding of the N-terminal domain of 
MDM2 to the Box-1 domain of p53 alters the structure of the tetramer. This exposes 
the ubiquitination signal within p53, the Box-V domain, the acidic domain is then 





1.6.5 Zinc finger 
 
The central region of MDM2 is very unstructured apart from the following motif: X4-
W-X-C-X2-4-C-X3-N-X6-C-X2-C-X5 (where x is any amino acid). This matches the 
consensus sequence for RanBP2/NZF C4 zinc fingers. C4 zinc fingers are ubiquitous 
and multi-functional domains found in isolation or in tandem in a wide variety of 
proteins
125,126
. Little is known about the role(s) of the C4 zinc finger of MDM2. The 
solution structure of the C4 zinc finger of MDM2 identified a structure similar to that 
of the zinc ribbon structural motif. Zinc ribbon domains are found in proteins 
involved in transcription, translation, DNA replication and signal transduction where 
they mediate a variety of protein-protein, protein-DNA and protein-RNA interactions. 
The C4 zinc finger of MDM2 shares sequence similarity with the zinc ribbon family 




Cancer types including follicular non-Hodgkin’s lymphoma, leukaemia, 
hepatocellular carcinoma and osteosarcoma exhibited large quantities of MDM2 
mRNA in the absence of MDM2 gene amplification. Instead they carried mis-sense, 
non-sense and frame shift mutations in the zinc finger of MDM2. The mis-sense 
mutations were found in tumour cells that contained a significant accumulation of 
MDM2 and a lack of nuclear p53
127
. Following nucleolar stress ribosomal proteins 
L5, L11 and L23 bind to MDM2 blocking MDM2-mediated p53 degradation. Mis-
30 
 
sense mutations in the zinc finger domain disrupt the interaction of MDM2 with 
ribosomal proteins L5 and L11. Unlike wt MDM2 whose p53 suppressive activity can 
be inhibited by L11, the mis-sense mutants escape inhibition by L11, increasing 




1.6.6 RING domain 
 
MDM2 contains a C-terminal RING domain , a fact that took a while to confirm due 
to the unique nature of the MDM2 RING when compared to the RING domain of 
other E3 ligases. RING domains coordinate two metal ions and the coordination sites 





coordination sites is also highly conserved. MDM2 can bind two zinc ions, but shares 





 coordinating residue is not conserved. This led to the general consensus that 
MDM2 did contain a RING domain but there was some dispute over its zinc 
coordinating residues
129
. It was not until the solution structure of the MDM2 RING 
was solved that the true zinc coordinating residues were identified. MDM2 has a 
unique, among known RING domains, Cys2His2Cys4 metal coordinating site in which 




Before the identification of the RING domain MDM2 had been identified as an E3 
ligase towards p53 and itself
131
. The C-terminal RING domain is essential for this 
activity
132
, what is more the 12 amino acid ‘tail’ of MDM2 is required for E3 
activity
133
. Mutating the zinc coordinating residues diminished E3 ligase activity of 
MDM2 suggesting that the tertiary structure of the RING is important for E3 function. 
 
As well as the crucial role of the RING in the E3 ligase activity of MDM2, the RING 
has other functions. The RING binds to RNA
134
, with residues 425-491 being both 
necessary and sufficient for binding RNA and binding is not zinc-dependant
129
.  
The RING domain contains a cryptic nucleolar localisation signal (aa 466-473), this 
sequence is exposed as a consequence of binding between MDM2 and p14/19ARF, 
which is essential for MDM2 nucleolar localisation
135
. The RING domain also 
contains a conserved Walker A or P loop motif, a motif that is a common feature of 
ATP/GTP binding proteins. The consensus sequence of the P loop is 
31 
 
GXXXXGK(T/S) (where X is any amino acid); in MDM2 the sequence is 
GCIVHGKT. This sequence is present in all MDM2 homologues including MDM4. 




 zinc coordinating 
residues. Among all known E3 ligases MDM2 is unique in possessing this motif. ATP 
binding is not required for E3 ligase activity. P loop mutants are impaired in p14
ARF 
independent nucleolar localisation, this is consistent with the fact that ATP bound 




Although there is no structure of MDM2 in its entirety the solution structure for the 
RING of MDM2 has been solved. In this structure MDM2 is found in a homodimer, 
though it could also form a stable complex with MDM4. Each subunit of the 
homodimer folds into a compact globular domain with a short three stranded anti-
parallel β sheet, a three turn α helix and several extended loops which are primarily 
involved in zinc coordination. The subunit structure is stabilised by the two zinc 
binding sites. Each subunit has a small hydrophobic core, the zinc binding sites are 
located at each end of this core, clamping the subunit together (figure 1.7)
130
. The 
solution structure showed that MDM2 could dimerise as either a homodimer or 
heterodimer, dimerisation of MDM2 will be discussed shortly but the RING domain 
of MDM2 is the region of MDM2 thought to be critical for this dimerisation. There 
also exists a crystal structure of the MDM2 RING
137
 in a heterodimer with the MDM4 
RING, as with the solution structure this crystal structure shows MDM2 in dimeric 
form.   
 
As previously mentioned the domains of MDM2 do not function in isolation but are 
allosterically linked to one another. A gain in the ability of MDM2 to transrepress p53 
dependant transcription was seen when zinc coordinating residues within the RING 
were mutated. This indicates that there is cross talk between the C-terminal RING and 




The N-terminal hydrophobic pocket is highly flexible and mutants in the RING 
allosterically modulated not only the affinity of the pocket but also its specificity. This 
suggests that binding of interacting proteins to the RING in cells is likely to act on 
MDM2 transrepression activity, and is worth considering when investigating the 
effacy of drugs that target their hydrophobic pocket in tumour cells
138




























Figure 1.7: Solution structure of MDM2  RING (429-491) domain. a) Superposition of the 20 
lowest energy structures of the MDM2 (429-491) homodimer, with the two subunits shown in yellow 
and green. Zinc ions are shown as grey spheres. b) Ribbon representation of the lowest energy structure 
of a single subunit of MDM2 (429-491) showing secondary structures and the localisation of two zinc 
binding sites. The side chains contacting the zinc ligand are shown as balls and coloured black (C), 
blue (N) and yellow (S)
130








1.6.7 Dimerisation of MDM2 
 
MDM2 can form homodimers
130,139
 or heterodimers with its homologue MDM4
140
, 
heterodimers appear to be preferential
139




The solution structure of the MDM2 RING homodimer shows that the residues 
involved in the interface primarily include Val451, Lys453, Thr455, Gly456, Leu458, 
Met459, Val486, Leu487, Thr488, Tyr489, Phe490, Pro491
130
. Six of these residues 
lie in the 12 amino acid tail of MDM2, the necessity of the tail in the dimerisation of 




Many RING/U box domains are found in a dimeric form, such as the heterodimer 
BRCA1/BARD
142
, the homodimer CHIP
143
 and the U box homodimer Prp19
144
. The 
formation of the dimer for these E3 ligases is important for their activity. The 
structures of these dimeric RING domains have been well characterised. When the 
homodimer of MDM2, from the solution structure, was compared with these 
characterised dimeric RING domains the relative positioning of the subunits was 
similar, however the two MDM2 subunits are at a different angle with respect to each 
other compared to the other structures, the other structures are symmetrical, this can 




For some other RING containing E3 ligases dimerisation is not required for their 
activity. Whether or not MDM2 is required to form a dimer for E3 ligase activity 
remains controversial. Some studies report that E3 ligase activity of MDM2 towards 
p53 is seen regardless of whether MDM2 is present as a monomer or dimer
141
, others 





























Figure 1.8: Comparison of MDM2 dimer organisation with other RING/U-box dimers. a) MDM2 
(429-491) RING domain homodimer. b) BRCA1/BARD1 heterodimer. c) Ring1b/Bmi1 heterodimer. 
d) Zebra fish CHIP U-box homodimer. e) Prp19 U-box homodimer. Both subunit chains in all 
structures are coloured in a rainbow scheme, from blue at the N-terminus to red at the C-terminus
130









If MDM2 was required to be a dimer for E3 activity it is unclear whether it would be 
as a homodimer, heterodimer or even both. BRCA1/BARD is an example of an E3 
ligase that is active as a heterodimer. BARD does not have E3 ligase activity but 
stabilises and enhances the E3 activity of BRCA1
145
. It might be that MDM2 and 
MDM4 cooperate in a manner similar to this, or it might be that their dimerisation is 
related to other functions, such as each others cellular localisation or cellular levels, 
this will be covered in later sections. 
































p53 was identified in 1979, it was initially thought to be oncogenic as it collaborated 
with the oncogene Ras, not unlike the previously identified oncogene myc
146
. These 
studies had been done using p53 synthesised from tumour samples. p53 subsequently 
cloned from the mRNA of normal cells supressed cell transformation indicating that 




Human p53 is a transcription factor comprised of four domains, an N-terminal 
transactivation domain, a central DNA binding domain, a tetramerisation domain and 
a C-terminal basic domain
148
. Tetramerisation is required for the tumour suppressor 
activity of p53
149
 (figure 1.9) and mutations within the tetramerisation domain have 




1.7.2 p53 pathway 
 
The p53 pathway is composed of a network of genes and their products, that are 
targeted to respond to a number of stress signals, that impact upon mechanisms such 
as DNA replication , chromosome segregation and cell division
152
. Both intrinsic and 
external stresses on the cell can act upon the p53 pathway. Signals that activate p53 
protein include damage to the integrity of the DNA template, irradiation of the cell, 
gamma or UV, alkylation of bases or reaction with oxidative free radicals. Different 




Differing types of DNA damage activate different enzyme activities that modify p53 
differently i.e. ubiquitination, phosphorylation, sumoylation, acetylation and 
methylation
154
. For example gamma radiation activates ATM kinase that can 
phosphorylate p53 and p53 is phosphorylated and acetylated in response to hypoxia, 

























Figure 1.9: Crystal structure of the p53 tetramerisation domain. The tetramerisation domain of p53 
is revealed here by X-ray crystallography. The four helical domains of each subunit, each show in a 

















The modifications of p53 alter its activity in two ways, firstly the half-life of the 
protein increases, resulting in an increased concentration of p53 in the cell. Secondly 
the ability of p53 to bind to specific DNA sequences, termed the p53 response 
element, and promote the transcription of genes regulated by these sequences is 
enhanced
156
. Once the p53 protein has been activated it initiates a transcriptional 
program that reflects the nature of the stress signal. The genes in this network initiate 
one of three responses, resulting in cell cycle arrest, cellular senescence or apoptosis. 
 
An example of a p53 activated gene is p21, the p21 gene product plays a major role in 
cell cycle arrest, p21 inhibits cyclin E-cdk2. In the proliferating cell this cyclin 
dependant kinase acts upon Rb protein to depress E2F1 activity, this promotes the 
transcription of genes involved in preparing a cell to progress from the G to S phase 





p53 dependant pathways leading to cellular senescence are less well characterised 
than pathways involved in cell cycle arrest and apoptosis. Introduction of the Ras 
oncogene into primary cell culture mediates a p53 dependent senescence. Activation 






, is mediated 
in part by a positive feedback loop that results in transcription of p14/19
ARF
. This in 
turn inhibits MDM2, resulting in increased p53 levels in the cell. 
 
p53 dependant apoptosis is widely studied. Several p53 dependant genes (including 
bax and puma) enhance the secretion of cytochrome c into the cytoplasm from the 
mitochondria, this interacts with APAF-1 (another p53 regulated protein) initiating a 
protease cascade that leads to activation of caspases followed by apoptosis. This 
pathway is known as the intrinsic apoptotic pathway and is activated by a number of 
stress signals. p53 also regulates a series of genes that initiate the extrinsic apoptotic 




In addition to activating genes involved in cell cycle arrest, cellular senescence or 
apoptosis p53 also regulates genes that produce secreted proteins such as maspin and 
thrombospondin. These secreted proteins are employed to communicate signals to 
surrounding cells, informing them of stress response
158
.                   
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p53 is a highly popular research target as it is the gene found to be most frequently 
mutated in human cancer cell genomes examined to date, being present in mutant 
forms in approximately 50 % of all human tumours. Point mutated alleles of p53, 
almost always leading to amino acid substitution, represent the greatest majority of 
mutant p53 alleles found in human tumours, the vast majority of p53 mutations affect 
the DNA binding domain of p53
159
, supporting the concept that gene regulation is the 
most important function of p53. 
 
p53 clearly activates and interacts with many genes and gene products involved in cell 
cycle regulation, outlined above is just a very small example. The regulation and 
control of p53 in proliferating cells and in response to stress must be tightly controlled 
or disease, such as cancer can develop. As a result it is not only p53 that is a popular 
research target, downstream targets of p53 and its regulators are also possible 
therapeutic targets. MDM2 is one of the p53 regulators that has received much 
attention as a therapeutic target.   
 
1.7.3 Inhibition of p53 induced gene expression 
 
MDM2 interacts with the activation domain of p53, the region of p53 that is important 
for p53 transcriptional activity
110
. p300 is a coactivating protein that binds to p53 
enhancing the expression of its downstream target genes, MDM2 competes with p300 
for the transactivation domain of p53
114
. As outlined previously the N -terminal 
hydrophobic domain of MDM2 binds to the N-terminal transactivation domain of p53 
and blocks p53 dependant transcription, interestingly the MDM2 RING domain is 




It is possible that MDM2 inhibits p53 induced gene expression via a dual mechanism. 
It has been shown that the adenovirus E1B contains an inhibitory domain that is 
targeted to the p53 promoter by interacting with p53. Once at the promoter E1B 
inhibits expression of p53 induced genes, by inhibiting additional activators or 
repressing the activity of the basal transcriptional machinery
160
. MDM2 may directly 
block p53 dependant transcription and also inhibit the ability of general transcription 
factors to potentiate mRNA synthesis
112
, as with E1B. To support a dual mechanism 
hypothesis a similar mechanism has been proposed, in which Rb protein inhibits E2F 
40 
 





1.7.4 Translation of p53 
 
A study showed that MDM2 could induce translation of p53 and that this translation 
induction required MDM2 to interact with the nascent polypeptide of p53
98
. This 





 produced a model in which MDM2 is recruited to active 
polyribosomes by nascent p53 N-termini, resulting in cis regulation of p53 mRNA 
translation
98
. MDM2 induces translation of the p53 mRNA from two alternative sites. 
This produces full length p53 and another protein with a relative molecular mass of 
47kDa, this protein is known as p53/47. MDM2 effects translation of p53 and p53/47 
by directly interacting with p53 protein. p53/47 lacks an N-terminal MDM2 binding 
domain and as such is not degraded by MDM2. It does however have a fully 
functional tetramerisation domain and can oligomerise with full length p53. MDM2 
can change the ratio of p53 and p53/47 by inducing translation of both then 




The N-terminus of p53 has two independent transcription activation domains
162
. 
p53/47 lacks the first (TAI) but contains the second (TAII). The different activation 
domains induce the expression of different downstream targets. TAI transactivates 
p21
WAF1
 and TAII transactivates MDM2, Bax and GADD45. A change in the ratio of 
p53/47 and p53 will alter the ratio of these downstream targets, 
 
The proportion of p53/47 to p53 has implications for the cells biological response to 
p53 activation. In one mouse model overexpression of p53/47 leads to p53 dependant 
cellular senescence and premature aging
163
. This model indicates that p53/47 may be 
a factor in directing the p53 dependant cell stress response (repair, senescence or 
apoptosis) and the synthesis of p53 and p53.47 have been shown to be regulated 
through distinct stress induced pathways, which help orchestrate the cellular outcome 
in response to stress
164
. It should be noted that there are many more p53 isoforms, 




There is currently not a large amount of information on p53/47. Further study is 
needed to ascertain its role in p53 activation, degradation and the cell response to 
different stresses.  
 
1.7.5 Chaperone for p53 
 
Molecular chaperones are defined as a vast class of structurally unrelated proteins that 
assist in correct non-covalent assembly of other polypeptide containing structures. 
They are not components of the assembled structure when they perform their 
biological functions
99
. Several studies show that MDM2 possesses similar activities as 
described for molecular chaperones
165
 including binding to a nascent polypeptide 
chain
98
, modulation of transcription factors
166
, protection and activation of DNA 
polymerases
167




Hsp90 is a molecular chaperone that in an ATP-dependant reaction folds p53. MDM2 
can work synergistically with Hsp90 enhancing the binding of p53 to promoter 
derived sequences
99
. Interestingly MDM2 alone could substitute for Hsp90 and, in an 
ATP-dependant reaction, promote the binding of p53 to the p21 promoter sequence. 
MDM2 protein possesses a nucleotide binding motif, mediated by the consensus P 
Walker motif, within its RING domain, this ATP binding site is not required for E3 
ligase activity
136
. This study provided the first direct role for the ATP binding domain 
of MDM2. 
 
MDM2 localises with latent p53 on the chromatin near p21
WAF1
 and MDM2 genes 
before but not after DNA damage
169
. This chaperone study suggests that the transient 
complex of p53 with chaperones such a MDM2 may be important for the decision of 
whether to activate or degrade p53 by employing a series of post translational 
modifications such as ubiquitination, sumoylation, acetylation, methylation etc.                    
 
1.7.6 E3 ligase activity 
 
As previously discussed MDM2 is an E3 ligase for p53. There are many questions 
concerning the mechanism of the E3 ubiquitin ligase activity of MDM2. The general 
mechanism for how all RING domain containing proteins facilitate the transfer of 
42 
 
ubiquitin from their partner E3 to the target substrate remains unknown. There are 
more unknowns specifically related to MDM2, it is currently unclear whether MDM2 
must dimerise to be active as an E3
102,141
, furthermore if MDM2 is required to 





 with its homologue MDM4. The MDM2 RING possesses a 12 amino 
acid ‘free’ tail, unlike other RINGS, and this tail is essential for E3 ligase activity
133
 
yet the reason(s) why remains unknown, it has been implicated in dimer formation
141
 
or it may be involved in the allosteric activation of it E2
35
. There is also a question as 
to whether MDM2 would polyubiquitinate p53, it has been suggested that MDM2 
works alongside an E4, in this case p300
64
, in order to polyubiquitinate p53 and target 





MDM2 regulates the degradation of p53 in normal unperturbed cells, recognising p53 
as a target that should be ubiquitinated shortly after synthesis and therefore targeted 
for degradation. In some circumstances, specifically when cells are suffering certain 
types of stress or damage, p53 must be protected from MDM2 facilitated degradation 
so that it can accumulate to functionally significant levels in the cell. 
 
Levels of p53 are controlled by feedback loops. Ten feedback loops have been 
identified in the p53 pathway. Of these seven are negative feedback loops, these down 
regulate p53 activity, and three are positive feedback loops, these up regulate p53 
activity. All of these loops are auto regulatory in that that they are either induced by 
p53 activity at the transcriptional level, transcriptionally repressed by p53 or are 





1.7.7 Positive feedback loops 
 
In response to DNA damage kinases such as ATM, Chk1 and Chk2 phosphorylate the 
N-terminus of p53 which prevents its association with MDM2. At the same time 
ATM can phosphorylate MDM2 resulting in its functional inactivation, this allows 




1.7.7.1 PTEN pathway 
 
The P13 kinase (P13K) phosphorylates phosphatidylinositol (4,5)-bisphosphate 
(PIP2), phosphatidylinositol (3,4,5)-triphosphate (PIP3) can then activate Akt/PKB 
kinase which phosphorylates MDM2, this results in the translocation of MDM2 from 
the cytoplasm to the nucleus where it is able to act on p53. p53 protein induces 
transcription of PTEN genes, the PTEN protein is a phosphatase that 
dephosphorylates PIP3 to PIP2, this results in the inactivation of the Akt/PKB pathway 
and the up regulation of p53
156
 (figure 1.10). 
 
1.7.7.2 Retinoblastoma pathway 
 
Retinoblastoma (Rb) protein is multiply phosphorylated by the cyclin dependant 
kinase Cyclin E-cdk2, this hyperphosphorylation state releases a group of 
transcription factors known as E2Fs allowing them to stimulate transcription of target 
genes, the target genes of E2Fs are involved in cell cycle progression. When p53 is 
activated it stimulates the synthesis of the p21 protein, this inhibits Cyclin E-cdk2 
activity, Rb is able to bind E2F preventing it from facilitating transcription of its 
target genes. Hypophosphorylated Rb also forms complexes with MDM2 and p53, the 





1.7.7.3 p14/19ARF pathway 
 
The p14/19ARF protein binds to MDM2 localising is to the nucleolus where it is 
unable to act on p53
123










 signalling. Interestingly p14/19 ARF activity is negatively regulated by p53 
itself
156
 (figure 1.10).        
 
















Figure 1.10: Diagram showing the involvement of MDM2 in the p53 positive feedback loops. 
MDM2 is inhibited by P19/14ARF. PTEN inhibits factors that activate MDM2. MDM2 is inhibited by 

















1.7.8 Negative feedback loops 
 
1.7.8.1 Siah-1 pathway 
 
The Siah-1 gene contains a p53 response element and p53 protein positively regulates 
the transcription of the RING domain containing ubiquitin ligase Siah-1
174
. Siah-1 
interacts sequentially with siah interacting protein (SIP), Skp1 and EBI. EBI binds 
directly to β-catenin and initiates subsequent proteasome mediated degradation
175
. β-
catenin levels regulate the p14/19 ARF gene
173
, subsequently the protein sequesters 
MDM2 in the nucleolus allowing p53 levels to accumulate in the cell. Siah-1 down 
regulates this positive feedback loop, decreasing levels of p53 (figure 1.11). 
 
1.7.8.2 Cyclin G pathway 
 
Cyclin G is one of the most active of the p53 responsive genes; it is rapidly 
transcribed to high levels after p53 activation in a wide range of cell types
176-178
. 
Cyclin G protein forms a complex with PP2A phosphatase, this removes a phosphate 
residue from MDM2
179
, this phosphate residue would have been previously added to 
MDM2 by Cyclin A-cdk2. Phosphorylation of MDM2 by Cyclin A-cdk2 inhibits its 
activity thus the Cyclin G PP2A phosphatase enhances MDM2 activity and inhibits 
p53
156
. Cyclin G null mouse fibroblasts have elevated p53 levels in an absence of 
stress
179
, this indicates that this negative feedback loop acts upon basal levels of p53 
in cells and not only on higher p53 levels induced after stress
156
 (figure 1.11). 
 
1.7.8.3 MDM2 feedback loop 
 
MDM2 is a very important downstream target of p53; p53 induces the transcription of 
MDM2, an agent of its own destruction. This creates a negative feedback loop
156
 that 
functions to ensure that p53 molecules are degraded soon after their synthesis, 
keeping very low steady state levels of p53 proteins in normal unperturbed cells. In 
human cancer cells that carry mutant p53 alleles the p53 protein is invariably present 
in high concentrations, in contrast to normal cells. This initially appears paradoxical 
since high levels of a tumour suppressor, such as p53, would seem incompatible with 
46 
 
malignant cell proliferation. This paradox is resolved by the fact that the great 
majority of mutations affecting the p53 gene cause the protein to lose its transcription 
activating activity. Consequently p53 is unable to induce MDM2 transcription and 
thus MDM2 synthesis. In the absence of MDM2 p53 escapes degradation and the 
result is an accumulation of high levels of inert p53
180




































Figure 1.11: Diagram showing the involvement of MDM2 in the p53 negative feedback loops. 












1.8 Roles of MDM2, p53 independent 
 
Although M2DM2 is an important regulator of p53 there is evidence that MDM2 has 
p53-independent functions, such as roles in DNA repair, transcription and ribosome 
biosynthesis. Evidence for p53 independent roles include the fact that MDM2 
overexpression in tumours accompanied by mutant p53 or a lack of p53 is observed in 






MDM4, also known as MDMX, HDMX and HDM4, was identified in 1996. A 
protein 490 amino acids in length, it has high structural homology to MDM2. The 
highest level of sequence homology between the two proteins is in the N-terminal 
domain, in addition the zinc binding domain and C-terminal RING domain show high 





Similarities between MDM2 and MDM4 include the ability of MDM4 to bind to p53 
and block transactivation of a p53-responsive reporter genes
182
. In contrast MDM4 
has no E3 ligase activity and cannot degrade p53, it is also unable to facilitate nuclear 
export. MDM4 is not induced in response to DNA damage and so, unlike MDM2, is 





When MDM2 knockout mice were created they were embryonic lethal
95
, this 
indicates that MDM4 cannot compensate for MDM2 in early development. 
Interestingly the MDM4 knockout is also embryonic lethal thus neither homologue 
can compensate for each other, both MDM2 and MDM4 are essential regulators of 




Not long after the discovery of MDM4, MDM2 and MDM4 were found to form 
heterodimers, an interaction that is facilitated by their RING finger domains. 
Coexpression of MDM4 inhibited degradation of MDM2, suggesting a role for 
49 
 
MDM4 as a regulator of MDM2 levels
140
. This is true, they are actually dependant on 
each other for their function. When there is no MDM4 present in the cell, MDM2 is 
ineffective at down regulating p53 due to a very short half-life
184
, association with 
MDM4 leads to an increase in steady state levels of MDM2
185
. MDM4 is cytoplasmic 
and requires MDM2 to locate to the nucleus where it can inactivate p53 by blocking 
its transactivation
184
. MDM4 is targeted for degradation by MDM2
186
, DNA damage 
activates ATM which phosphorylates MDM4 at S403, this results in MDM2 targeting 




MDM4 has been shown to have a role in certain cancers; it has been described as an 
oncogene that becomes activated upon its overexpression. Screening showed that 
MDM4 was overexpressed in a wide variety of human tumours and amplified in 5 % 
of breast tumours screened, all which retained wt p53. In combination with oncogenic 
Ras, MDM4 overexpression contributes to cell immortalisation and neoplastic 
transformation
187
. As overexpression of MDM4 contributes to cancer it is a potential 
target for cancer therapy. Currently interest lies in developing small molecule 




1.8.2 DNA repair 
 
Five primary human DNA repair pathways regulate the fidelity of duplex DNA and 
are able to counteract specific subsets of lesions that can potentially alter genomic 
integrity. An accumulation of DNA damage and/or the inability to repair damage 
directs human cells towards a tumorigenic phenotype
189
. The involvement of MDM2 
in DNA repair is starting to be investigated. 
 
Base exclusion repair (BER) attempts to fix single strand breaks, altered bases, and 
abasic sites
190
. Ape1 is a key enzyme in the BER pathway, its importance is 
demonstrated by embryonic lethality and apoptosis in cells lacking this enzyme
191-193
. 
Ape1 was found to be polyubiquitinated in the human cancer cell line HCT116, and 
MDM2 led to the ubiquitination of Ape1. Monoubiquitination of Ape1 appears to lead 
to its exclusion from the nucleus which may be a proapoptotic mechanism for 
interactions with Bcl2 in mitochondria versus DNA repair
194
. Considering that Ape1 
50 
 
has a critical role in the BER pathway. MDM2 may play a pivotal role in this DNA 
repair mechanism. 
 
Homologous recombination (HR) repairs DNA double strand breaks. Nbs1 is a 
protein cofactor of the MRN complex that is involved in HR
189
. MDM2 interacts with 
Nbs1 and colocalises with Nbs1 at sites of double strand DNA damage
195
 
Overexpression of MDM2 leads to an inhibition of Nbs1 directed repair of double 
strand breaks
196
, this information supports the role of MDM2 in oncogenesis.  
 
DNA mismatch repair (MMR) facilitates the removal of incorrect nucleotides on the 
opposite DNA strand. Proliferating cell nuclear antigen (PCNA) is a protein involved 
in MMR. MDM2 is in part regulated by PCNA
189
, yet it has not been investigated in 
context of the MMR pathway, MDM2 may have the potential to play a role in this 
pathway. 
 
Nucleotide excision repair (NER) promotes the repair of bulky, helix distorting 
lesions. The general mechanism of NER involves scanning and detection of DNA 
lesions, formation of a denaturation bubble, damaged strand incision, removal of the 
lesion containing oligonucleotide, gap filling and DNA ligation
197
. Small DNA 
lesions are recognised by the XPC complex
198
 and DDB is a protein that forms a 
complex with other protein components to form a ubiquitin ligase complex that 
regulates XPC through polyubiquitination
199
 Preliminary studies suggest that MDM2 




 and play a role in the NER pathway. 
 
Non homologous end joining (NHEJ) repairs breaks induced by ionizing radiation, 
oxidative free radicals, inhibition of topoisomerases and other mechanical stresses
205
. 
Once DNA repair factors have executed their enzymatic function they are no longer 
needed around duplex DNA. MDM2 has been shown to interact with NHEJ proteins 
such as Ku70
206
, interaction between MDM2 and NHEJ proteins represents a potential 







MDM2 interacts with DNA polymerase ε, as shown by a yeast two hybrid screen, in 
vitro binding assay and in vivo immunoprecipitation
208
. The C-terminal domain of 
DNA polymerase ε, to which MDM2 binds and the N-terminus of MDM2, to which 
DNA polymerase ε binds, are essential for the stimulation of DNA polymerase ε 
activity by MDM2. Proposed roles of DNA polymerase ε include DNA repair, 
recombination, damage sensing and chromatin remodelling
207
. 
             
1.8.3 Ribosomal proteins 
 
MDM2 has a nuclear localisation signal (NLS) and resides in the nucleus; this is 
where ribosomes are biosynthesised and assembled. The interaction of MDM2 with 
ribosomal proteins L5, L11 and L23
209-211
 suggests that MDM2 may play a role in 






MDM2 has been shown to induce the p65 subunit of NF-κβ through effects on the 
p65 promoter
213
. NF-κβ has various roles including inhibition of apoptosis in response 
to chemotherapy in certain cells. MM2 overexpression in leukaemia bone marrow 
cells has been associated with elevated expression of p65 and in vitro resistance to 
doxorubicin
214
. Further studies are required to establish whether the induction of p65 
by MDM2 is an important p53-independnat role of MDM2 in tumorigenesis. 
 
1.8.5 MDM2 binding protein 
 
MDM2 binding protein (MTBP) has been identified as a protein that interacts with 
MDM2, a 380 amino acid region at the C-terminus of MTBP is sufficient for 
interaction with the acidic domain of MDM2
215
. Overexpression of MTBP inhibits 
proliferation and also metastasis of several human cancer cell lines, regardless of p53 
status, suggesting that MTBP has a role in the suppression of tumorigeneis
216
. While 
overexpression of MDM2 can inhibit MTBP induced cell proliferation arrest it is 





1.9 Thesis objectives 
 
The main objectives of this PhD were: 
 
1. To investigate the mechanism of MDM2 E3 ligase activity 
2. To investigate the oligomeric nature of MDM2 
3. To investigate the role of the C-terminal tail of MDM2 
 
This was done by employing a range of biochemical assays, including protein binding 
ELISAs, to investigate the binding of MDM2 to other ubiquitination cascade 
components (Chapter 3).  
 
Biophysical assays, such as HD exchange, were utilised to further investigate the 
mechanism of MDM2 and the allosteric affect it has on UbcH5α (Chapter 4). 
Biophysical assays were also used to study the oligomeric nature of MDM2 (Chapter 
6). 
 
Peptide phage display was used in a novel way to confirm biochemical and 
biophysical data regarding the allosteric activation of UbcH5α as well as providing 
new information in regards to the binding partners of UbcH5α (Chapter 5). 
 
In this thesis I outline how I have investigated the objectives and provide new 













Chapter 2: MATERIALS AND METHODS 
 
2.1 Plasmids, chemicals and reagents 
 
pGEx6-MDM2-WT and pET15b-mod-CHIP were a kind gift from Alicja Zylicz; 
pGex6-MDM2ΔT and pET14b-UbcH5α were from Susanna Pettersson; pT7-7Hup53 
was from Ted Hupp. 
 
The general chemicals and reagents used in this thesis were from Sigma or Merck-
BDH, unless otherwise indicated.  
 
Peptides were used for a number of biochemical and biophysical assays, the full 
sequence of the peptides, alongside their names, are detailed in table 2 below. 
 
Peptides were purchased from Chiron Mimotopes and were synthesised with an N-
terminal biotin tag and Ser-Gly-Ser-Gly spacer. 
 
Peptide name  Protein peptide 
is derived from  
Sequence 
Peptide 1 MDM2 RING Biotin-
SGSGCVICQGRPKNGCIVHGKTGH 
Peptide 2 MDM2 RING Biotin-
SGSGGRPKNGCIVHGKTGHLMACF 
Peptide 3 MDM2 RING Biotin-
SGSGGCIVHGKTGHLMACFTCAKK 
Peptide 4 MDM2 RING Biotin-
SGSGGKTGHLMACFTCAKKLKKRN 
Peptide 5 MDM2 RING Biotin-
SGSGLMACFTCAKKLKKRNKPCPV 
Peptide 6 MDM2 RING Biotin-SGSGTCAKKLKKRNKPCPVCRQPI 
Peptide 7 MDM2 RING Biotin-SGSGLKKRNKPCPVCRQPIQMIVL 
Peptide 8 MDM2 RING Biotin-SGSGNKPCPVCRQPIQMIVLTYFP 
Peptide 9 MDM2 RING Biotin-SGSGQPIQMIVLTYFP 
N472A MDM2 RING Biotin-SGSGAKPCPVCRQPIQMIVLTYFP 
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K473A MDM2 RING Biotin-SGSGNAPCPVCRQPIQMIVLTYFP 
P474A MDM2 RING Biotin-SGSGNKACPVCRQPIQMIVLTYFP 
C475A MDM2 RING Biotin-SGSGNKPAPVCRQPIQMIVLTYFP 
P476A MDM2 RING Biotin-SGSGNKPCAVCRQPIQMIVLTYFP 
V477A MDM2 RING Biotin-SGSGNKPCPACRQPIQMIVLTYFP 
C478A MDM2 RING Biotin-SGSGNKPCPVARQPIQMIVLTYFP 
R479A MDM2 RING Biotin-SGSGNKPCPVCAQPIQMIVLTYFP 
Q480A MDM2 RING Biotin-SGSGNKPCPVCRAPIQMIVLTYFP 
P481A MDM2 RING Biotin-SGSGNKPCPVCRQAIQMIVLTYFP 
I482A MDM2 RING Biotin-SGSGNKPCPVCRQPAQMIVLTYFP 
Q483A MDM2 RING Biotin-SGSGNKPCPVCRQPIAMIVLTYFP 
M484A MDM2 RING Biotin-SGSGNKPCPVCRQPIQAIVLTYFP 
I485A MDM2 RING Biotin-SGSGNKPCPVCRQPIQMAVLTYFP 
V486A MDM2 RING Biotin-SGSGNKPCPVCRQPIQMIALTYFP 
L487A MDM2 RING Biotin-SGSGNKPCPVCRQPIQMIVATYFP 
T488A MDM2 RING Biotin-SGSGNKPCPVCRQPIQMIVLAYFP 
Y489A MDM2 RING Biotin-SGSGNKPCPVCRQPIQMIVLTAFP 
F490A MDM2 RING Biotin-SGSGKPCPVCRQPIQMIVLTYAP 
P491A MDM2 RING Biotin-SGSGNKPCPVCRQPIQMIVLTYFA 
Box 1 p53 SGSGPPLSQETFSDLWKLLP 
Peptide 12.1 p53 SGSGMPRFMDYWEGLN 
Peptide 12.1
WΔA p53 SGSGMPRFMDYAEGLN 
Peptide 12 Aptamer screen Biotin-SGSGAKFDMHIATRLS 
Peptide 37 Aptamer screen Biotin-SGSGFIPAQLHFHWRS 
Peptide 58 Aptamer screen FIPAQLQFHWRSGSG-Biotin 
Peptide 68 Aptamer screen KHSAFMWWTVKSGSG-Biotin 
 








2.2 Microbiological Techniques 
 
2.2.1 Bacterial cultures 
 
Bacterial cultures were grown in Luria-Bertani (LB) broth in an incubator shaker at 
37 
o
C, 220 rpm. Sterile vessels with 4x the capacity of the culture being grown were 
used for adequate aeration of the culture. Selective antibiotics were used at the 
following concentrations 100 µg/ml ampicillin and 25 µg/ml kanamycin. 
 
LB plates were prepared by heating agar until liquid, cooling to 42 
o
C, adding 
selective antibiotic (at the concentrations above) and pouring into 90 mm petri dishes 
(Sterilin). The agar was further cooled until solid and the plates dried at 37 
o
C for 10 
minutes-1 hour before use.  
 
LB broth      LB agar 
 
1 % (w/v) tryptone     1 % (w/v) tryptone 
0.5 % (w/v) yeast extract    0.5 % (w/v) yeast extract 
1 % (w/v) NaCl     1 % (w/v) NaCl 
       1.5 % (w/v) agar 
Autoclave, 121 
o
C, 20 minutes   Autoclave, 121 
o
C, 20 minutes 
 
On occasion glucose was added to LB broth at a final concentration of 0.015 % (w/v). 
 
During expression trials 2x TY media was used instead of LB broth, the protocol for 
bacterial growth is as described for LB broth. 
 
2x TY media 
 
1.6 % (w/v) tryptone 
1 % (w/v) yeast extract 




2.2.2 Glycerol stocks 
 
The preparation of glycerol stocks, for the long term storage of bacteria, was achieved 
by adding 800 µl of mid log phase bacterial culture (OD600 nm ~ 0.6) to a cryotube 
(Nunc) along with 200 µl of sterile glycerol and mixing gently. The cells were rapidly 




2.2.3 Preparation of competent cells, heat shock method 
 
Bacterial cells from glycerol stocks were inoculated in 2 ml of LB broth, minus 
antibiotic, and incubated overnight at 37 
o
C and 220 rpm. 250 µl of the overnight 
culture was added to 50 ml fresh LB broth and incubated until the OD600 nm was 0.4. 
The culture was centrifuged at 4000g for 15 minutes at 4 
o
C. The pellet was 
resuspended in 16 ml of ice cold buffer I, incubated on ice for 10 minutes and 
centrifuged as above. The pellet was gently resuspended in 2 ml of ice cold buffer II 
and incubated on ice for 10 minutes. Aliquots (30 µl) were prepared in pre-chilled 




Buffer I    Buffer II 
 
60 mM CH3COOK   10 mM MOPS 
10 mM RbCl    10 mM RbCl 
10 mM CaCl2    75 mM CaCl2 
40 mM MgCl    15 % (v/v) glycerol 
15 % (v/v) glycerol 
pH 5.8 with CH3COOH  pH 6.5 with NaOH 
Sterilise by filtration   Sterilise by filtration 
 
2.2.4 Transformation of bacteria, heat shock method 
 
A thawed aliquot of competent bacterial cells (30 µl) was mixed with plasmid DNA 
(250 ng) and incubated on ice for 30 minutes. Cells were heat shocked at 42 
o
C in a 
water bath for 90 seconds and cooled on ice for a further two minutes. LB broth (1 
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ml), minus antibiotic, was added to the cells and they were incubated at 37 
o
C, 220 
rpm for 60-90 minutes.   
Aliquots (100 µl and 100 µl of a 1:10 dilution) were plated onto LB agar plates 





2.3 Molecular biology methods 
 
2.3.1 Plasmid DNA amplification 
 
Plasmid DNA was amplified using either the Mini-prep or HiSpeed Maxi-prep kits 
from Qiagen, following the manufacturer’s instructions. Plasmid DNA was eluted at 
room temperature in nuclease free water. Plasmid DNA was then quantified using a 
NanoDrop ND-1000 spectrophotometer, using nuclease free water as the blank before 




2.3.2 Agarose gel electrophoresis of DNA 
 
Agarose gel electrophoresis was used to separate, identify and purify DNA fragments. 
Agarose gels (1 %) were prepared by dissolving agarose in 1xTAE. To detect the 
DNA either the fluorescent intercalating dye ethidium bromide (0.5 µg/ml) or 
SYBR®Safe (Invitrogen) were added to the gel prior to pouring the gel. The switch 
between ethidium bromide occurred as SYBR®Safe is now considered safer and less 
mutagenic then ethidium bromide. Loading dye (6x) was added to the DNA samples 
prior to loading onto the agarose gel; the gel was run in 1x TAE buffer at 100 V for 
~1 hour.  
 
1x TAE buffer     6x DNA loading dye 
 
40 mM Tris     0.25 % (w/v) bromophenol blue 
1 mM EDTA     0.25 % (w/v) xylene cyanol 




2.3.3 DNA sequencing 
 
Sequencing was carried out by Source Bioscience (LifeSciences). Plasmid DNA was 
obtained from clones by using the Qiagen Mini-prep kit, following manufacturer’s 




2.3.4.1 Traditional cloning using restriction enzymes 
 
Traditional cloning using restriction enzymes (RE) is done in three steps. 1) PCR 
amplification of the desired insert, including suitable restriction sites. 2) Restriction 
enzyme double digests of insert and vector. 3) Ligation of digested vector and insert. 
 
2.3.4.2 PCR amplification 
 
Suitable plasmid DNA for the insert was used as a template. Primers were designed 
that incorporated different RE sites into the 3’ and 5’ end. It is important to make sure 
that the inserted gene is in frame with any tags within the vector it is to be cloned. 
Nucleotide bases are added alongside the RE sites to allow for efficient binding. 
These nucleotides are random and are manipulated to get good G/C content and a 


















Tag encoded by 
vector 
Primers 5’-3’ Template 

































Table 2.2: Primers used for traditional cloning 
Key: Blue- Nucleotide bases added to allow for efficient RE binding 
 Red- RE recognition site 
 Green- Inserted base to make sure that my insert is in frame 
 Black- Desired gene 








Restriction Enzyme Recognition sequence 5’-3’ 







           
Table 2.3: Restriction enzymes used in traditional cloning 
 
The PCR reaction was set up in nuclease free tubes using 2 x Pfu master mix 
(Rovalab) as follows: 
 25 µl 2x Pfu master mix1 
 5 µl Band doctor (Rovalab) 
 5 ng template DNA 
 1 µl forward primer (20 µM stock) 
 1 µl reverse primer (20 µM stock) 
 Nuclease free water up to 50 µl 
 
Thermal cycling conditions: 
 
 Incubate at 95 oC for 2 minutes 
 Incubate at 95 oC for 20 seconds 
 Incubate at 68 oC for 40 seconds 
 Incubate at 72 oC for 1 minute 
 Cycle to step 2 for 30 cycles 
 Incubate at 72 oC for 1 minute 
 Hold at 4 oC forever 
                                                 
1
 pfu master mix contains pfu polymerase (isolated from Polycoccus furiosus) which, when compared 
to other polymerases such as Taq, has superior proofreading properties and higher thermostabilty. Its 
error rate is 1 in 1.3 million bases, but these higher proofreading capabilities results in slower DNA 




Post PCR the amplified DNA was cleaned using the Qiagen PCR clean up kit and 
eluted in 50 µl of nuclease free water.  
 
2.3.4.3 Restriction digests of vector and insert 
 
Restriction digests were carried out using restriction enzymes (RE) and buffers from 
New England Biolabs and digest conditions recommended by the supplier.  
 
Insert digest     Vector digest 
 
40 µl PCR product    5 µg pet28b vector 
5 µl EcoRI buffer    5 µl EcoRI buffer 
0.5 µl BSA (10 mg/ml)   0.5 µl BSA (10 mg/ml) 
1 µl BamH1     1 µl BamH1 
1 µl EcoRI     1 µl EcoRI 
Nuclease free water up to 50 µl  Nuclease free water up to 50 µl 
 
It is important to add the RE last to each digest reaction. 
 
Double digests were incubated at 37 
o
C for 90 minutes. Following the digest the RE 
were inactivated by incubating at 65 
o
C for 10 minutes. 
 
Following the double digestion the digest mix was loaded onto a 1 % agarose gel. The 
gel was viewed under UV light and the bands corresponding to digested insert and 
vector cut out and purified using the Qiagen Gel extraction kit. Purified DNA was 
eluted in 50 µl nuclease free water.  
 
2.3.4.4 Ligation of vector and insert 
 
Ligation of vector and insert was carried out using T4 DNA ligase (Promega), 




A standard amount of vector (100 ng) was used and the amount of insert required was 
calculated using the following formula: 
 
Insertng = Vectorng x Insert sixekb x Molar ratio of insert 
Vector sizekb       vector 
A 1:1 and 3:1 molar ratio of insert to vector was always tested.  
 
Ligation reactions were as follows: 
 
 1 µl ligase buffer (10x) 
 100 ng vector 
 X ng insert 
 1 µl T4 DNA ligase 
 Nuclease free water to 10 µl water 
 
Occasionally if the vector was not particularly concentrated the reaction would have a 
total volume of 20 µl to compensate for the volume of vector used.  
 
Ligation reactions were carried out at room temperature for 1 hour. Following which 
2.5 µl of the mix was transformed into DH5α competent cells and plated onto 
ampicillin containing LB agar plates. Colonies were selected and plasmid DNA 














Site directed mutagenesis 
 




Tag encoded by 
vector 
Primer 
(mutated nucleotides in red) 
Template 










































The PCR reaction was set up in nuclease free tubes using 2 x Pfu master mix 
(Rovalab) as follows: 
 
 25 µl 2x Pfu master mix 
 5 µl Band doctor (Rovalab) 
 20 ng template DNA 
 1 µl forward primer (20 µM stock) 
 1 µl reverse primer (20 µM stock) 
 Nuclease free water up to 50 µl 
 
Thermal cycling conditions: 
 
 Incubate at 95 oC for 2 minutes 
 Incubate at 95 oC for 1 minute 
 Incubate at 60 oC for 1 minute 
 Incubate at 72 oC for 5 minutes 
 Cycle to step 2 for 16 cycles 
 Incubate at 72 oC for 5 minutes 
 Hold at 4 oC forever 
 
Post PCR 1 µl DpnI (20000 U/ml, NEB) was added directly to each reaction tube and 
incubated at 37 
o
C for 1 hour. Dpn1 was inactivated after this time by incubating at 65 
o
C for 10 minutes.   
 
PCR reactions (2.5 µl) were transformed into DH5α competent cells and plated onto 
ampicillin containing LB agar plates. Colonies were selected and plasmid DNA 








2.4 Biochemical techniques 
 
2.4.1 Protein quantification 
 
Protein concentration was estimated in a number of ways. 1) Using Bradford’s 
reagent (Bio-Rad), following manufacturers instructions. Absorbance (595 nm) was 
measured using the victor 3 plate reader (Perkin Elmer). 2) Comparison against BSA 
concentration standards, run on a coomassie gel. 3) Quantification using a NanoDrop 
ND-1000 spectrophotometer, using the storage buffer of the protein to be quantified 




Polyacrylamide gels were prepared as described by Laemmli, using the recipes listed 
below and the Biorad Mini-PROTEAN® 3 Cell.  
The appropriate separating gel was cast and overlaid with isopropanol. The 
isopropanol acts in two ways, it levels out the top of the separating gel and prevents 
oxygen from reaching the gel, allowing the even polymerisation of the acrylamide. 
Once the separating gel had polymerised the isopropanol was removed and the 
stacking gel cast. Samples to be loaded were first mixed with sample buffer (2x) in a 
1:1 ratio and heated for 3-5 minutes at 90 
o
C. Prestained protein markers (Fermentas) 
were loaded and used as size markers. 
Gels were run at ~ 150 V for ~1 hour in running buffer (1x) and terminated once the 
dye front had reached the end of the gel.  
 
10 % separating gel    15 % separating gel  
 
30 % acrylamide mix 10 % (v/v)  30 % acrylamide mix  15% (v/v)  
1.5 M TRIS (pH 8.8) 0.39 M   1.5 M TRIS (pH 8.8) 0.39 M 
10 % (w/v) SDS 0.1 % (v/v)  10 % (w/v) SDS 0.1 % (v/v) 
10 % (w/v) APS 0.1 % (v/v)  10 % (w/v) APS 0.1 % (v/v) 
TEMED (v/v)  0.04 % (v/v)  TEMED (v/v)  0.04 % (v/v) 





30 % acrylamide mix  5 % (v/v)      
1 M TRIS (pH 6.8)  0.13 M     
10 % (w/v) SDS  0.1 % (v/v)     
10 % (w/v) APS  0.1 % (v/v)     
TEMED    0.1 % (v//v)     
H2O to final volume    
 
*Acrylamide mix (Protogel, National diagnostics) consists of 30 % acrylamide and 
0.8 % (w/v) bis-acrylamide. 
 
2X Sample Buffer     Running Buffer 
 
300 mM TRIS (pH 6.8)    192 mM glycine 
5 % (w/v) SDS     25 mM TRIS 
25 % (v/v) glycerol     0.1 % (w/v) SDS 
400 mM DTT 
bromophenol blue to desired colour 
 
2.4.3 Precast gel protocol 
 
All ubiquitination and discharge assay samples were run on precast gradient gels (4-
12 % Bis-Tris Gels, Invitrogen) in MOPS buffer (1x) (Invitrogen) and run at 180 V 
for ~60 minutes. 
 
 
2.4.4 Coomassie staining 
 
To detect proteins, after SDS-PAGE, by coomassie staining, the gels were submerged 
in coomassie blue stain (20 ml) for 10-20 minutes. The stained gel was then destained 
for 10 minutes, the destain was then removed, fresh added and the gels left to destain 
for as long as desired (2 hours-overnight). 
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The destained the gels were rinsed in water and dried using a heated vacuum gel drier 
(Gel master model 1426, Welche Rietschle Thomas). 
 
Stain       Destain 
 
50 % (v/v) methanol     7.5 % (v/v) methanol 
10 % (v/v) glacial acetic acid    10 % (v/v) glacial acetic acid 
0.2 % (w/v) coomassie brilliant blue R-250 
   
2.4.5 Immuno blotting 
 
Proteins separated using SDS-PAGE gels are transferred onto 0.2 µM nitrocellulose 
membrane (Protran, Schleicher and Schuell Biosciences). The transfer was carried out 
in tanks containing transfer buffer (1x) and an ice pack, to prevent overheating, at 100 
V for 1 hour or 30 mV overnight. Transfer apparatus supplied by Biorad. 
 
Following transfer the membrane was washed with Phosphate Buffered Saline (PBS) 
containing 0.1 % (v/v) TWEEN-20 (PBST), 3 washes at 5 minutes. The membrane 
was blocked with blocking buffer (3 % (w/v) (skimmed milk powder in PBST) for 30 
minutes. The membrane was incubated with primary antibody (table 6) in blocking 
buffer for 1 hour at room temperature, alternatively overnight at 4 
o
C, and then 
washed with PBST, as above. The membrane was incubated with horseradish 
peroxidise conjugated secondary antibody (1:1000, Dako) in blocking buffer for 1 
hour at room temperature, and again washed as above.  
 
Antibody signal was detected using enhanced chemiluminescence (ECL). Blots were 
overlaid with a fresh mix of ECL I and ECL II (1:1) for 1 minute, blotted to dry and 
exposed to Hyperfilm ECL (Amersham) for the desired period of time. Film was 
developed using a Konica medical film processor (model SRX-101A). 
 
1x Transfer Buffer    
192 mM glycine 
25 mM TRIS 
20 % (v/v) methanol 
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ECL I     ECL II 
 
100 mM TRIS (pH 8.5)  100 mM TRIS (pH 8.5) 
2.5 mM luminol   0.02 % (v/v) H2O2 
0.4 mM p-Coumaric acid 
 
2.4.6 Stripping nitrocellulose blots 
 
Antibodies were stripped from membranes in order that the same blot could be probed 
with different antibodies. The membranes were incubated with stripping buffer for 30 
minutes at room temperature with gentle agitation. Blots were thoroughly washed 
with PBST (3x 5 minutes), blocked with milk 3 % (w/v) /PBST, and then incubated 




62.5 mM TRIS (pH 6.8) 
2 % (w/v) SDS 
0.6 % (v/v) BME 
 
The primary antibodies mentioned in this thesis, alongside their supplier and working 














Antibody to Type Name Supplier Dilution 
His tag Mouse 
monoclonal 
Anti-his Novagen 1:1000 
FL MDM2  Mouse 
monoclonal 
3G5 Gift from B. Vojtesek 1:1000 
FL MDM2  Mouse 
monoclonal 
4B2 Gift from B. Vojtesek 1:1000 
MDM2 RING Mouse 
monoclonal 
2A10 Gift from B. Vojtesek 1:1000 
p53 Mouse 
monoclonal 







Table 2.5: Primary antibodies. Table showing all the primary antibodies, their source, and the 
dilution used at, throughout the course of my PhD. 
 
 
2.5 Protein expression and purification 
 
2.5.1 Purification of GST-tagged proteins 
 
An overnight culture (10 ml) of BL21-DE3 competent cells containing 
pGEx6MDM2-wt or pcDNA-MDM2ΔT was added to LB broth (1 L) containing 
ampicillin (100 µg/ml). The cells were incubated at 37 
o
C (220 rpm) until the OD600 
reached 0.4, protein expression was induced by the addition of IPTG (1 mM) and the 
culture incubated for a further 3 hours at 37 
o
C (220 rpm).  
 
The culture was centrifuged at 6000g for 15 minutes at 4 
o
C and the supernatant 
discarded. The pellet was resuspended in lysis buffer (20 ml lysis buffer per 1 L 
pellet), rapidly frozen in liquid nitrogen and stored at -80 
o
C. When required the pellet 
was thawed in a water/ice bath. Sucrose (10 % w/v), lysozyme (5 mg), DTT (5 mM), 
Benzamadine (1 mM) and protease inhibitor (PI) mix (1 ml) were added and the 
resuspended pellet lysed on ice for 30-45 minutes. The cells were sonicated (Soniprep 
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150 sonicator), 3x 15 seconds (amplitude 10 microns) with 30 second intervals on ice. 




The supernatant was filtered (22 µM Millex® Syringe-driven filter unit, Millipore) 
and mixed with glutathione-sepharose 4B beads (1 ml, 50 % slurry)  (Amersham GE), 
previously washed in sterile PBS (2x) and wash buffer (2x), and incubated for 1 hour 
at 4 
o
C on a rotating table.  
 
The mix was transferred to a 5 ml disposable column (MoBiTec) and left to empty by 
gravity, following which the beads were washed with wash buffer (4x 5 ml). GST 
tagged proteins were eluted from the column using elution buffer (10x 0.5 ml), 
benzamadine (1 mM) and pefabloc (40 µg/ml) were added, and the eluted fractions 




Lysis Buffer     Wash Buffer    
 
50 mM TRIS pH8    20 mM HEPES pH7.5  
150 mM NaCl     150 mM NaCl    
0.5 % (v/v) NP40    1 mM DTT    




25 mM HEPES pH 7.5 
1 mM DTT 
10 % (v/v) glycerol 
150 mM NaCl 









2.5.2 GST tag cleavage using PreScission Protease 
 
Full length MDM2 was expressed with a GST tag. The linker region contained a site 
recognised by PreScission Protease (GE healthcare). In instances where untagged 
protein was required the following protocol was used.  
GST tagged MDM2 was purified as described in ‘Purification of GST tagged 
proteins’ up to, and including, the wash step. The column was then washed with 
prescission buffer (0.5 ml) to equilibrate the beads. The column was capped and 
preScission buffer containing PreScission protease was added (40 µl in 0.5 ml). The 
column was left rotating at 4 
o
C overnight. The cleaved MDM2 was eluted by gravity, 






25 mM HEPES pH 7.5 
1 mM DTT 
10 % (v/v) glycerol 
150 mM NaCl 
 
2.5.3 Purification of his tagged proteins 
 









 or pet15b -UbcH5α 
was added to LB broth (1 L) containing ampicillin (100 µg/ml). In the case of 
UbcH5α glucose was added to the LB broth as described in ‘Bacterial cultures’. The 
cells were incubated at 37 
o
C (220 rpm) until the OD600 reached 0.4, protein 
expression was induced by the addition of IPTG (1 mM) and the culture incubated for 




The culture was centrifuged at 6000g for 15 minutes at 4 
o
C and the supernatant 
discarded. The pellet was resuspended in lysis buffer (20 ml lysis buffer per 1 L 
pellet), rapidly frozen in liquid nitrogen and stored at -80 
o
C. 
When required the pellet was thawed in an ice/water bath. Imidazole (20 mM), 
lysozyme (100 µg/ml) and protease inhibitor (PI) mix (1 ml) were added and the 
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resuspended pellet lysed on ice for 35-45 minutes. The cells were then sonicated 
(Soniprep 150 sonicator), 3x 15 seconds (amplitude 100 microns) with 30 second 





The centrifuged samples were filtered (22 µM Millex® Syringe drawn filter unit, 
Millipore) and mixed with Ni-NTA agarose beads (1 ml, 50 % slurry)  (Qiagen), 
previously washed in sterile lysis buffer (2x) and wash buffer I (2x), and incubated for 
1 hour at 4 
o
C on a rotating table.  
 
The mix was transferred to a disposable column (5 ml, MoBiTec) and left to empty by 
gravity. The beads were washed with wash buffer I (2x 5 ml) followed by wash buffer 
II (3x 5 ml). His tagged proteins were eluted from the column using elution buffer 
(10x 0.5 ml).  
 
In the case of UbcH5α the eluted fractions were aliquoted, rapidly frozen in liquid 
nitrogen and stored at -80 
o
C. In the case of all MDM2 RING proteins the eluted 




469 nM leopeptin 
1.5 nM aprotinin 
28.7 nM pepstatin 
5 nM soya bean trypsin inhibitor 
10 mM benzamadine 
20 mM pefabloc 









Lysis buffer      Wash buffer I 
 
20 mM Tris (pH8)     20 mM Tris (pH8) 
150 mM NaCl      150 mM NaCl 
0.1 % v/v NP40     0.1 % v/v NP40 
10 % v/v glycerol     10 % v/v glycerol 
10 mM MgCl2      10 mM MgCl2 
       20 mM imidazole 
 
 
Wash buffer      Elution buffer 
 
20 mM Tris (pH8)     20 mM Tris (pH8) 
150 mM NaCl      150 mM NaCl 
0.1 % v/v NP40     0.1 % v/vNP40 
10 % v/v glycerol     10 % v/v glycerol 
10 mM MgCl2      10 mM MgCl2   
40 mM imidazole     150 mM imidazole 
 
2.5.4 Buffer exchange 
 
MDM2 ring proteins had to be instantly buffer exchanged following protein 
purification to prevent their aggregation. 
 
The eluate was collected and subsequently exchanged into MDM2 buffer, using Zeba 
Desalt Spin Columns (Pierce), according to the manufacturers instructions. Once 
exchanged BME (5 mM) was added to the eluate which was aliquoted and stored 






50 mM tris, pH 7.5 
150 mM NaCl 
10 µM zinc 
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2.5.5 His-tag cleavage using free thrombin 
 
For the removal of the his tag from UbcH5α, thrombin (GE healthcare) digestion was 
performed following elution from the nickel column. 
 
The thrombin is supplied dry in 500U, this was dissolved in ice cold PBS (0.5 ml), 
aliquoted and stored at -20 
o
C. One unit theoretically cleaves 100 ng of protein in 16 
hours at room temperature. Add 10 cleavage units (10 µl) per mg of protein mix 
gently and incubate for 16 hours at room temperature. Cleavage and the purity of the 
protein can be confirmed by coomassie staining. 
 
2.5.6 UbcH5α purification in preparation for hydrogen-deuterium (HD) 
exchange   
 
In the previously outlined his purification method NP-40 was used as the detergent. 
This interferes with the HD exchange apparatus; the following method purifies His-
UbcH5α that is suitable for analysis by HD exchange.  
 
An overnight culture (10 ml) of BL21-DE3 cells containing pet15b -UbcH5α was 
added to LB broth (1 L) containing ampicillin (100 µg/ml), glucose was added to the 
LB broth as described in ‘Bacterial cultures’. The cells were incubated at 37 
o
C (220 
rpm) until the OD600 reached 0.4, protein expression was induced by the addition of 




The culture was centrifuged at 6000g for 15 minutes at 4 
o
C and the supernatant 
discarded. The pellet was resuspended in lysis buffer (20 ml lysis buffer per 1 L 
pellet), rapidly frozen in liquid nitrogen and stored at -80 
o
C. 
When required the pellet was thawed in an ice/water bath. Imidazole (20 mM), 
lysozyme (100 µg/ml) and protease inhibitor (PI) mix (1 ml) were added and the 
resuspended pellet lysed on ice for 35-45 minutes. The cells were then sonicated 
(Soniprep 150 sonicator), 3x 15 seconds (amplitude 100 microns) with 30 second 







The centrifuged samples were filtered (22 µM Millex® Syringe drawn filter unit, 
Millipore) and mixed with Ni-NTA agarose beads (1 ml, 50 % slurry)  (Qiagen), 
previously washed in CV sterile lysis buffer (2x) and  CV IMAC 5 (5x), and 
incubated for 1 hour at 4 
o
C on a rotating table.  
 
The mix was transferred to a disposable column (5 ml MoBiTec) and left to empty by 
gravity. The beads were washed with IMAC 5 (5x CV) followed by IMAC 5 + 
detergent (25x CV) then washed with IMAC 25 (5x CV). His tagged UbcH5α was 
eluted from the column using IMAC 150 (10x 0.5ml). The eluted fractions were 




Lysis Buffer     IMAC 5 
 
20 mM TRIS (pH8)    20 mM TRIS (pH8)  
150 mM NaCl     500 mM NaCl  
0.1 % (w/v) n-Dodecyl-β-D-maltoside 5 mM imidazole    
10 % (v/v) glycerol       
10 mM MgCl2 
 
IMAC 25     IMAC 25 + detergent 
 
20 mM TRIS (pH8)    20 mM TRIS (pH8) 
500 mM NaCl     500 mM NaCl 
25 mM imidazole    25 mM imidazole 
      0.5 % v/v Triton X-100 




20 mM TRIS (pH8) 
500 mM NaCl 




2.6 Biochemical Assays 
 
2.6.1 In vitro ubiquitination of p53 
 
This activity assay measures the ability of a protein/peptide to ubiquitinate p53 in 
vitro.  
 
Purified ubiquitin and Ubiquitin Activating Enzyme (UBE1) were from Boston 
Biochem, creatine phosphate (CP), creatine phosphokinase (CK) and ATP were from 
Sigma. 
UbcH5α (E2) was purified as described in ‘Purification of His tagged proteins’. p53 
was purified from E.coli by Kathryn Ball and Ted Hupp. 
 
Master mix (16 reactions) 
 
The master mix and separate ubiquitination reaction tubes are all assembled on ice. 
 
366 µl water 
10 µl 1 M HEPES (pH 8) 
2.4 µl 1 M MgCl2 
2 µl 10 % (v/v) Triton X-100  
0.2 µl 1 M DTT 
0.4 µl 1 M benzamadine 
6 µl 0.2 M ATP 
3.2 µl 10 mg/ml ubiquitin 
 
At this point the tube was gently mixed by inversion, and briefly centrifuged to 
remove any solution detained in the lid.  
 
12 µl 1 M CP 
2 µl 10 mg/ml CK 
 




0.7 µl 1 µg/µl UBE1 
1µl 1 mg/ml E2 




The tube was gently mixed by inversion and briefly centrifuged. 
 
The master mix was aliquoted into separate reactions (22 µl). There was always a 
control aliquot containing no E3 protein (or peptide). MDM2 proteins and/or peptides 
were titrated as desired. When peptides were used a DMSO only control was also 
present. The reactions were incubated in a waterbath at 30 
o
C for 15 minutes, on 
occasion the reaction was allowed to progress for 30 minutes. 
 
The reaction was terminated by the addition of sample buffer (2x). Sample buffer was 
used at a 1:1 ratio with the total reaction volume i.e. master mix plus peptide, protein 
etc. Samples (16 µl) were loaded onto a 4-12 % gradient NuPAGE gel (Invitrogen) 
and run in MOPS buffer (1x) before analysis via immunoblotting. 
 
2.6.2 In vitro discharge assay 
 
This activity assay measures the ability of a protein/peptide to facilitate the discharge 
of ubiquitin from E2.  
 
Purified components for this assay were either purchased or purified as described in 
the above method for ubiquitination of p53. 
 





                                                 
2
 The ratio of folded to unfolded p53 will vary with each batch purified. 40 ng/µl is total protein 
amount, both folded and unfolded.  A titration of p53 established quantity of p53 required for this assay 
from this specific batch.  
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Master mix (16 reactions) 
 
366 µl water 
10 µl 1 M HEPES (pH 8) 
2.4 µl 1 M MgCl2 
2 µl 10 % (v/v) Triton X-100  
0.2 µl 1 M DTT 
0.4 µl 1 M benzamadine 
15 µl 20 µM ATP 
3.2 µl 10 mg/ml ubiquitin 
 
At this point the tube was gently mixed by inversion, and briefly centrifuged to 
remove any solution detained in the lid.  
 
0.7 µl 1 µg/µl UBE1 
1 µl 1 mg/ml E2 
 
The tube was gently mixed by inversion and briefly centrifuged. 
 
The master mix was aliquoted into separate reactions (22 µl). The reactions were 
incubated in a waterbath at 30 
o
C for 5 minutes, in order for the E2 to become charged 
with ubiquitin by the UBE1, and then placed back on ice. 
 
Two controls exist for this assay; one contains no protein and/or peptide, to check for 
spontaneous discharge of ubiquitin from the E2. The second control has DTT added 
(1 µl, 1 M) to check for the presence of thioester and/or isopeptide bonds, thioester 
bonds are reversible by DTT. Protein and/or peptide was titrated into the remaining 
aliquots as desired. The reactions were incubated in a waterbath at 30 
o
C for 15 
minutes.  
 
The reaction was terminated by the addition of sample buffer (2x). Sample buffer was 
used at a 1:1 ratio with the total reaction volume i.e. master mix plus peptide, protein 
etc. Samples (16 µl) were loaded onto a 4-12 % gradient NuPAGE gel (Invitrogen) 
and run in MOPS buffer (1x) before analysis via immunoblotting. 
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2.6.3 Protein binding ELISA 
 









 and His-UbcH5α purified 
using the protocol outlined previously. Additionally ubiquitin purchased from Boston 
Biochem was also used in these assays.  
 
Purified protein (100 ng per well) was coated onto a Costar™ white 96 well plate 
(Fisher) in 0.1 M NaHCO3 (50 µl) overnight at 4 
o
C. The following day wells were 
washed with PBST (5x 200 µl, 0.1 % (v/v) TWEEN-20) and blocked with PBS (200 
µl) containing 3 % (w/v) BSA (PBS + BSA), for 1 hour at room temperature, with 
shaking.  The wells were then washed with PBST as described above. A titration of 
protein 2 was added to wells (the wells preincubated with protein 1) in PBS + BSA 
(50 µl) and incubated for 1 hour at room temperature, with shaking. The wells were 
then washed as described above and incubated with primary antibody (to protein 2) 
diluted in PBS + BSA (50 µl) for 1 hour at room temperature, with shaking. The wells 
were washed as above then incubated with HRP-conjugated secondary antibody 
diluted in PBS + BSA (50 µl) for 1 hour at room temperature, with shaking. The wells 
were washed for a final time, as described above, and protein-protein binding was 
detected by electrochemical luminescence (50 µl ECL per well) and quantified using 
a luminometer (Labsystems Fluroscan Ascent FL).    
 
2.6.4 Peptide binding ELISA 
 
Streptavidin (1 µg per well) was coated onto a Costar™ white 96 well plate (Fisher) 
in water (50 µl) overnight at 37 
o
C. The following day wells were washed with PBST 
(5x 200 µl, 0.1 % (v/v) TWEEN-20) and then incubated with biotin tagged peptide, 
enough to saturate the streptavidin (500 ng per well), in water (50 µl). The wells were 
washed as above and blocked with Pierce Protein-Free Blocking Buffer (200 µl, 
Thermo Scientific), for 1 hour at room temperature, with shaking.  The wells were 
then washed with PBST as described above. A titration of the protein of interest was 
added to wells (the wells preincubated with peptide) in Pierce Protein-Free Blocking 
Buffer (50 µl) and incubated for 1 hour at room temperature, with shaking. The wells 
were then washed as described above and incubated with primary antibody diluted in 
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Pierce Protein-Free Blocking Buffer (50 µl) for 1 hour at room temperature, with 
shaking. The wells were washed as above then incubated with HRP-conjugated 
secondary antibody diluted in Pierce Protein-Free Blocking Buffer (50 µl) for 1 hour 
at room temperature, with shaking. The wells were washed for a final time, as 
described above, and peptide-protein binding was detected by electrochemical 
luminescence (50 µl ECL per well) and quantified using a luminometer (Labsystems 
Fluroscan Ascent FL).    
 
2.6.5 Competition ELISA 
 
This ELISA was designed to investigate the inhibitory effect of certain peptides on 
protein-peptide binding.  
 
The assay was carried out in a similar manner to the peptide binding ELISA detailed 
above, except that a fixed amount of protein was incubated with a titration of 
inhibitory peptide, in 0.1 M NaHCO3 (50 µl) for 10 minutes at room temperature  
before titration onto the plate coated with a fixed amount of peptide 1.  
 
2.6.6 Protein-peptide-protein ELISA 
 
This ELISA was designed to investigate the interaction of two proteins with one 
peptide simultaneously.  
 
Purified protein 1 (100 ng per well) was coated onto a Costar™ white 96 well plate 
(Fisher) in 0.1 M NaHCO3 (50 µl) overnight at 4 
o
C. The following day wells were 
washed with PBST (5x 200 µl, 0.1 % (v/v) TWEEN-20) and blocked with Pierce 
Protein-Free Blocking Buffer (200 µl) for 1 hour at room temperature, with shaking. 
Peptide was added (500 ng per well) to the wells and incubated for 1 hour at room 
temperature, with shaking. The wells were then washed with PBST as described 
above. A titration of protein 2 was added to wells (the wells preincubated with protein 
1 and peptide) in Pierce Protein-Free Blocking Buffer (50 µl) and incubated for 1 
hour at room temperature, with shaking. The wells were then washed as described 
above and incubated with primary antibody (to protein 2) diluted in Pierce Protein-
Free Blocking Buffer (50 µl) for 1 hour at room temperature, with shaking. The wells 
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were washed as above then incubated with HRP-conjugated secondary antibody 
diluted in Pierce Protein-Free Blocking Buffer (50 µl) for 1 hour at room temperature, 
with shaking. The wells were washed for a final time, as described above, and 
protein-peptide-protein binding was detected by electrochemical luminescence (50 µl 





The AlphaScreen® is a sensitive bead-based proximity assay for the measurement of 
protein interactions. Low affinity interactions that can be difficult to measure using 
traditional binding assays can be assessed by AlphaScreen. There are a variety of 
beads to mix and match depending on the interaction to be studied. I used donor 
glutathione beads, as MDM2 had a GST tag, and Protein A beads preincubated with 
anti-his as UbcH5α had a His-tag. 
 
The required area of a Costar™ white 96 well plate (Fisher) was blocked using 
dilution buffer (100 µl per well) for 1 hour at room temperature. The required amount 
of Donor beads (20 µl per well) were diluted 1:100 in dilution buffer, a titration of the 
first interacting protein was added to the diluted beads and incubated for 1 hour at 
room temperature in the dark. The amount of light the beads are exposed to should be 
kept to a minimum otherwise the final signal will be affected, pipette and incubate in 
the dark. 
The required amount of Protein A beads (20 µl per well) were diluted 1:100 in 
dilution buffer, antibody specific for the second interacted protein was added and as 
before the mix incubated for 1 hour at room temperature in the dark. As a general rule 
an antibody used at 1:1000 in a protein binding ELISA works well at 0.05 µl per well 
in an AlphaScreen. 
Following incubation Donor beads (20 µl); Protein A beads (20 µl) and second 
interacting protein (10 µl) were added to each well. The plate was wrapped in foil and 
incubated for 1 hour, with shaking.  
Protein binding was detected by an Envision™ 2101 Multilabel Reader (Perkin 
Elmer). Fluorescence intensity was measured by using excitation wavelengths of 680 






50 mM Hepes pH 8 
150 mM NaCl 
0.5 % (w/v) BSA 
0.05 % (v/v) TWEEN 20 
 




This experiment is set up in duplicate on two separate plates to analyse the data when 
comparing fast washes and slow washes. The first steps are simultaneous. 
 
Purified protein (100 ng per well) was coated onto a Costar™ white 96 well plate 
(Fisher) in 0.1 M NaHCO3 (50 µl) overnight at 4 
o
C. To analyse and compare page 
binding to protein peptide/ligand complexes the protein was pre incubated with 
peptide/ligand for 5 minutes at room temperature before adding 0.1 M NaHCO3 (50 
µl) and coating onto the plate. 
 
The following day wells were washed with Tris buffered saline containing (3x, 0.1 % 
(v/v) TWEEN-20 (TBST) and then blocked with Tris buffered saline (TBS, 200 µl) 
containing 3 % (w/v) BSA. The phage (Ph.D™-12 phage display library, New 
England Biolabs) was added to wells (4 µl in 96 µl TBST), to those wells containing 
the protein peptide/ligand complex peptide/ligand was added at the same 
concentration that was used to coat the plate (4 µl phage library, x µl peptide/ligand, 
100 µl-4 µl-x µl TBST). For the fast wash data the wells of one plate were washed 
with TBST (10x 200 µl). The phage was eluted with 0.2 M glycine-HCl pH2.2 (100 
µl) containing BSA (1 mg/mg) for 15 minutes at room temperature with rocking. It is 
important that this step is not allowed to progress past 15 minutes. The eluted phage 
was transferred to a fresh eppendorf and 1M Tris-HCl (15 µl) was added to neutralise 
the phage solution. It is important that this neutralisation is carried out immediately. 
The eluted phage was then stored at 4 
o
C.  For the slow data wells were washed with 
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TBST (6x 200 µl), 5 minutes per wash. In the wells that contained the protein 
peptide/ligand complex, peptide, at the same concentration used in the coating step, 
was added to the TBST wash. Following the washes the phage were eluted and 
neutralised as before. An overnight was set up with ER2738 cells (New England 
Biolabs) in LB (10 ml) containing tetracycline (1 µg/µl) at 37 
o
C, 220 rpm.  
 
The overnight culture was diluted 1:200 in LB (20 ml) and grown for 1 hour at 37 
o
C, 
220 rpm. It was then inoculated with the eluted phage (100 µl) and incubated for 4.5 
hours at 37 
o
C, 220 rpm. The culture was centrifuged for 10 minutes, 12000g, 4 
o
C 
and the supernatant transferred to a fresh tube and centrifuged for 10 minutes, 
12000g, 4 
o
C. The top 80 % of supernatant was transferred to a fresh tube and 20 % 
(w/v) PEG/2.5 M NaCl was added (1/6 of the supernatant volume) to precipitate the 
phage, the phage was precipitated overnight at 4 
o
C.In preparation of the second 
round the following day, purified protein (100 ng per well) was coated onto a 
Costar™ white 96 well plate (Fisher) in 0.1 M NaHCO3 (50 µl) overnight at 4 
o
C. If 
protein peptide/ligand complexes were examined they too were coated onto plates as 
detailed above. As above the plates were set up in duplicate. 
 
The following day the PEG solution was spun for 15 minutes, 12000g, 4 
o
C and the 
supernatant discarded, the tube was left upside down to drain for 10 minutes. The 
pellet was resuspended in TBS 200 µl, transferred to an eppendorf and centrifuged for 
5 minutes, 13000 rpm, 4 
o
C. The supernatant was transferred to a new tube, and the 






Round 2 was carried out following the method for round one, except, instead of 
adding phage library to the wells, amplified phage (10 µl in 100 µl total volume in 










Both the eluted and amplified phage sequences from rounds 1 and 2 were amplified 
by PCR and sent for sequencing.    
 
 The PCR reaction was set up in nuclease free tubes as follows: 
 
 5 µl 5 M bertaine 
 10 µl 5x herculase II buffer 
 5 µl  132 mM trehalose 
 2.5 µl 10 mM dNTP 
 1 µl 100 mM reverse primer 
 1 µl herculase II enzyme 
 1 µl forward primer 
 10 µl phage 
 Nuclease free water to 50 µl 
 
Thermal cycling conditions were as follows: 
 
 Incubate at 95 oC for 60 seconds 
 Incubate at 95 oC for 15 seconds 
 Incubate at 55 oC for 20 seconds 
 Incubate at 70 oC for 60 seconds 
 Cycle to step 2 for 30 cycles 
 Incubate at 70 oC for 210 seconds 
 Hold at 4 oC forever 
 
2.6.9 Enzymatic protein digest 
 
UbcH5α (12-20 µg), purified as described above, and peptide 8 (5 µg) were 
preincubated for 10 minutes at room temperature. Trypsin (0.5 mg/ml, Roche), 
glutamine-C (0.5 mg/ml, Roche) or arginine-A (0.5 mg/ml Roche) was added (1:50 
(w/w) and the reaction mix incubated at 4 
o
C or 30 
o
C for 0-30 minutes. The reaction 
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was terminated at certain time points (0, 5, 10, 15 and 30 minutes) by the addition of 
SDS sample buffer (1x) containing DTT (1:4) and heating for 3 minutes at 80 
o
C. The 
samples (total reaction volume) were loaded onto an agarose gel (15 %) and digestion 
products were visualised by coomassie staining.       
 
2.7 Biophysical assays 
 
2.7.1 Gel filtration 
 
Gel filtration was carried out using a Superdex 200 10/300 GL column (GE 
Healthcare Life Sciences). The column was equilibrated with MDM2 buffer and 
proteins were run through the column using this buffer, The manufacturers manual for 
the column was followed for standard column operating procedure and the RING 




50 mM tris, pH 7.5 
150 mM NaCl 
10 µM zinc 
5 mM BME 
 
2.7.2 In gel enzymatic digestion of protein samples for mass spectrometry 
analysis 
 
Coomassie stained protein bands were excised from the gel. Washed twice with 
deionised water and, if large, were cut into smaller pieces using a sterile pipette tip. 
Washing and hydration buffer (250 µl) was added and samples incubated at 30 
o
C for 
20 minutes to destain. The supernatant was removed; equilibration and cleavage 
buffer (250 µl) was added to the samples and incubated at 30 
o
C for 30 minutes before 
the supernatant was removed. In the case of insufficient destaining the washing and 




The gel slices were dried by the addition of 100 % acetonitrile (100 µl), incubated at 
room temperature for 10 minutes, and then removed. 
 
Trypsin (0.25 µl, 0.2 µg/µl, Roche) was mixed with equilibration and cleavage buffer 
(5 µl), added directly to each gel sample and cultivated at 4 
o
C for 20 minutes. 
Alternatively chymotrypsin (0.25 µl, 0.4 µg/µl, Roche) was mixed with 100 mM 
TRIS pH 8 (5 µl), added directly to each gel sample and cultivated at 4 
o
C for 20 
minutes. From here on the method is identical regardless of which enzyme was used.  
Equilibration and cleavage buffer (40 µl) was added to completely submerge the gel 
piece and the samples incubated overnight at 37 
o
C. The digestion was terminated by 
the addition of 2 % (v/v) trifluoroacetic acid (TFA) (5 µl) in 98 % (v/v) acetonitrile to 
acidify the sample solution. The supernatant was transferred to a new eppendorf and 
the sample was dried using a speed vacuum. This could be stored at -20 
o
C before 
commencing the purification of the peptides for mass spec analysis.   
 
 
Washing and rehydration buffer pH 7.8 Equilibration and cleavage buffer pH 7.8 
 
200 mM ammonium bicarbonate  50 mM ammonium bicarbonate 
40 % (v/v) acetonitrile   5 % (v/v) acetonitrile 
 
2.7.3 Peptide purification for mass spectrometry 
 
Peptides were purified using a C18 MicroTrap™ (MICHROM Bioresources, Inc.) 
column. 
 
The dry peptides were dissolved in equilibration buffer (100 µl). The column was first 
washed with wash buffer (5x 25 µl) then equilibrated with equilibration buffer (5x 25 
µl). The entire sample was loaded onto the column and any salts eluted with 
equilibration buffer (5x 25 µl). Peptides were eluted from the column using elution 
buffer (3x 25 µl), and the column washed with wash buffer (5x 25 µl). The peptide 







Wash Buffer     Equilibration Buffer 
 
90 % (v/v) acetonitrile   0.4 % (v/v) TFA  




50 % (v/v) acetonitrile 
0.4 % (v/v) TFA  
 
2.7.4 Hydrogen -deuterium exchange 
 
UbcH5α (4 µM) was prepared in H2O (control) and D2O for set time intervals (1, 2, 5, 
10, 30, 60 and 180 minutes) before the exchange was terminated by quenching with 
Trifluoroacetic acid. 
 
UbcH5α and peptide 1 (control) or peptide 8 were incubated (molar ratios 1:1, 1:10 
and 1:100, E2:peptide) at room temperature (30 minutes) to allow for complex 
formation. The samples were then prepared for exchange as for UbcH5α. 
 
The samples were measured on the Orbitrap Elite mass spectrometer connected to HD 
robot and liquid chromatography.  HD exchange analysis was done in MS mode in 
orbitrap analyser with 120 000 resolution. Two different fragmentation methods were 
applied, collision induced dissociation (CID) and higher-energy collisional 
dissociation (HCD) and peptide mapping was measured in MSMS mode with data 
dependant analysis (TOP3).  
 
2.7.5 Thermal denaturation 
 
Protein denaturation was measured by fluorescent SYPRO Orange Dye (Invitrogen). 
The stock (5000X) was diluted to a concentration of 50X, using buffer A and used at 




Ubiquitin (Bosten Biochem) was re-dissolved in sterile water (10 mg/ml) and diluted 
to concentrations between 2.5-10 µM with buffer A. If required, guanidine was added 
to the ubiquitin samples at concentrations between 0-4 M, with 0.5 M increments. 
Following the addition of SYPRO orange final sample volumes were made up to 50 
µl with buffer A. 
 
UbcH5α, purified as described in the methods above, was diluted to concentrations 
between 1.25-5 µM with buffer A. If required peptide 8 was added to UbcH5α (5 µM) 
samples at molar ratios of UbcH5α to peptide 8 between 1:1.25-1:10. DMSO was 
added to bring the final percentage of DMSO in the sample up to 2 %.  
Following the addition of SYPRO orange final sample volumes were made up to 50 
µl with buffer A. 
 
Samples were aliquoted onto a 96 well PCR plate and sealed with optical quality 
sealing film (Bio-Rad). The plate was centrifuged at 100g for 2 minutes at 21
o
C to 
ensure that no bubbles were present in the samples. Protein denaturation was 
measured using an iCycler iQ Real Time PCR system (Bio-Rad) by heating the 
samples from 20-90 
o
C at 1 
o
C increments, with 30 second incubations at each 
increment. Fluorescence intensity was measured using excitation wavelengths of 485 
nm and emission wavelengths of 575 nm in RFU.  
 
Buffer A pH 8 
 
150 mM Hepes  











Chapter 3: RESULTS 
 




As previously described MDM2 is a RING E3 ligase. At the start of my PhD a 
number of facts were known concerning the RING domain of MDM2. Firstly it has a 
12 amino acid C-terminal tail; this free tail is not seen in all RING domains. The tail 
of MDM2 is critical for E3 ligase activity though it is not conclusively shown why. 
One suggestion for the role of the tail was it having a role in dimerisation, with a 
dimer being necessary for MDM2 E3 activity
141
. Secondly the MDM2 RING is the 
only RING protein to contain an ATP binding site within its RING domain
136
. The 
reason for this difference and the relevance to MDM2 activity it may have is 
unknown. Finally the RING contains a unique sequence for the coordination of two 
zinc ions
130
. It is possible that the novel coordination has more significance than is 
currently realised.     
 
 RING E3 ligases are widely thought to act as a scaffold, contacting their target 
substrate, and E2 charged with ubiquitin, before catalysing the transfer of ubiquitin 
from the E2 to the target. The mechanism of ubiquitin transfer is universally unclear 
across the range of E2:E3 binding partners. 
 
In 1994 a novel human E2 was identified, it was highly similar to yeast UB4 and 
UB5, so was named UbcH5. As with all identified E2 proteins it contained a 
conserved active site cysteine
217
.Discovery of two related human E2 proteins with 89 
% similarity to UBCH5 resulted in it being subsequently named UbcH5α
218
. 
Interestingly this family of UbcH5 proteins were closely related to Saccharomyces 
cerevisiae UB4 and UB5, these yeast E2 proteins are involved in the stress response 
and target regulatory proteins for degradation
219
. One study identified that MDM2 
was an E3 ligase for p53 and that the E2 protein required for successful ubiquitination 













. A study into another 
binding partner of UbcH5α, u-Cbl, indicates a consensus E2:E3 contact surface, this 
predicted a contact area is ~15Å away from the active site cysteine of E2. This study 
claims that the interaction between UbcH5 and the RING domain is a low affinity 
interaction and therefore cannot be detected in pull down assays. They mutated 
hydrophobic residues within the RING that they concluded to be important based on 
the E2:E3 binding consensus sequence and they used changes in E3 activity as a test 
for E2 binding
34
. It has not been shown that UbcH5α can bind the RING in solution, 
so how is it possible to conclude that mutating certain residues results in a loss of E2 
binding? Mutating certain residues certainly may affect E3 activity but this could be 
due to an affect other than E2 binding.  
 
In the case of MDM2 understanding the mechanism of UbcH5α recruitment and 
binding is a particular problem, as the interaction is reported to be very unstable
220
, 
this is similar to the low affinity for UbcH5α
137




1) Is MDM2 able to form a stable, isolatable complex with UbcH5α and if so 
which RING domain amino acids are required for UbCh5α binding? 
 
2) Previous studies have suggested that MDM2 constructs in which the tail has 
been deleted are inactive as E3 ligases. 
 
a. How does the tail impact on RING activity? 










3.1.2 Purification of recombinant MDM2 
 
To study the interaction of MDM2 with ubiquitination pathway components I first 
cloned and purified various MDM2 proteins. The literature states that the RING is the 
domain responsible for E3 activity and that the 12 amino acid C-terminal tail is 
critical for this activity
133
. This led me to ask, what is the role of the tail in E3 
activity? Does the loss of the tail result in loss of binding to certain ubiquitination 
components and does this result in a loss of activity? To investigate these questions I 
first wished to set up a number of in vitro assays that required purified MDM2. 
MDM2 was cloned and expressed in both a full length form and as an isolated RING; 
in both cases the constructs were made with and without the 12 amino acid tail 
(figure 3.1). 
 
Expression trials were carried out in order to determine the bacterial growth 
conditions for optimum expression of soluble MDM2 protein. As well as the 
commonly used LB broth 2x TY media and autoinduction media were trialled. The 2x 
TY media is simply a variation of LB broth. Autoinduction media is formulated to 
grow IPTG inducible strains of E.coli., initially without induction, and then induce 
production of the target protein automatically, usually when cell density is high. Trace 
elements are also added to autoinduction media, the trace metals can potentially 
increase the yield of protein and/or correctly folded protein. 
 
Three E.coli cell lines were tested in the trials. BL21 (DE3) is a common strain used 
for the expression of recombinant proteins within a T7 promoter based plasmid, when 
the proteins expressed are non-toxic to the bacteria. The BLD1 (DE3) STAR cells 
have the same properties as the BL21 (DE3) strain but also contain a genotype that 
promotes high mRNA stability and protein yield. The final strain tested was C41 
(DE3); this strain is derived from BL21 (DE3) but contains a mutation which prevents 
cell death associated with toxic recombinant proteins.  
 








Figure 3.1: Schematic diagram showing the features of the four original MDM2 constructs. a) 
Full length MDM2 (FL MDM2) b) Full length MDM2 delta tail (MDM2ΔT) c) Extended RING 
domain of MDM2 (FL RING) d) Extended RING domain of MDM2 delta tail (RING ΔT). NLS- 








The optimum temperature for E.coli growth is 37 
o
C, they can tolerate lower 
temperatures though rate of growth will be slower. Growing E.coli at lower 
temperatures however can produce more soluble folded proteins; cells were therefore 




Each E.coli strain was grown in each media at each temperature (data not shown). 
Although a high yield of protein is desirable should it be too high it can accumulate in 
insoluble inclusion bodies within the E.coli.  
BL21-DE3 cells showed the best results, they produced much more soluble MDM2 
protein when compared to the other strains. The main considerations were which 
media and temperature to use (figure 3.2). When grown in LB media the BL21-DE3 
cells look to promote less degradation of MDM2, within the soluble fraction, than 
when grown in autoinduction media (figure 3.2a, lane 4 and figure 3.2b, lane 5). 
There appears to be less degradation of MDM2 protein, within the soluble fraction, 
when grown and induced at 20 
o
C compared to 37 
o
C (figure 3.2b lanes 1 +5) 
however there was a greater ratio of soluble protein at 37 
o
C when compared to 20 
o
C 
(figure  3.2b lanes 1 +5). The levels of degradation of MDM2 are not greatly reduced 
when grown at 20 
o
C, not enough to make a significant difference, especially when 
compared to the actual soluble protein levels when grown at 37 
o
C. All this taken into 




Optimum induction time, following addition of IPTG, varies from protein to protein. 
A couple of hours can be enough for proteins that are highly expressed, for proteins 
with lower expression levels induction may need to proceed for much longer. 
Interestingly, Interferon regulatory factor 1 (IRF1) a transcriptional activator or 
repressor of a wide variety of target genes, degrades very rapidly if left to induce for 
even a short period of time. Induction carried out for 30 minutes is the best 












Figure 3.2: Cell expression trials for full length MDM2. a) BL21 (DE3) cells were grown in 
autoinduction media at 20, 30 and 37 
o
C until the OD ~0.4, they were then induced with IPTG for 3 
hours. Western blot shows protein present in the soluble and insoluble fractions. b) BL21 (DE3) cells 
were grown in LB media at 20, 30 and 37 
o
C until the OD ~0.4, they were then induced with IPTG for 
3 hours. Western blot shows protein present in the soluble and insoluble fractions.  c) BL21 (DE3) cells 
were grown in LB media at 37 
o
C until the OD ~0.4, following induction by IPTG, samples (5ml) were 
taken at indicated time points.  Western blot shows the time course of protein production. 16µl of each 
sample loaded onto all gels. All blots probed with 2A10 (1:1000). S- soluble, IS- insoluble. Fermentas 
PageRuler Prestained Protein Ladder used for molecular weight maker, all molecular weights displayed 











With this in mind I carried out a time course to see where MDM2 fell on the induction 
time scale. Small samples (5ml) of the induced culture were removed at 30 minutes, 
1, 2, 3 and 4 hours, the cells were then lysed and the soluble fraction analysed by 
SDS-PAGE and immune blotting (figure 3.2c). MDM2 expression and protein levels 
continue to increase up to 3 hours after induction (figure 3.2c, lanes 1-5), if left for 4 
hours protein levels begin to fall and more degradation products begin to appear 
(figure 3.2c, lane 6). For MDM2 3 hours is the optimum time for induction. 
It is worth noting that the antibody used to probe the immunoblots shown in figure 
5.2 was 2A10. Whilst there is likely to be some degradation products of MDM2, it is 
unlikely  
to be as much as the immunoblots imply. 2A10 has a high background, this could be 
because it recognises at least two short epitopes in MDM2
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. If these blots were to be 
repeated a different antibody may well produce a cleaner outcome.  
 
When cloning full length MDM2, or indeed any protein, certain consideration has to 
be given to the tag.  A Post-doctoral colleague in the Ball lab was trying to purify 
untagged MDM2 and was encountering a number of problems, including very low 
protein expression and yield; bearing this in mind I cloned MDM2 with a cleavable 
tag. 
When choosing between a His and GST-tag there are a number of factors to consider. 
The size of these two tags tag vary greatly, the His tag is ~1kDa compared to the 
~26kDa of GST. The His tag can be advantageous as its small size means that his is 
unlikely to be contributing to affects seen in biochemical assays. The GST-tag does 
however have its own advantages, it is very soluble and can help keep a protein in 
solution if it is less than inclined to do so. 
As the literature does not indicate that MDM2 is particularly insoluble, I chose to 
clone MDM2 with a His tag, primarily chosen due to its small size.  
 
With expression trials complete the next step was to purify his-MDM2. The result of 
the purification was not as predicted (figure 3.3a and b) as the majority of the protein 
was in the flow through and washes (figure 3.3a, lanes 2,3 and 5 and 3.3b, lanes 2-
5). There was some protein in the elution but the amount is not comparable to the 





Figure 3.3: Purification of FL MDM2 and MDM2 ΔT. a) BL21 (DE3) cell pellet was lysed on ice, 
centrifuged and the resultant supernatant purified on a nickel column. Western Blot shows the mobility 
of His-tagged MDM2 b) BL21 (DE3) cell pellet was lysed on ice, centrifuged and the resultant 
supernatant purified on a nickel column. Western Blot shows the mobility of His-tagged MDM2 c) 
BL21 (DE3) cell pellet was lysed on ice, centrifuged and the resultant supernatant purified on a nickel 
column. The flow through was reloaded onto a second nickel column. Western Blot shows the mobility 
of His-tagged MDM2 eluted from the second nickel column d) BL21 (DE3) cell pellet was lysed on 
ice, centrifuged and the resultant supernatant denatured with 4M urea before being applied to a nickel 
column. Western Blot shows the mobility of His-tagged MDM2 e) BL21 (DE3) cell pellet was lysed on 
ice, centrifuged and the resultant supernatant purified on a Glutathione sepharose column. Western Blot 
shows the mobility of GST-tagged MDM2 f) Coomassie stained SDS-PAGE gel showing GST-tagged 
FL MDM2 and MDM2 ΔT following purification on glutathione sepharose beads. Blots 3a + e were 
probed with 3G5, blots 3b, c + d were probed with 2A10. L- load, FT- flow through, WI- wash I, WII- 
wash II, WIII- wash III, E- elution, FL- FL MDM2, ΔT- MDM2 ΔT. Fermentas PageRuler Prestained 
Protein Ladder used for molecular weight maker, all molecular weights displayed are in kDa.  
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It was possible that the amount of MDM2 protein was simply too high for it all to 
bind to the beads however reloading the flow through onto a fresh column did not 
result in increased protein binding, once again the majority of protein was in the flow 
through and the washes (figure 3.3c). These results indicate that the MDM2 protein is 
having some difficulty binding to the column. A possible explanation for this is that 
the His tag is cryptic i.e. the MDM2 protein has folded in such a way that it is 
obscuring the His tag and preventing it binding to the nickel. To test this the MDM2 
was unfolded by pre-incubating the load with 4M urea (figure 3.3d), this urea treated 
protein was more capable of binding the column with minimal protein appearing in 
the flow through, although some is released in early washes, possibly due to weak 
interactions, and the rest was eluted in the presence of increased imidazole (figure 
3.3d, lane 2, 3 and 6). As I wished to assay MDM2 activity I did not want to use 
renatured protein, I therefore re-cloned MDM2, this time with a cleavable GST-tag. 
Full expression trials were not carried out as before, instead the optimum conditions 
previously identified were used as a starting point with a view to changing them 
should there be a problem, which there was not (data not shown). The GST-tag was 
not cryptic and FL MDM2 and MDM2ΔT both purify well (figure 3.3e and f).   
 
Alongside cloning of full length constructs of MDM2 shorter constructs containing 
the RING domain of MDM2 were also cloned (figure 3.1). A former PhD student had 
cloned two RING constructs, containing 41 (438-479) or 53 (438-491) amino acids; 
however these constructs proved to be highly unstable. Researchers in a different 
laboratory, with whom the Ball group collaborate, had been having more success with 
a longer RING domain construct. Using this information two RING domain 
constructs were cloned that contained not only the RING domain but an extra 116 
amino acids, beginning just after the zinc finger of MDM2 at residue 322. As with the 
full length MDM2 constructs the RING was cloned both with and without the 12 
amino acid tail critical for E3 activity (FL RING and RING ΔT) (figure 3.1c and d). 
 
To optimise expression of the RING constructs BL21 (DE3) cells were grown and 
induced in LB media at a range of temperatures (20, 30 and 37 
o
C). The greatest level 
of protein expression was seen at 37 
o
C (figure 3.4a and b, lanes 7). 
The RING constructs were cloned with a His tag and unlike the full length constructs 
the tag was not cryptic, and purification by nickel beads proceeded as expected 
98 
 
(figure 3.4c and d). Some protein was seen in the flow through and washes but there 
was much higher amounts in the elution fractions. It is possible that there was simply 
too much protein to bind the nickel beads. For all subsequent purifications a greater 
volume of beads was used.  
 
Protein is routinely rapidly frozen in liquid nitrogen and stored at -80 
o
C for 
biochemical research however when the RING was stored this way it rapidly formed 
higher order structures and aggregates (figure 3.4e). This affect was especially seen in 
FL RING (figure 3.4f) where the effect could be seen immediately. The RING 
constructs were therefore stored at -20 
o
C, no higher order structures or aggregates 





























Figure 3.4: Expression and purification of MDM2 RING constructs. a) BL21 (DE3) cells were 
grown in LB media at 20, 30 and 37 
o
C until the OD ~0.4, they were then induced with IPTG for 3 
hours. Western blot shows RING ΔT.  b) BL21 (DE3) cells were grown in LB media at 20, 30 and 37 
o
C until the OD ~0.4, they were then induced with IPTG for 3 hours. Western blot shows FL RING. c) 
BL21 (DE3) cell pellet was lysed on ice, centrifuged and the resultant supernatant purified on a nickel 
column. Western Blot shows the mobility of His- tagged RING ΔT.  d) BL21 (DE3) cell pellet was 
lysed on ice, centrifuged and the resultant supernatant purified on a nickel column. Western Blot shows 
the mobility of His-tagged FL RING. e) Coomassie stained SDS PAGE gel showing His-tagged RING 
ΔT 
and
 FL RING following storage at -80 
o
C. f) Coomassie stained SDS-PAGE gel showing His-tagged 
RING ΔT and FL RING following storage at -20 
o
C. Blots were probed with 2A10. FT- flow through, 
WI- wash I, WII- wash II, WIII- wash III, E- elution, ΔT- RING ΔT
 
, FL- FL RING. Fermentas 
PageRuler Prestained Protein Ladder used for molecular weight maker, all molecular weights displayed 




3.1.3 E3 ligase activity of MDM2 
 
The literature states that MDM2 is an E3 ligase specific for p53 and that without the 
presence of the C-terminal 12 amino acid tail E3 ligase activity is lost
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. The 
consensus is that the tail is crucial for the E3 ligase activity of MDM2; however the 
reason(s) as to why it is critical remain elusive. 
 
I initially carried out activity assays to test that the purified proteins were folded 
correctly and working as predicted from the literature. The first assay used to test for 
protein activity was a substrate ubiquitination assay. In this assay all the components 
of the ubiquitination cascade are present and the reaction is started by the addition of 
E3 ligase. This ubiquitination assay has been optimised so that the E3 ligase is the rate 
limiting factor, if ubiquitination is not seen it is due to some property of the ligase and 
not any other component of the reaction. Contrary to what is seen in the literature my 
ubiquitination assay is a stopped enzyme assay, it is not permitted to run to 
completion. This is because I was interested in what factors could affect the rate of 
ubiquitination (Vmax). Assuming that all components are active and are at the correct 
ratio to each other, the E3 ligase should ubiquitinate the target, this ubiquitination can 
be in the form of mono ubiquitination, multi monoubiquitination and/or 
polyubiquitination and can be detected by immunoblotting (figure 3.5a) 
 
The results show that FL MDM2 was able to ubiquitinate p53 and is therefore active 
as an E3 ligase (figure 3.5b, lanes 6-8), conversely MDM2 ΔT was not able to 
ubiquitinate p53 and is inactive as an E3 ligase in his assay (figure 3.5b, lanes 3-5). 
This result was predicted based on the literature but does prove that the protein has 
been folded correctly.  FL RING was able to ubiquitinate p53 and therefore is active 
as an E3 ligase (figure 3.5c, lanes 6-8), again this was predicted based on the 
literature but this result confirms that this specific RING construct behaves similarly 
to FL MDM2 in terms of E3 activity. RING ΔT was not able to ubiquitinate p53 and 
is inactive as an E3 ligase (figure 3.5c, lanes 3-5); this construct behaves in a manner 









Figure 3.5: Ubiquitination of p53 by MDM2. a) Schematic diagram showing components and 
methods of a ubiquitination assay. The blue circles represent ubiquitin. b) Blot showing no 
ubiquitination of p53 by MDM2 ΔT (lanes 3-5) and ubiquitination of p53 by FL MDM2 (lanes 6-8). c) 
Blot showing no ubiquitination of p53 by RING ΔT (lanes 3-5) and ubiquitination of p53 by FL RING 
(lanes 6-8). UbcH5α is capable of monoubiquitinating p53 in the absence of an E3 ligase. This is the 
reason for the band seen in the negative control and ΔT lanes. In each blot the positive control protein 













It should be noted that a single monoubiquitination band can be seen in both the 
negative control lane (figure 3.5b and c, lane 1) and also in lanes where E3 ligase 
dead MDM2 ΔT and RING ΔT are present (figures 3.5b and c, lanes 3-5). Different 
batches of E2 can sometimes be sufficient for monoubiquitination of the target protein 
without the E3 needing to be present. As this monoubiquination band can be seen in 
the negative control, as well as those proteins considered to be inactive, it can be 
assumed that this band is due to the E2 and not some minor E3 ligase activity of the 
MDM2 proteins missing the C-terminal tail. 
 
Another activity assay used was the discharge assay. This assay was used to look at 
whether a protein can discharge ubiquitin from an E2. This is a very labile assay and 
as such it is important to have a control that tests for spontaneous discharge of the 
ubiquitin from the E2. It is also important to have a control containing a reducing 
agent. Two bonds can exist between an E2 and ubiquitin, the first, a labile thioester 
linkage, and the second a covalent isopeptide bond i.e. the E2 can become 
ubiquitinated. It is possible for both to be present in the same assay, the thioester bond 
is collapsible by DTT, and the isopeptide bond is not. This assay has been optimised 
to reduce the presence of isopeptide bonds. 
This assay can only show that a protein discharges ubiquitin from the E2, it does not 
show whether the protein can then transfer the ubiquitin to a target protein. In theory 
it is possible that a protein may be able to discharge ubiquitin from an E2 without 
actually being able to transfer it to a ubiquitination target. In this assay an E2 was 
loaded  with ubiquitin before being incubated with the protein of interest, whether or 
not the protein can discharge ubiquitin from the E2 was be detected by 
immunoblotting (figure 3.6a). 
 
FL MDM2 facilitates discharge of ubiquitin from UbcH5α (figure 3.6b. lanes 4-6) 
this was expected as FL MDM2 was active as an E3 ligase. In this assay the discharge 
of ubiquitin is not complete. This could be due to the amount of FL M2M2 present. 
MDM2 ΔT was not able to discharge ubiquitin from UbcH5α (figure 3.6b, lanes 7-9) 










Figure 3.6: Discharge of ubiquitin from UbcH5α by MDM2. a) Schematic diagram showing 
components and methods of a discharge assay. The blue circles represent ubiquitin. b) Blot showing no 
discharge of ubiquitin from UbcH5α by MDM2 ΔT (lanes 7-9) and discharge of ubiquitin from 
UbcH5α by FL MDM2 (lanes 4-6). c) Blot showing no discharge of ubiquitin from UbcH5α by RING 
ΔT
 
(lanes 1-3) and discharge of ubiquitin from UbcH5α by FL RING (lanes 4-6). Blots were probed by 
















When I examined the associated RING domain constructs FL RING could discharge 
ubiquitin from UbcH5α (figure 3.6c, lanes 4-6) whereas RING ΔT
 
was not able to  
discharge ubiquitin from the E2 (figure 3.6c, lanes 1-3). As in the ubiquitination 
assay the RING constructs exhibit the same activity as their full length counterparts. It 
should be noted that the FL RING is able to facilitate complete discharge of ubiquitin 
from the E2 compared to the partial discharge seen with FL MDM2, possible reasons 
for this are outlined in the discussion. 
 
MDM2 ΔT and RING ΔT
 
are both inactive as E3 ligases in the activity assays 
described previously, this supports cell based assays presented in the literature
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. It 
could be argued however, that the reason for the differences between these proteins 
and FL MDM2 and FL RING is not solely down to the absent tail. These assays 
confirm no E3 ligase activity but they do not show that this is due to loss of tail 
function as it could be argued that these proteins have an aberrant or misfolded 
structure and that the role of the tail is structural rather than functional.     
     
In order to differentiate between E3 inactivity and misfolded protein an assay was 
needed that compares an activity of the proteins other than E3 ligase activity; this 
could then prove that E3 loss is indeed down to absent tail and not aberrant 
conformation. 
MDM2 is known to bind p53; the N-terminal hydrophobic pocket of MDM2 binds to 
the Box I domain of p53 and the acidic domain within MDM2 binds to the Box V 
domain of p53. Whilst MDM2 does exhibit allosteric behaviour between these two 
domains the tail has not been reported to be critical for p53 binding.  
Due to possible allosteric activity, the binding of FL MDM2 vs MDM2 ΔT to box I 
and box V peptides may not be identical; still a binding assay may help confirm that 
the MDM2 ΔT can perform activities that are not reliant on the tail. 
 
A peptide binding assay was carried out in which binding of FL MDM2 and MDM2 
ΔT to the box I and box V peptides of p53 was measured. This is an assay that 
measures stable binding.  
Both FL MDM2 and MDM2 ΔT bound Box I peptide with almost identical affinity 
(figure 3.7a), the loss of the tail does not affect the ability of the hydrophobic pocket 










Figure 3.7: FL MDM2 and MDM2 ΔT binding to box I and box V peptides. a) Biotin labelled box 
1 (SGSGPPLSQETFSDLWKLLP)  (100 ng/well) was captured onto streptavidin coated microtitre 
wells, a titration of FL MDM2 or MDM2 ΔT was added and incubated for 1 hour at room temperature, 
unbound protein was removed by extensive washing and bound MDM2 was detected by using the 
monoclonal antibody 2A10. Graph shows protein binding as Relative Light Units (R.L.U) FL MDM2 
and ΔT MDM2 bind to box I peptide. b) Biotin labelled box V peptide  (100ng/well) was captured onto 
streptavidin coated microtitre wells, a titration of FL MDM2 or MDM2 ΔT was added in the mobile 
phase and incubated for 1 hour at room temperature, unbound protein was removed by extensive 
washing and bound protein was detected by 2A10. Graph shows protein binding as R.L.U. FL MDM2 












In addition FL MDM2 and MDM2 ΔT bind to Box V peptide however, interestingly 
MDM2 ΔT binds the peptide with greater affinity than the wt protein (figure 3.7b). It 
is unlikely that this reflects a difference in the amount of protein added as FL MDM2 
and MDM2 ΔT were normalised by ELISA (data not shown) and no difference in  
binding of these two proteins to Box I was observed. Another explanation for the 
increased affinity for box V is that without the tail some conformational constraint of 
FL MDM2 is lost, allowing for a greater level of binding. 
These results would suggest that MDM2 ΔT is folded correctly as it is behaving in a 
similar manner to FL MDM2 in binding assays and therefore retains some activities 
and selectively loses E3 function. 
This assay can clearly not be used to test RING ΔT as the RING construct has no 
hydrophobic pocket or acidic domain. Different binding assays, discussed shortly, 
confirmed that RING ΔT behaved like FL RING in non E3 ligase activities, 























3.1.4 MDM2 binds to UbcH5α  
 
As previously outlined the general consensus for RING domain containing proteins is 
that they contact their E2 partner then catalyse the transfer of ubiquitin to the target 
protein, however no one has shown exactly how this mechanism may work. 
There are crystal structures and models of other E2:E3 binding partners, and contact 
sites on both MDM2 and UbcH5α have been predicted, but no one has actively shown 
that they bind to each other in solution. In fact it has been stated that the E2:RING 
cannot form a complex that is stable enough to investigate
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. To investigate the 
mechanism of ubiquitin transfer, first MDM2 and UbcH5α binding must be better 
understood. 
 
A protein binding assay (figure 3.8a) was carried out between UbcH5α and MDM2. 
In this assay UbcH5α was immobilised onto a microtitre well and the MDM2 
constructs were present in the mobile phase. MDM2 binding was detected using the 
MDM2 specific monoclonal antibody 2A10 which bind to a region in the RING and 
acidic domain of MDM2. FL MDM2 and MDM2 ΔT can both bind UbcH5α in a 
protein binding ELISA (figure 3.8b). This assay does not work if it is performed in 
the opposite orientation i.e. MDM2 immobilised onto the well and E2 in solution. 
This suggests that the conformational flexibility of MDM2 is an important 
determinant of E2 binding and may explain why crystallisation of the MDM2 RING 
and E2 has not been achieved. The result shows that MDM2 ΔT binds UbcH5α with 
greater affinity than FL MDM2; it is possible that MDM2 without the tail forms a 
conformation that allows for greater UbcH5α binding. 
 
RING ΔT and FL RING can both bind to UbcH5α in a protein binding assay (figure 
3.8c); unlike FL MDM2 they can bind to UbcH5α in either the immobile or solution 
phase. The results from this assay suggest that FL RING may be binding with 
marginally greater affinity than the ΔT construct. 
This protein binding assay is also an example of an activity other than E3 ligase 
activity. The fact that RING ΔT can bind UbcH5α helps to confirm that the protein is 








Figure 3.8: MDM2 binds to UbcH5α in solution. a) Schematic diagram showing the basic 
methodology of this protein binding assay. b) UbcH5α was captured onto microtitre wells (100 
ng/well); a titration of FL MDM2 or MDM2 ΔT was added in the mobile phase and incubated for 1 
hour at room temperature. Unbound protein was removed by extensive washing and bound protein was 
detected using monoclonal antibody 2A10. Graphs show UbcH5α binding expressed as relative light 
units (R.L.U). c) UbcH5α was captured onto microtitre wells (100ng/well), titrations of RING ΔT
 
or 
FL RING was added and detected as above.   












It is interesting that the proteins missing the tail can bind to UbcH5α with a similar 
affinity as the proteins with the tail. As the constructs without the tail are inactive as 
E3 ligases one hypothesis has been that they are not able to bind UbcH5α and 
therefore not able to catalyse the transfer of ubiquitin to the target protein, in this case 
p53, these results demonstrate that this is clearly not the case. This idea will be 
explored further in the discussion. 
 
As the protein binding assay unexpectedly demonstrated readily detected interactions 
between MDM2 and UbcH5α I wished to confirm the data using a second solution 
based assay. An alpha screen (figure 3.9a) was therefore carried out with FL MDM2, 
MDM2 ΔT and UbcH5α. An alpha screen has a number of advantages over a protein 
binding ELISA where one component is immobilised on a charged plastic surface. it 
is very sensitive and can measure interactions at the picomole level with both the 
proteins being in solution, and presented in the same orientation, perhaps most 
importantly it is a real time assay that is carried out at equilibrium. 
 
The assay was set up so that FL MDM2 or MDM2 ΔT was displayed on protein A 
acceptor beads preloaded with 4B2 and incubated with nickel coated donor beads 
displaying His-tagged UbcH5α. The beads were combined and preincubated for 1 
hour before energy transfer measurements were carried out, by exciting the donor 
beads at 680 nm and measuring the emission from the acceptor beads at 520-620 nm. 
Energy transfer can only take place if the donor and acceptor beads are within 200 nm 
suggesting a direct protein:protein interaction has taken place. 
FL MDM2 and MDM2 ΔT both bind to UbcH5α in an alpha screen (figure 3.9b), 
they bind with almost identical affinity. This confirms the protein binding assay, 
















Figure 3.9: MDM2 binds to UbcH5α in solution, alpha screen. a) Schematic diagram showing the 
basic methodology of this alpha screen. b) Protein A acceptor beads (20 µl) preincubated with mouse 
monoclonal 4B2 then bound to FL MDM2 and MDM2 ΔT were incubated (in darkness) with nickel 
donor beads (20 µl) loaded with UbcH5α  at room temperature for 1 hour. Graph shows the two 










3.1.5 MDM2 binds to ubiquitin 
 
As discussed in the introduction, there are more than one class of E3 ligase. Those E3 
ligases that contain a HECT domain accept ubiquitin from their partner E2, onto an 
active site cysteine, then transfer it to the target protein themselves. This is in contrast 
to E3 ligases containing a RING domain which are not considered to accept ubiquitin 
from their partner E2.  
 
In order to determine whether, as recently suggested for RNF4 and ubiquitin
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, the 
RING of MDM2 can bind ubiquitin, a protein binding assay was carried out with 
ubiquitin and all four MDM2 constructs. In each case ubiquitin was captured onto the 
microtitre well and MDM2 was in the mobile phase (figure 3.10a).  
FL MDM2 and MDM2 ΔT both bound to ubiquitin in a protein binding assay (figure 
3.10b), this result is not seen if MDM2 is immobilised to the plate, again suggesting 
that the conformational flexibility of MDM2 is an important determinant of ubiquitin 
binding, just as for E2 binding. 
This result is interesting for a couple of reasons; firstly given what is predicted about 
the E3 ligase mechanism, the question of why ubiquitin is binding is raised, possible 
explanations for binding are outlined in the discussion. Secondly this ELISA is very 
changeable, although binding is always seen the curves are variable, suggesting a low 
affinity but specific binding, Traditionally high affinity interactions have been thought 
to be more important physiologically, however it has been recently suggested that 
ubiquitin functions through many low affinity interactions
222
, perhaps the interaction 
between ubiquitin and MDM2 is one of these low affinity interactions. 
I next determined if the isolated RING domain was sufficient for ubiquitin binding. 
RING ΔT and FL RING could both bind ubiquitin in a protein binding assay, unlike 
FL MDM2 they can bind ubiquitin regardless of whether they are immobilised or in 
the solution phase. The presence of the tail looks to have no effect on binding affinity. 











Figure 3.10: MDM2 binds ubiquitin in solution. a) Schematic diagram showing the basic 
methodology of this protein binding assay. b) Ubiquitin was captured onto microtitre wells (100 
ng/well), a titration of FL MDM2 or MDM2 ΔT was added and incubated for 1 hour at room 
temperature. Unbound protein was removed by extensive washing and bound protein was detected 
using monoclonal antibody 2A10. Graphs show ubiquitin binding expressed as relative light units. c) 
Ubiquitin was captured onto microtitre wells (100ng/well), a titration of RING ΔT or FL RING was 










3.1.6 UbcH5α and ubiquitin bind to the same region of the RING domain 
 
The previous experiments have shown that MDM2 can bind Ubch5α and ubiquitin, 
they further demonstrated that both proteins bind within the extended RING domain 
of MDM2 (i.e. residues  322-491). It is possible that one or both are binding to the 
unstructured region of outwith the RING domain i.e. amino acids 322-437. Based on 
what is known about other E2:E3 binding pairs however it is likely that UbcH5α, at 
least, is binding within the RING domain. Considering the link between UbcH5α, 
ubiquitin and the RING in the ubiquitination cascade it also appears possible that 
ubiquitin is binding within the RING domain. 
The RING domain is 54 amino acids in length, assuming that both UbcH5α and 
ubiquitin bind within this domain the next point of investigation was to study where 
within the RING domain they bind. I first screened a RING-based peptide library. 
Each peptide is 20 amino acids in length and the peptides were highly degenerate with 
an overlap of 15 amino acids (16 in the case of peptide 8). There is one extra peptide 
(peptide 9) that is only 12 amino acids in length, this peptide represents the tail of 
MDM2. Each peptide has an N-terminal biotin tag with a Ser-Gly-Ser-Gly spacer 
(figure 3.11a). 
 
A peptide binding assay was carried out with the RING peptides and UbcH5α (figure 
3.11b). The aim was to first to confirm that UbcH5α bound within the RING domain 
of MDM2 and second to narrow down a specific area region(s) of the RING that are 
directly involved in UbcH5α binding. In each case the peptide was displayed on a 
streptavidin coated well before addition of UbcH5α in the mobile phase . 
UbcH5α bound to peptide 8 to form a stable complex (figure 3.11c). This peptide 
contains the tail residues of MDM2 along with an extra 8 amino acids, it can be 
concluded therefore that one or more of these extra residues is important for binding 
as UbcH5α does not bind peptide 9, containing the tail residues in isolation.  
There is some binding to peptide 7, this is unsurprising as it shares the 8 extra amino 
acids that may be important for binding, interestingly, although it does share these 
amino acids, UbcH5α binds with lower affinity. It is possible that the tail is involved 
in the binding of in UbcH5α as peptide 9 shows weak but reproducible binding. Taken 
with earlier data this suggests that the tail of MDM2 may play a positive role in 





Figure 3.11: UbcH5α and ubiquitin bind to RING peptides. a) Diagram showing the amino acid 
sequences of the RING peptides. Colour sequence indicates overlapping residues. b) Schematic 
diagram showing the method of this peptide binding assay. The microtitre well is coated with 
streptavidin; biotinylated peptide is added and incubated, followed by the addition and incubation of 
protein.  c) A series of biotin labelled RING peptides (100 ng/well) were captured onto streptavidin 
coated microtitre wells, UbcH5α (100 ng/well) was added and incubated for 1 hour at room 
temperature. Unbound UbcH5α was removed by extensive washing and bound protein was detected 
using anti-His antibody. Graph shows UbcH5α binding expressed as relative light units (R.L.U). d) A 
series of biotin labelled RING peptides (100 ng/well) were captured onto streptavidin coated microtitre 











peptide 7 that are not present in peptide 8 could be having some sort of inhibitory 
affect, it is possible that they are partially blocking binding. There is also some 
binding to peptide 2, though it is weaker than peptide 8 binding this is consistent with 
data from other RING:E2 conformations which show a conserved point of contact in 
this reigon
37,223,224
.    
 
A second binding assay was carried out, this time with the RING peptides and 
ubiquitin. As before the RING peptides were displayed on a streptavidin coated well 
and ubiquitin was in the mobile phase.  
Strikingly ubiquitin bound predominantly to peptide 8 and to a lesser extent peptide 7 
(figure 3.11d), the ideas laid out above in relation to UbcH5α and peptide 7 binding 
may also apply here. The binding to peptide 7 and 8 is very similar to what is seen 
with Ubch5α however ubiquitin did not bind the tail peptide (peptide 9) as is seen 
with UbcH5α. This suggests that the tail by itself is not sufficient for ubiquitin to 
bind.   
 
The results confirm that both UbcH5α and ubiquitin bind to MDM2, furthermore they 
imply that UbcH5α and ubiquitin bind to the same region of the RING domain though 


















3.1.7 Can the RING of MDM2, UbcH5α and ubiquitin form a trimeric 
complex? 
 
Based on the data presented in the previous section the following question arises, can 
ubiquitin and UbcH5α bind the peptide 8 region of the RING to form a trimeric 
complex or is binding mutually exclusive (figure 3.12a)? 
 
To answer this question a peptide binding assay was designed to determine which of 
these models was correct. It was known, from the results of a fellow student in the 
Ball group, that when UbcH5α is captured onto the plate and ubiquitin is in solution 
no ubiquitin binding is detected however when ubiquitin is captured onto the plate 
and UbcH5α is in solution UbcH5α binding can be detected. Knowing this an assay 
was carried out as follows, UbcH5α was captured onto the plate, peptide 8 was then 
added at a concentration high enough to saturate the binding sites of UbcH5α, 
unbound peptide 8 was subsequently washed away and a titration of ubiquitin was 
added. In theory if ubiquitin could bind to peptide 8 at the same time as UbcH5α, 
ubiquitin binding would be detected, if ubiquitin could not bind to peptide 8 at the 
same time as UbcH5α there would be no detection of ubiquitin binding (figure 
3.12b). When ubiquitin was titrated into the assay an increase in ubiquitin binding 
was detected (figure 3.13a). The maximum concentration of ubiquitin was also added 
to a control well, with immobilised UbcH5α and no peptide 8, no ubiquitin binding 
was detected therefore it can be concluded that UbcH5α and ubiquitin can bind to 


















Figure 3.12: Can UbcH5α, ubiquitin and peptide 8 form a trimeric complex? a) Schematic 
diagram showing the possible models for UbcH5α and ubiquitin binding to the RING. They could form 
a trimeric complex or binding of the two proteins to a similar region of the RING could be mutually 
exclusive. b) Schematic diagram showing the basic methodology of the peptide binding assay designed 
































Figure 3.13: UbcH5α and ubiquitin bind to peptide 8 simultaneously. a) UbcH5α (100 ng/well) 
was coated onto microtitre wells, peptide 8 (100 ng/well) was added and incubated for 1 hour at room 
temperature. Unbound peptide 8 was removed by extensive washing. Ubiquitin was titrated in and 
incubated for 1 hour at room temperature. Unbound protein was removed by extensive washing and 
bound protein was detected by anti-ub antibody. Graph shows ubiquitin binding expressed as relative 
light units. The control had no peptide present and the maximum concentration of ubiquitin was titrated 














3.1.8 Narrowing down residues important for UbcH5α and ubiquitin binding 
 
What the previous result cannot confirm is the nature of binding of the two proteins, 
are they binding to completely different residues within the peptide or are they 
binding to opposing faces of the same peptide as has been described for PCNA and 
cyclin D binding to p2 
225
 (figure 3.14a). 
One possible way of identifying which one of the models of simultaneous binding is 
correct is to look in more detail at which specific residues in peptide 8 are important 
for UbcH5α and ubiquitin binding.    
 
To do this an alanine scan of peptide 8 was used. An alanine scan of a peptide 
involves each residue being substituted for an alanine in turn. An alanine scan of 
peptide 8 for example resulted in 20 peptides that were all 20 amino acids in length 
and had an N-terminal biotin tag with ser-gly-ser-gly spacer (figure 3.14b). Using 
these peptides a peptide binding assay was carried out with the alanine scan peptides 
and UbcH5α, in each case the peptides were displayed on streptavidin coated wells 
with UbcH5α in solution. There was reduced binding to many of the alanine scan 
peptides (figure 3.15a), in particular when a tyrosine at position 489 of MDM2 was 
substituted for alanine (figure 3.15a, peptide 28) binding to both UbcH5α and 
ubiquitin was greatly reduced.  
 
A second binding ELISA was carried out with the alanine scan peptides and ubiquitin. 
There was reduced binding to the majority of the alanine scan peptides (figure 3.15b), 
the binding trend is actually very similar to that of UbcH5α, once again substitution of 
the tyrosine at position 489 results in almost no binding of ubiquitin.  The results 
suggest a broad interface is required for UbcH5α to bind. This binding interface does 
overlap with the binding interface for ubiquitin but there are residues which are 
specifically involved in ubiquitin binding. One such example is peptide 18, this 
peptide has an alanine in place of an arginine at position 479 of MDM2 and this 
substitution results in a significant decrease in ubiquitin binding, and only a marginal 













Figure 3.14: UbcH5α and ubiquitin bind the same region of the RING simultaneously, what is the 
nature of this binding? a) Schematic diagram showing two possible models for simultaneous binding 
of UbcH5α and ubiquitin to peptide 8. b) Diagram showing the amino acid sequences of the alanine 






































Figure 3.15: UbcH5α and ubiquitin binding to alanine scan peptides in comparison to peptide 8.  
A series of biotin labelled alanine scan peptides (100 ng/well) were captured onto streptavidin coated 
microtitre wells, UbcH5α (100 ng/well) (a) or ubiquitin (100 ng/well) (b) was added and incubated for 
1 hour at room temperature, unbound protein was removed by extensive washing. UbcH5α was 
detected using anti-his antibody and ubiquitin was detected using anti-ub antibody. Graph shows 











As well as showing that there are differences in the binding interfaces of UbcH5α and 
ubiquitin this result also serves as quality control for the experiment. It cannot be 
argued that ubiquitin does not bind to peptide 18 because of some issue with peptide 
18, i.e. none present in well, aggregated peptide, because UbcH5α does exhibit 
binding to peptide 18. This result is especially important in showing quality control as 
the binding interfaces between the two proteins are so similar. 
The alanine scan has provided information regarding the residues involved in peptide 
8 binding to UbcH5α and ubiquitin. It did not however help to decipher whether 
UbcH5α and ubiquitin bind to similar or distant residues (figure 3.14a). Substitution 
at 489 affects binding of both and this would suggest they bound similar residues, 
however a substitution at 479 only greatly affects ubiquitin, suggesting they bind 
distant residues. It is possible that both of them could have more than one point of 
contact with the RING and while they bind some residues that are distant from each 
other they also share a common point of contact too.  
 
Reduced binding is seen for the most part when residues within the tail are 
substituted, when residues outside of the tail are substituted any change in binding 
affinity is slight. If this is considered along with all the previous results it suggests 
that the tail is not required for MDM2 to bind to UbcH5α and ubiquitin but conversely 
















3.1.9 Specific residues within the RING domain of MDM2 are important for 
UbcH5α and ubiquitin binding and for E3 ligase activity 
 
Point mutations were introduced into the RING construct to replicate the data 
obtained using the alanine scan peptides. Peptides are useful tools for studying 
protein-protein interactions but it is important to consider that although the sequence 
is the same any tertiary structure that the protein has, any allosteric affect the domains 
exhibit towards each other, will not be replicated by the peptide. This is the reason for 
cloning the alanine substitutions into the protein. Thus an alanine was introduced at 
position 479, replacing an arginine, this protein shall be known as RING
R479A
. In the 
other construct an alanine was introduced at position 489, replacing a tyrosine, this 
protein will be known as RING
Y489A
. The point mutants were expressed, purified and 
stored in the same manner as RING ΔT and FL RING. The soluble protein yield of 
the point mutants is comparable and similar to RING ΔT and FL RING (figure 3.16).  
 
In order to determine the properties of the RING point mutant proteins a protein 
binding assay was initially carried out to compare binding of the point mutants plus 





exhibit considerably less binding to UbcH5α than RING ΔT and FL RING 
(figure 3.17a) and RING
R479A
 displays less binding than RING
Y489A
, while the ability 
to form a stable complex is less both RING alanine mutants do still bind to UbcH5α. 
 
Next the ability of the four RING domain protein constructs to bind to ubiquitin was 
compared using a protein binding assay. Ubiquitin was captured onto the well and the 
RING proteins were titrated in the mobile phase. 
RING
Y489A
 exhibited considerably less binding to ubiquitin than RING ΔT
 
and FL 
RING, the ability of RING
R479A 
to bind to ubiquitin was essentially abolished 
consistent with the effect of this substitution in peptide 8 (Figure 3.17b). 
It is hard to reconcile the fact that when the entire tail is absent MDM2 can bind to 
UbcH5α and ubiquitin just as well as when the tail is present, yet one substitution in 
the tail can substantially decrease or near abolish binding. In the discussion the 
possible idea that the presence of the tail greatly influences the structure of MDM2 
























Figure 3.16: Purification of RING domain proteins.  Coomassie stained 10 % polyacrylamide gel 
showing the purification of all four RING domain proteins in comparison to BSA protein standards. 
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Finally I asked how the decreased E2 and ubiquitin binding function of the RING 
mutants related to their activity in the E3 ligase assay. The four RING domain protein 
constructs were therefore compared in a ubiquitination assay to look for differences in 
E3 activity on p53 (figure 3.17c). 
Interestingly the RING
Y489A
 protein was not active as an E3 ligase (figure 3.17c, 
lanes 6-7). This RING could bind to UbcH5α and ubiquitin, albeit less than the wild 
type RING, suggesting that simply binding to Ubch5α and ubiquitin is not sufficient 
for E3 ligase activity, this is similar to RING ΔT
 
which can bind UbcH5α and 
ubiquitin but is also inactive as an E3 ligase. The difference of course is that 
RING
Y489A
 has the tail needed for E3 activity, but the tail has a mutation, these results 




 was barely active as an E3 ligase (figure 3.17c, lane 8-9) there was a little 
activity but was far less than that of FL RING. RING
R479A
 bound with much less 
affinity to UbcH5α and ubiquitin, a possible reason for its reduced E3 ligase activity. 
 
These results show that both point substitutions result in decreased binding to 
UbcH5α and ubiquitin, this confirms the alanine scan peptide binding results. They 
also show that binding to UbcH5α and ubiquitin does not correlate precisely with E3 






















Figure 3.17: E3 ligase activity and Ubch5α and ubiquitin binding of all four RING domain 
protein constructs. UbcH5α (a) or ubiquitin (b) was captured onto microtitre wells (100 ng/well), a 




 was added and incubated for 1 hour at 
room temperature. Unbound protein was removed by extensive washing and bound protein was 
detected using monoclonal antibody 2A10. Graphs show binding expressed as relative light units 
(R.L.U). c) Blot showing no ubiquitination of p53 by RING ΔT (lanes 2-3), ubiquitination of p53 by 
FL RING (lanes 4-5), no ubiquitination of p53 by RING
Y489A
 (lanes 6-7) and ubiquitination of p53 by 
RING
R479A
 (lanes 8-9). Blot was probed by DO1. C-control, –ve negative control, ΔT- RING ΔT, FL- 




















The results presented in this chapter show that the 12 amino acid tail of MDM2 is 
necessary for E3 ligase activity. It is required for the discharge of ubiquitin from 
UbcH5α and also potentially the subsequent transfer of ubiquitin to the target p53. 
The obvious question arising from these results is ‘Why is the tail critical for E3 
activity?’ Some research would suggest that the dimerization of MDM2 is key to 
answering this question.  
 
Some RING domain containing proteins have been shown to dimerise, furthermore 
this dimerisation, either as a heterodimer such as BRCA1/BARD1
142
 or a homodimer 
such as CHIP
143





 with MDM4. Regardless of dimer type the tail has been implicated 
in dimer formation. One study showed that deletion of the 5 C-terminal amino acids 
of MDM2 resulted in no dimer formation
141
. In this study the last 5 or 7 C-terminal 
amino acids were deleted, and two new GST-tagged MDM2 proteins produced. They 
were analysed by gel filtration, and the two tail mutants eluted from the column in the 
same peak, they were resolved on a 12 % SDS page gel and both tail mutants present 
bands that correspond to monomeric protein.  Conversely gel filtration studies of the 
RING by a former PhD student, working with Professors Walkinshaw and Ball, 
suggest that when the 12 amino acid tail was deleted the RING protein could still 
form a dimer. These results are at odds with each other but in the first study the entire 
tail was not deleted, just the last 5 amino acids. Maybe the structure of MDM2 
changes less when the entire tail is deleted as opposed to just the five amino acids, 
and perhaps structure is just as important for dimer formation as contact residues. 
From the solution structure of the RING MDM2/MDM4 heterodimer a number of 
residues were implicated in the dimer interface, 5 were located within the tail (483, 
485, 487, 488 and 489), but a further 6 were not
130
. It is possible that all these points 
of contact are important but it is also possible that some could be lost, such as in the 
tail, and a dimer would still be able to form. The solution structure shows that the tail 
is buried in the heterodimer with MDM4 (Figure 3.18), work from the Walkinshaw 
and Ball lab suggest the possibility that the tail is in a different position when E2 is 






















Figure 3.18: Structure of the MDM2/MDM4 RING domain heterodimer. a) Cartoon diagram of 
the MDM2l/MDMX RING domain heterodimer structure. MDM2 RING is shown in orange and 
MDMX RING in yellow, with the zinc ions and coordinating residues shown as spheres and sticks, 
respectively.  
 
Figure from Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL. Structure of the 
MDM2/MDMX RING domain heterodimer reveals dimerization is required for their 











Secondly if the position of the tail, when E2 is bound, means that it is no longer 
involved in dimer formation can MDM2 still form a dimer or does it act as a 
monomer with E2 bound? 
 
Research is conflicting as to whether MDM2 must be a dimer to be active as an E3 
ligase, there are those that report E3 ligase activity regardless of whether MDM2 is in 
monomer or dimer form
141
, others report that it must be a dimer to be active
102
. 
Looking at some dimer studies it is unclear whether a monomer was used as a control 
for activity. Research is still clearly ongoing regarding MDM2, dimerisation and 
activity. If however dimerisation is required for activity and the tail is required for this 
dimerisation then this would explain why MDM2 ΔT is inactive as an E3 ligase. 
 
Another explanation for the necessity of the tail in E3 ligase activity is the role that 
the tail may play as an allosteric activator, this leads to the UbcH5α results. At the 
start of this chapter I set out to show that MDM2 could bind to UbcH5α in solution. 
The results show that FL MDM2 and MDM2 ΔT can both bind to UbcH5α and that 
the tail is not necessary for this binding. Clearly simply binding to UbcH5α is not 
sufficient for E3 ligase activity, as MDM2 ΔT is not active. The tail must have 
another role in E3 ligase activity other than binding to UbcH5α. 
 
There is the view that proteins containing a RING domain act as a scaffold, 
orientating a substrate and ubiquitin conjugating enzyme in a manner optimum for 
ubiquitination
28,34
. This hypothesis is challenged by crystal structures of RING 
domain containing complexes which show the substrate and ubiquitin conjugating 
enzyme a distance apart
39
 making it unclear whether the ubiquitin could be transferred 
from ubiquitin conjugating enzyme to the substrate. My results also challenge the 
orientation hypothesis, MDM2 ΔT can bind both p53 and UbcH5α and yet there is no 
ubiquitination of p53. Whilst not discounting orientation entirely, certainly it may 
play an important role in E3 ligase activity, there must be more to MDM2s E3 ligase 
activity than simply binding and orientating UbcH5α. 
 
One idea is that E3 ligases can allosterically activate their partner E2s, and it has been 





If UbcH5α can be allosterically activated and MDM2 is the cause of the activation 
then it is possible that residues within the tail are responsible for the activation of 
UbcH5α and subsequent E3 ligase activity.     
 
It has been suggested in the literature that MDM2 cannot form a stable interaction 
with UcbH5α in vitro and there is no published data for MDM2 bound to UbcH5α. In 
contrast I have shown that MDM2 can bind UbcH5α in solution, although this precise 
result had not been previously shown, the result was not totally unexpected, there are 
many examples of E3 ligases binding to their specific E2. However my results show 
that the RING and UbcH5α can form a stable complex in the absence of ubiquitin, 
data that has not been show until now. A much more unexpected result was that of 
MDM2 binding to ubiquitin. It was unexpected as E3 ligases containing a RING 
domain are traditionally thought to act as a scaffold protein bringing to together their 
E2, charged with ubiquitin and target substrate before catalysing the transfer of 
ubiquitin between the two, this does not involve the RING binding to ubiquitin. 
It has been reported that RNF4, another E3 ligase that contains a RING domain, can 
bind to ubiquitin, there are however a number of difference between their experiments 
and my results. They report that ubiquitin alone has no detectable binding affinity for 
the RING of RNF4, they only show ubiquitin contacting the RING after it is linked 
via a thioester bond to E2
220
. It is also worth noting that this study describes the 
interaction between free UbcH5α and RNF4 as very weak, RNF4 only binds tightly to 
UbcH5α when it is charged with ubiquitin.  
 
RNF4 and MDM2 both contain RING domains and UbcH5α is their E2 partner, but it 
is important to remember that they are different proteins, within the RING domain 
MDM2 has unique zinc coordination and also contains an integrated ATP binding 
site, the like of which is only found in MDM2 and MDM4. It is possible that MDM2 
can bind to ubiquitin and UbcH5α alone, without the need for them to be linked to 
each other and equally possible that RNF4 can only bind to ubiquitin and, to some 
degree, UbcH5α once they have the thioester link to each other. Considering the data 
obtained from the RNF4 study it could also be that although MDM2 can bind to 
ubiquitin and UbcH5α alone, as my results show, it is possible that the RING will 
have higher affinity for ubiquitin once it is bound to UbcH5α and also likewise higher 
affinity for UbcH5α once it is bound to ubiquitin. In fact during the course of my PhD 
131 
 
I attempted to use the complex utilised in the Hay paper
220
, in which the E2 was 
mutated so that it was constantly linked to ubiquitin. I wanted to use this E2-ubiquitin 
to test the affinity of MDM2 for the complex in contrast to the free E2 and ubiquitin. I 
was kindly sent the plasmid to work with, however I found this mutated E2-ubiquitin 
complex to be highly unstable, the ubiquitin would spontaneously discharge from the 
E2, students of the Hay lab had warned that it was very difficult to work with and in 
the end I decided that this mutated complex was not suitable for my experiments.    
 
If MDM2 can bind to ubiquitin this could suggest that it is acting more like an E3 
ligase that contains a HECT domain, and accepting ubiquitin from UbcH5α before 
transferring to the target. Or, more likely, MDM2 still catalyses the transfer of 
ubiquitin to targets via UbcH5α, with ubiquitin contact playing a different role 
altogether. As I have shown that free ubiquitin binds to MDM2 it is possible that 
MDM2 is acting as a ubiquitin binding domain protein. 
 
I have shown that MDM2 binds to both UbcH5α and ubiquitin. My results from 
peptide binding ELISAs (figure 3.11c and d) indicate that UbcH5α and ubiquitin are 
binding to the same region of the MDM2 RING domain, they both interact with a 
residue or residues within peptide 8. There was some cause for hesitation in believing 
that this was a true result, there was always the possibility that some characteristic of 
the peptide resulted in it being ‘sticky’. A closer look at the peptide binding ELISA 
profiles revealed that whilst they are very similar there a some distinct differences, for 
example UbcH5α shows some binding affinity for peptide 9, binding that ubiquitin 
does not exhibit. Some of the binding seen for certain peptides then is protein specific, 
and it is possible that UbcH5α and ubiquitin both have a genuine binding affinity for 
peptide 8. 
At the time these peptide binding ELISA results were being obtained a fellow PhD 
student, Dr Vivien Landre, was studying the computer modelling of complexes, using 
programmes HADDOCK, that docks proteins onto one another, and molecular 
dynamic simulations, that predicted the most energetically favourable structure for a 
complex. Independently of my peptide ELISA results she produced a model of the 
MDM2 RING with UbcH5α and ubiquitin, showing the predicted location on the 










Figure 3.19: Predicted model of MDM2 RING:UbcH5α:ubiquitin complex. UbcH5α is represented 
by the pink molecule, ubiquitin is represented by the green molecule and MDM2 RING is represented 
by the blue and yellow molecule. The residues of peptide 8 have been highlighted in yellow. They form 











In this model I have highlighted the residues that correspond to peptide 8 (figure 3.19, 
residues highlighted in yellow), these residues form a free flexile loop that leads on 
to the C-terminal tail. The program predicts that both UbcH5α and ubiquitin can bind 
to this region, orientating them close to the free flexible loop. The fact that ubiquitin 
may possibly bind to this region is at odds with the literature, the majority of 
characterised ubiquitin binding domains are α helical
65
. If ubiquitin can truly bind to 
this region it would be very different to previously defined ubiquitin interactions. All 
the helical ubiquitin binding domains bind to the residue Ile 44, in the model this 
residue is far from the predicted ubiquitin:RING interface.  
This model does help to confirm that my peptide binding ELISA results are showing 
true binding affinity and are likely not the result of a sticky peptide.  
 
3.1.10.1 Comparison of MDM2 RING and RNF4 RING binding to 
UbCH5α and ubiquitin 
 
Compiling all the data so far I was confident that UbcH5α and ubiquitin were binding 
to a similar region of the RING domain. What still remained unclear was whether 
they could bind to this same region simultaneously or if they could only bind one at a 
time, perhaps due to steric conformation or both proteins requiring the same residue 
for binding. At the start of my PhD there was no published data relating to a RING, 
E2, and ubiquitin model. The predicted model (figure 3.19) developed by Dr Vivien 
Landre, indicated that both UbcH5α and ubiquitin are binding the RING 
simultaneously, however this was only a prediction and needed to be validated 
experimentally.  
 
At about this time the Hay lab brought out two sequential papers
37,220
 discussing the 
RNF4 RING, E2, ubiquitin complex. I am going to discuss these two papers and the 
similarities and differences seen in my results. 
 
The first study published contradicted the predicted model that I had, as the study 
with RNF4 reported that one subunit of the dimer contacted the E2 and the other 
subunit contacted ubiquitin, the same subunit did not contact both, as indicated in my 
model. They showed that one monomer of the RNF4 homodimer contacted the 
ubiquitin charged UbcH5α and that the thioester linked ubiquitin then reached across 
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the dimer to contact the second monomer. In this model Ile44 of ubiquitin is involved 
in RING contact, corresponding with what is known about ubiquitin binding, they 
reported that Ile 44 contacts a tyrosine within the RING, this tyrosine is involved in 
the dimer interface and is not involved in an α helix
220
. If this is true it is similar to my 
results in that I see ubiquitin binding to a region other than an α helix. This study 
presumes that the interaction of UbcH5α with one monomer and ubiquitin with the 
other alters the conformation of the active site of UbcH5α facilitating ubiquitin 
transfer, but there is no mechanism provided for this theory. 
 
Considering the conflicting models from the computer simulation and from the RNF4 
study I designed an ELISA that would confirm if MDM2 could bind to UbcH5α and 
ubiquitin simultaneously or separately. The ELISA showed that UbcH5α and 
ubiquitin could bind to peptide 8 simultaneously (figure 3.13). In this ELISA both 
UbcH5α and ubiquitin were free, they were not linked by a thioester, or amide, bond. 
In contrast to the RNF4 study my results show that as well as binding to the RING 
domain simultaneously, UbcH5α and ubiquitin also bind independently of one 
another. My ELISA does not provide information on the binding location of the two 
proteins, we do not know if they are binding completely different regions of the 
peptide or if they are binding different interfaces of the same residues with the peptide 
acting as a molecular glue (figure 3.15a). 
 
The follow up study on RNF4, published a year later shows a complete turn of events. 
This study provides a crystal structure of the RNF4 homodimer linked to UbcH5α 
charged with ubiquitin. From the crystal structure they conclude that some residues of 
ubiquitin contact the same monomer as UbcH5α while others contact either the 
second monomer or even both subunits of the dimer
37
. Ile44 highlighted to be so 
important for contact in the first study was not mentioned in the second, in fact the 
previous model is not mentioned in this second study. If I take the crystal structure 
from this second study to be the correct model from the two published papers, then it 
does correspond well with my ELISA results and predicted model. 
 
I overlaid the crystal structure of the RNF4 homodimer with the MDM2/MDM4 
heterodimer, then inserted the MDM2/MDM4 heterodimer into the crystal structure of 






Figure 3.20: MDM2/MDM4 heterodimer inserted into the RNF4 RING:UbcH5α:ubiquitin 
complex. Only the MDM2 monomer half of the dimer is shown. UbcH5α is represented by the blue 
molecule, ubiquitin is represented by the pink molecule and MDM2 RING is represented by the purple 
and yellow molecule. The residues of peptide 8 have been highlighted in yellow. They form a free 
flexible loop that is still in position to bind UbcH5α and ubiquitin. This model from the crystal 









actually very similar to the predicted model, peptide 8 still forms the free flexible loop 
and UbcH5α and ubiquitin are orientated so that they could contact this region.  
This is a positive outcome for the validity of my results but there are a number of 
issues with the crystal structure that need to be considered. In the crystal structure the 
ubiquitin is linked to UbcH5α not by a thioester bond but instead an amide bond, it is 
possible that this could have an affect with the points of contact with the RING for 
one or both proteins. Also in this crystal structure the C-terminus of one monomer has 
been directly cloned onto the N-terminus of the other monomer, the tail, which is 
thought to be so important for E3 activity in MDM2, is not free. Not only might this 
compromise the true contact residues of UbcH5α and ubiquitin with the RING it also 
means that there is no indication for the role of the tail in E3 activity. 
 
If I am to assume that UbcH5α and ubiquitin are binding to the same subunit of the 
RING then questions arise about the role of the tail. It may be involved in dimer 
formation, this information is not provided in the crystal structure, as the dimer is 
‘forced’. If the tail is involved in dimer formation then why is the dimer itself so 
important if both proteins are binding to the same subunit of the dimer? The tail could 
also be involved in the allosteric activation of UbcH5α and/or ubiquitin once they are 
bound to the RING, facilitating the transfer of ubiquitin to the target, again the crystal 
structure cannot provide any information regarding this as the tail is static, not free. 
 
In conclusion the crystal structure in the second published study gives validity to the 
predicted computer model of the MDM2-E2-ubiquitin complex and also my ELISA 
results that show UbcH5α and ubiquitin can bind the same region of the RING 
simultaneously. The published structure does not however provide me with 
information regarding the oligomeric status of MDM2, nor does it offer a role of the 
tail of MDM2 in either dimer formation or activity. 
 
3.1.10.2 Further dissecting UbcH5α and ubiquitin binding to the RING of 
MDM2   
 
From the alanine scan binding results (figure 3.15) it looks as if multiple residues are 
important for both UbcH5α and ubiquitin binding to the MDM2 RING, no one 
residue is solely responsible for protein binding. The binding profiles of UbcH5α and 
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ubiquitin to the alanine scan peptides look fairly similar with the tail residues being 
important, especially the tyrosine at position 489 of MDM2. There are some 
differences, the ubiquitin interface is possibly more compact than the UbcH5α 
interface and one distinct difference in the profiles is that when an arginine at position 
479 is substituted for alanine the impact on ubiquitin binding is much more severe 
than that on UbcH5α binding. These mutations impacted on E3 ligase activity as well 
as protein binding, RING
R479A
 showed decreased E3 ligase activity whereas in 
RING
Y489A
 E3 ligase activity was completely lost. The result with RING
Y489
 
corresponds to the result already published, in which the tyrosine at position 489 in 
FL MDM2 is mutated to alanine
133
. These results simply add to the questions 
surrounding the tail. 
The tail is not necessary for MDM2 RING binding to UbcH5α or ubiquitin, from the 
model this makes sense as the tail is nowhere near these two proteins. When the tail is 
present however the results suggest that the integrity of the residues within the tail is 
very important, as one substitution significantly affects protein binding. It is possible 
that the tail is not necessary for the structure of the RING required to bind UbcH5α or 
ubiquitin, hence why MDM2 ΔT can bind to both, yet when the tail is present it 
greatly influences the structure hence why a substitution of a tail residue could cause 
such a decrease in protein binding. Some of these questions could be potentially 
addressed by using E2-linked ubiquitin. As the system outlined in the Hay studies
220
 
proved to be unstable I would investigate using a more stable E2-ubiquitin complex, 
for example a stable complex made using ‘click chemistry’. Click chemistry has 
already been used to stably link ubiquitin to PCNA. In this technique artificial amino 
acids that carried an azide or alkyne side chain were incorporated into ubiquitin and 
PCNA respectively. The two proteins were then linked site specifically by the Cu (I)- 
catalysed azide-alkyne cycloaddition
226
.    
 
The alanine substitution at position 479 of MDM2 provides yet more puzzling 
information. MDM2 ΔT shows us that simply binding to UbcH5α and ubiquitin is not 
enough for E3 ligase activity. RING
R479A 
shows decreased binding to both UbcH5α 
and ubiquitin and exhibits decreased E3 ligase activity, this result could imply that, in 
this case at least, binding is related to E3 ligase activity. Other explanations for this 
correlation include the arginine that is involved in protein binding is also involved in 
allosteric E3 ligase activity, and so substituting it results in decreased activity. 
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Alternatively, as well as protein binding, this residue could be involved in maintaining 
the correct structure of MDM2, and this structure could be important for E3 activity. 
Lastly this mutant exhibits negligible ubiquitin binding, either this small amount of 
possible binding is enough for E3 ligase activity, or, although MDM2 can bind to 
ubiquitin, it does not actually need to for E3 ligase activity. 
 
When the tyrosine at position 489 of MDM2 is substituted for alanine once again 
there are more questions are raised than answers. RING
Y489
 can still bind to UbcH5α 
and ubiquitin but is completely inactive as an E3 ligase. Binding alone is not 
sufficient for E3 ligase activity so this tyrosine must play a different role in activity.  
It has been reported that an aromatic residue at this position is critical for E3 ligase 
activity
133
. A tyrosine or phenylalanine is often seen at the corresponding position in 
various RING E3 ligases. 
RNF4 has a tyrosine at the corresponding position within its RING domain, in this 
case the tyrosine is implicated in dimer formation
220
. When this tyrosine is substituted 
for alanine in the MDM2 RING however, MDM2 can still homo-oligomerise or 
hetero-dimerise with wt MDM4
133
. Interestingly the homo-oligomer displayed no E3 
ligase activity whereas the hetero-oligomer displayed the ability to target p53 for 
degradation in cells. This suggests that if MDM2 does function as a dimer that only 
one wt tail is required for activity. Perhaps one subunit binds to the proteins and the 
tail of the other allosterically activates them, facilitating ubiquitin discharge. MDM2 
has also been shown to act as a monomer, it may be that it can act as a monomer or 
dimer as long as at least one wt tail is present. I have shown that RING
Y489A
 can bind 
to UbcH5α and ubiquitin, if I gave this protein the chance to oligomerise with wt 
RING it is possible that E3 ligase could be restored due to the wt tail present on the 
RING. 
 
To summarise, the C-terminal tail of MDM2 is required for E3 ligase activity. The tail 
is not required for binding to UbcH5α or ubiquitin but when it is present residue 
integrity is important for binding. Binding to UbcH5α and ubiquitin is not sufficient 
for activity and certain residues within the tail are critical for E3 ligase activity. It is 
possible that residues within the tail are having an allosteric effect on either UbcH5α 
or ubiquitin, the mechanism of this possible activation and the subsequent ubiquitin 
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transfer to the target remains unclear. The next step in my investigation was to look at 






























Chapter 4: RESULTS 
 




Data in my previous chapter showed that the RING of MDM2 could bind to UbcH5α 
in solution. This was consistent with published data showing other RING proteins 
binding to an E2 partner
36-38
. My data also showed that the 20 C- terminal amino acids 
of the MDM2 RING were important for E2 binding. 
 
The next question to address was the role that E2-E3 binding had in the mechanism of 
RING-dependant E3 ligase activity. The mechanism for how RING E3s transfer 
ubiquitin to a target protein remains unclear, though there are theories that hint at the 
role(s) that this binding may play in the overall mechanism of ubiquitination. 
 
The first theory was that the RING E3s acted as scaffold proteins, bringing together 
ubiquitin bound E2 and the substrate and orientating them in such a position as to 
optimise ubiquitin transfer
28,34
. Later structural studies have revealed that this is 
unlikely to be the sole mechanism of RING E3 activity, though it may play a part, as 
the E3 binding site within E2 is ~15Å away from the active site cysteine
39,227
. Even in 
the correct orientation it is unclear whether ubiquitin could transfer from E2 to 
substrate at that distance. Structural studies also showed no clear structural difference 





More recent studies are now suggesting that E2s can be allosterically activated by 
their E3
35
. One such study looking at the interaction between the RING E3 ligases 
BRCA1/BARD and E4B with UbcH5c indicated an allosteric activation of the E2 by 
E3. Using NMR they showed that E2-ubiquitin conjugates favoured a more closed 
conformation upon E3 binding. The study also noted that leucine 104, a highly 
conserved residue throughout the E2 family was important for this closed 







1) Is UbcH5α allosterically activated by MDM2 
a. Can peptide 8 be used as a tool to study potential allosteric regulation? 
b. Can biochemical and biophysical assays be used to detect allosteric 
changes and the residues of UbcH5α involved? 
 
2) Can the areas of MDM2 responsible for activation be identified and is there a 








































4.1.2 Peptide 8 can be used to study the interaction between UbcH5α and 
ubiquitin 
 
My previous data (see Chapter one) has shown that peptide 8 can bind to UbcH5α and 
ubiquitin in a manner similar to FL MDM2 and FL RING. I therefore wondered if 
peptide 8 could replace FL MDM2/FL RING in activating UbcH5α to discharge 
ubiquitin onto a ubiquitin acceptor (figure 4.1a). 
 
I carried out a discharge assay in which I added MDM2 peptide, as opposed to 
MDM2 protein, after the E2 had formed a thioester bond with ubiquitin. Peptide 8 
was able to partially discharge ubiquitin from the E2 (figure 4.1b, lane 10). This 
result is similar to what is seen when FL MDM2 is used in this assay (figure 3.6b). 
Peptide 9 was also able to partially discharge ubiquitin from the E2 (figure 4.1b, lane 
11). This is interesting as it implies that the tail of MDM2 has a role in facilitating the 
transfer of ubiquitin from the E2 to the target even though the tail itself does not bind 
to ubiquitin (figure 3.11d). Ubiquitination assays carried out with peptide 8 were 
inconclusive (data not shown). No discharge of ubiquitin is seen by peptide 1, and so I 
used peptide 1 as a control as it does not exhibit binding to the E2 or ubiquitin. 
 
As peptide 8 and 9 were able to affect a partial discharge of ubiquitin from UbcH5α I 
next asked whether the ability of MDM2 to mediate p53 ubiquitination relied solely 
on its E2 activating activity or if this is only a part of its function in substrate 
ubiquitination. If activating the E2 was MDM2s  only function than peptide 8 should 
be sufficient to ubiquitinate p53. Ubiquitination assays were inconclusive; this is 
likely due to the fact that MDM2 has other roles in substrate ubiquitination other than 
activating the E2. However this assay can be difficult to optimise and would have to 
be repeated before any definite conclusions were made. As low amounts of UbcH5α 
can bind to peptide 8 and peptide 8 is able to mimic the majority of activity displayed 
by FL MDM2 in E2 activation, I used peptide 8 as a tool to determine whether 














Figure 4.1: Peptide 8 can mimic FL MDM2 in an activity assay. a) Schematic diagram showing the 
possible activity of peptide 8 There is the possibility that peptide 8 is sufficient to discharge ubiquitin 
from the RING, or there is the possibility that peptide 8 is not only sufficient to discharge ubiquitin 
from the RING but also able to transfer ubiquitin to the target substrate.  b) Blot showing discharge of 
ubiquitin from UbcH5α by peptide 8 and peptide 9 (lanes 10 + 11). Blot does not show discharge of 
ubiquitin by control peptide 1 (lane 1). Blot was probed by anti-His antibody. Ch- charged, DTT- DTT 


















4.1.3 Proteolysis of UbH5α  
 
The precise mechanism of how RING E3s transfer ubiquitin from the E2 protein to 
the substrate remains unclear. It has been suggested that E2s can be allosterically 
activated by the RING
35,228
. I have shown that the MDM2 RING binds to UbcH5α 
and so my next question was could I determine if the MDM2 RING allosterically 
activated UbcH5α. I used partial proteolysis to determine if evidence could be found 
for a difference in conformation between free E2 and an E2:peptide 8 complex. If 
there is a conformational change it may be possible to see different digestion products 
on a gel (figure 4.2). 
 
I set up a proteolysis assay in which UbcH5α (20 µg) was incubated at room 
temperature for 10 minutes with or without peptide 8 (5 µg). Following incubation a 
protease was added, this was either trypsin, Arg-C or Glu-C (0.5 µg/µl) at a ratio of 
1:100 (W/W) with UbcH5α. The reaction was allowed to proceed for a set length of 
time (15 or 30 min) at a set temperature (4 or 30 
o
C). The reaction was terminated by 
the addition of sample buffer (1x) and incubation at 80 
o
C for 3 min. The entire digest 
reaction was run on an SDS polyacrylamide gel before staining with coomassie blue 
to detect digest products. 
 
Trypsin cleaves at the C-terminus of lysine and arginine, except when followed by a 
proline and digests free UbcH5α (~15kDa) to form one primary product of molecular 
weight ~12kDa. On the other hand UbcH5α in complex with peptide 8 was relatively 
resistant to cleavage and a higher proportion of the E2 remained undigested (figure 
4.3a). After 15 min at 30 
o
C free UbcH5α was almost completely digested (figure 
4.3a, lane 4), when the reaction was allowed to proceed to 30 minutes digestion was 
complete (figure 4.3a, lane 2). In contrast, when in complex with peptide 8, the rate 
of digestion of UbcH5α was slowed (figure 4.3a, lanes 1 and 3). When the reaction 
was carried out at 4 
o
C the rate of digestion decreases but after 30 min free UbcH5α 
was still sensitive to cleavage. (figure 4.3a, lanes 5 and 6). Arg-C cleaves at the C-
terminus of arginine and also cleaved to produce an ~12kDa band however Arg-C 
was not as efficient at cleavage of UbcH5α as Trypsin under the conditions of the 
assay. Similar to the trypsin reactions the addition of peptide 8 increased the 













Figure 4.2: Model of how peptide 8 could result in a conformational change and different 
digestion products of UbcH5α.  If the E2 contains exposed recognition sites for a protease it will give 
a certain digestion pattern. If peptide 8 binding results in a conformational change of E2 then there is 
the possibility of previously exposed recognition sites for a protease being buried and buried 
recognition sites being exposed. This will provide different size/shape fragments which will present 




















Figure 4.3: Trypsin and Arg-C digest of UbcH5α. UbcH5α (20 µg) with or without peptide 8 (5 µg) 
was pre-incubated for ten min at room temperature. Trypsin (a) or Arg –C (b) was added (1:100 W/W) 
and the digest reaction carried out at 4 
o
C or 30 
o
C. The reaction was terminated at certain time points 
by adding SDS sample buffer, containing DTT, and heating for 3 min at 80 
o
C. The samples were run 
on a 15 % agarose gel and the rate of digestion viewed by coomassie staining. Fermentas PageRuler 











This result implies one of two things, either the peptide is a competitive substrate 
binding to and/or partially concealing the recognition site for the proteases, or 
alternatively, peptide 8 binding is resulting in a conformational change of UbcH5α 
that is partially burying the previously accessible recognition site (figure 4.4 i and 
iii).  
 
Strikingly when similar experiments were carried out using the protease Glu-c, which 
cleaves at the C-terminus of glutamic acid and aspartic acid, the results were reversed. 
Thus, in the presence of the peptide, UbcH5α was more sensitive to Glu-C cleavage 
whereas the unliganded protein was resistant to cleavage (figure 4.5). This difference 
in digestion was noticeable after 15 minutes (figure 4.5, lanes 5 and 6) when the 
reaction was incubated at 30 
o
C, and the difference clearly apparent after 30 minutes 
(figure 4.6, lanes 7 and 8).  
 
This Glu-C proteolysis result implies that upon binding to peptide 8 UbcH5α 
undergoes a conformational change that opens up a previously buried recognition site 
for Glu-C (figure 4.4 iv). 
 
Although the Trypsin and Arg-C data can be interpreted as a conformational change 
in UbcH5α on peptide binding, they are not definitive as it could also be argued that 
the peptide physically blocks cleavage. The results with Glu-C however lend strong 
support for the exposure of a previously buried recognition site, this could only 
happen should a conformational change take place within UbcH5α. If a 
conformational change is taking place upon peptide binding in this digest then it could 
suggest that conformation change in UbcH5α is the reason that digestion of the 
complex is slowed in the experiments with trypsin and Arg-C. These results are my 
first clear evidence that MDM2 may allosterically activate its E2 partner. 
 
In the case of the limited proteolysis using trypsin the UbcH5α-peptide 8 complex 
was more resistant to digestion than free UbcH5α. Trypsin recognises and cuts at 
lysine and arginine at the carboxyl side except if either is followed by a proline. It 
could be argued that as peptide 8 contains one recognition site for trypsin (arginine at 
residue 8) that the rate of digestion of the complex is simply decreased because 









Figure 4.4: Model showing how peptide 8 binding to UbcH5α may affect its digestion. i) The 
peptide may physically block the recognition site of the protease protecting UbcH5α from digestion. ii) 
The peptide may contain a recognition site for the protease resulting in the appearance of slowed 
digestion or protection from digestion of UbcH5α. iii) Binding of the peptide results in a 
conformational change of UbcH5α that buries a previously exposed recognition site, protecting 
UbcH5α from digestion. iv) Binding of the peptide results in a conformational change of UbcH5α that 

















Figure 4.5: Glu-C digest of UbcH5α. UbcH5α (20 µg) with or without peptide 8 (5 µg) was pre-
incubated for ten min at room temperature. Glu –C was added (1:100 W/W) and the digest reaction 
carried out at 4 
o
C or 30 
o
C. The reaction was terminated at certain time points by adding SDS sample 
buffer, containing DTT, and heating for 3 min at 80 
o
C. The samples were run on a 15 % agarose gel 
and the rate of digestion viewed by coomassie staining. Fermentas PageRuler Prestained Protein 




















My idea was to create a control that would account for this. I needed a peptide that did 
not bind to UbcH5α and had one trypsin recognition site. Unfortunately none of the 
MDM2 RING peptides fitted this criteria, many of them contain numerous 
recognition sites for trypsin. The closest peptide matching my criteria was peptide 1. 
Peptide 1 does not bind to UbcH5α but it does have two recognition sites for trypsin, 
it was not an ideal scenario as this peptide was even more likely to compete than 
peptide 8 but I chose to proceed with this control.  
 
This assay showed that in the control lane, containing peptide 1, the mere presence of 
the peptide slowed the rate of digestion of Ubch5α (figure 4.6a, lane 11 compared to 
10), as was seen with peptide 8 (figure 4.6a, lane 12). I do not believe this result is a 
consequence of peptide 1 binding to UbcH5α, based on my earlier experiments, I 
believe that the result is due to the fact that peptide 1 contains two recognition sites 
for trypsin as opposed to the one that peptide 8 has. 
 
I tried a second control using peptide 1 in the limited proteolysis assay using Glu-C. 
Glu-C recognises aspartic acid and glutamic acid, neither peptide 8 or peptide 1 
contains these amino acids. With this control I aimed to prove that a change in 
digestion of the UbcH5α-peptide 8 complex was due to the peptide eliciting a change 
in conformation upon binding and not just presence of the peptide. The result shows 
that when UbcH5α was in complex with peptide 8 it was less resistant to digestion by 
Glu-C than free UbcH5α (figure 4.6b, lane 12 compared to 10). When peptide 1 was 
present in the assay no change in digestion of the UbcH5α was detected between this 
UbcH5α and free UbcH5α (figure 4.6b, lane 11 compared to 10). This result shows 
that it is the peptide in complex with UbcH5α that is facilitating the change in 

































Figure 4.6: Controls for trypsin and Glu-C digests of UbcH5α. UbcH5α (20 µg) with either no 
peptide, peptide 1 or 8 (5 µg) was pre-incubated for ten min at room temperature. Trypsin (a) or Glu –
C (b) was added (1:100 W/W) and the digest reaction carried out at 30 
o
C. The reaction was terminated 
at certain time points by adding SDS sample buffer, containing DTT, and heating for 3 min at 80 
o
C. 
The samples were run on a 15 % agarose gel and the rate of digestion viewed by coomassie staining. 
Fermentas PageRuler Prestained Protein Ladder used for molecular weight maker, all molecular 













4.1.4 Mass spectrometry of limited proteolysis 
 
The results from the limited proteolysis suggest that UbcH5α undergoes a 
conformational change when bound to peptide 8. I wanted to investigate this further, 
limited proteolysis, although a useful tool for probing conformation differences, does 
not provide information regarding the area(s) undergoing the change. Richer data can 
be obtained from limited proteolysis when the results of this assay are combined with 
mass spectrometry, this is a novel method developed by us and Lenka Hernychova at 
the Masaryk Memorial Cancer Institute. The bands produced, when UbcH5α or 
UbcH5α in complex with peptide 8 are digested with Glu-C, undergo in-gel digestion 
by trypsin, the peptides are then purified and analysed using an Orbitrap elite mass 
spectrometer. 
 
The Orbitrap elite (thermo scientific) is a member of the family of linear trap 
quadruple (LTQ) mass spectrometer hybrid instruments. It incorporates a dual cell 
linear trap and the orbitrap analyser (figure 4.7a). The linear ion trap is an 
independent MS detector which can store, isolate and fragment ions then send them to 
the orbitrap for further analysis. From the linear trap to the orbitrap analyser ions 
move through the gas free octapole into the gas filled curved linear trap (C-trap) 
(figure 4.7b). Ions entering the C-trap lose their kinetic energy through collisions 
with nitrogen gas and are collected in the middle of the C-trap. For ion extraction 
extracting voltage pulses are applied to the electrodes, pushing ions orthogonally to 
the curved axis and through a slot in the inner electrode. Ions of each mass-to-charge 
ratio arrive at the entrance to the orbitrap in short packets, when these packets enter 
the orbitrap at a position offset from its equator (figure 4.7c) they start coherent axial 
oscillations without the need for any additional excitation cycle. At the heart of the 
orbitrap is an axially- symmetrical mass analyser. It consists of a spindle shaped 
electrode surrounded by a pair of bell-shaped outer electrodes, it employs electrical 
fields to capture and confine ions (figure 4.7d).  
 
The in-gel trypsin digest and subsequent peptide purification, using the FASP method,  
was carried out by myself. The programming and running of the Orbitrap Elite MS 
was carried out by Petra Dvorakova, in my presence, as was the interpretation of the 





Figure 4.7: The Orbitrap Elite MS analyser. a) Schematic of the Orbitrap Elite mass spectrometer. 
b) Layout of the Orbitrap Elite MS, showing the applied voltages. c)  Principle of electrodynamic 
squeezing of ion in the orbitrap analyser as field strength is increased. d) Schematic of the orbitrap cell 
and an example of stable ion trajectory.   
 
 













I carried out one more proteolysis assay with Glu-C, using increased amounts of 
protein in order to produce sufficient material for MS, figure 4.8a shows the result of 
this assay. The image is not clear, this is due to the fact that the gel could not be 
imaged in the usual way for fear of contaminating the gel, which would in turn 
compromise the MS results, and as such this image is a photograph of the gel in 
destain hence the lack of clarity. Figure 4.8b shows a schematic of how the gel 
actually looked. I first reasoned that the lowest molecular weight band in the absence 
of peptide, band 3, represented the stable core domain of UbCh5α as any peptides that 
had been cleaved away from the core would have run off the gel or with the dye front. 
I then reasoned that band 4, which was unique to the E2 and peptide reaction, and ran 
with a lower apparent mass than band 3, would be the stable core for UbcH5α and 
peptide.   
 
UbcH5c is an extremely close relation to UbcH5α both proteins are 147 amino acids 
in length with a highly homologous amino acid sequence, only differing at 16 single 
residues. The change in residue is often subtle, with the nature of the amino acid 
retained i.e. charged, small, hydrophobic. In figure 4.9 I have overlaid the two 
structures showing that I can use the model for UbcH5c in my analysis of UbcH5α.  
Using the molecular model of UbcH5c generated by Dr Vivien Landre, as shown in 
the previous chapter the peptides generated by MS were mapped onto the model to 
analyse the stable cores. Firstly it can be seen that there is a change to the stable core 
of UbcH5α when it is in complex with peptide 8 compared to when it is free (figure 
4.10a and b). When in complex with peptide 8 amino acids 16-42 of UbcH5α that 
form β-sheets are no longer part of the stable core. Interestingly amino acids 100-111 
that form an α-helix become more stable when UbcH5α is in complex with peptide 8. 
Peptide 8 makes contact at sites distant from these changes seen (figure 4.10c), this 
















Figure 4.8: Proteolysis assay with Glu-C in preparation for MS analysis. a) Photo of coomassie 
stained 12 % SDS PAGE gel showing the results of proteolysis with Glu-C. b) Schematic diagram 
representing a clear image of the gel. All bands were excised and proteins underwent in-gel digestion 
with trypsin (0.5 µg), the results from bands 3 and 4 were used for modelling the stable core of 








Figure 4.9: Comparing the crystal structures of UbcH5α and UbcH5c. a) Crystal structure of 
















Allosteric activation of UbcH5α will have implications for its activity. Interestingly 
when ubiquitin is added to the model showing the stable core of UbCh5α, when in 
complex with peptide, clues to how this activation may affect its activity come to 
light. The α-helix within Ubch5α that becomes more stable following peptide 8 
binding is the site of ubiquitin binding (figure 4.11a and b). Ubiquitin and peptide 8 
bind to different sites of UbcH5α (figure 4.11c and d) so any change in the 
interaction between UbcH5α and ubiquitin is not due to competition from peptide 8, 
this is further evidence for peptide 8 allosterically activating UbcH5α resulting in the 




























Figure 4.10: Stable core of UbcH5α. Grey residues indicate starting material, yellow residues indicate 
the stable core left after Glu-C digestion, red residues are sites of Glu-C recognition and pink residues 
represent peptide 8. a) Model showing the stable core of free UbcH5α. b) Model showing the stable 
core of UbcH5α when in complex with peptide 8. c +d) Model of the stable core of UbcH5α when in 














Figure 4.11: Interaction of UbcH5α, peptide 8 and ubiquitin. Grey residues indicate starting 
material, yellow residues indicate the stable core left after Glu-C digestion, red residues are sites of 
Glu-C recognition, pink residues represent peptide 8 and orange residues represent ubiquitin. a +b) 
Model shows the stable core of UbcH5α, when in complex with peptide 8, interacting with ubiquitin. c 
+d) Model showing the stable core of UbcH5α, when in complex with peptide 8, interacting with 










When the RING domain is added in its entirety to the model, the same result as with 
peptide 8 is seen. No part of the RING domain interacts with UbcH5α at the exact 
same point as ubiquitin (figure 4.12). The points of interaction are close though, this 
makes sense as my previous results show that the RING binds to UbcH5α and 
ubiquitin simultaneously, if the RING has to orientate itself to bind both 
simultaneously then it is not unexpected it binds UbcH5α close to ubiquitin. 
 
Interestingly when the RING is added to the model a second point of contact between 
the RING and UbcH5α is seen. In earlier ELISA assays I had established a point of 
contact between peptide 8 and UbCh5α but the model shows a different point of 
contact made with a different area of the RING.  This point of contact is between 
residues 9-10 that form an α-helix in UbcH5α and residues 441-442 in the RING 
(figure 4.13a and b). Perhaps even more interestingly this point of contact 
destabilises part of this α-helix when compared to the stability of the α-helix in free 
UbcH5α (figure 4.13a and c). 
 
Combining limited proteolysis with mass spectrometry has confirmed that UbcH5α 
undergoes a conformational change upon peptide 8 binding. It has also highlighted 
regions of UbcH5α that become more or less stable including the increased stability of 




















Figure 4.12: Interaction of UbcH5α, RING and ubiquitin. Grey residues indicate starting material, 
yellow residues indicate the stable core left after Glu-C digestion, red residues are sites of Glu-C 
recognition, pink residues represent peptide 8, blue residues are the rest of the RING domain and 
orange residues represent ubiquitin. a +b) Model showing the stable core of UbcH5α, when in complex 















Figure 4.13: RING contact point on UbcH5α. Grey residues indicate starting material, yellow 
residues indicate the stable core left after Glu-C digestion, red residues are sites of Glu-C recognition, 
pink residues represent peptide 8 and blue residues are the rest of the RING domain. a +b) The RING 
domain contacts UbcH5α at its N-terminal α-helix. a +c) Residues 6-8 within this α-helix re 












4.1.5 Hydrogen deuterium exchange 
 
My results up to this point had suggested a conformational change of UbcH5α, 
activated upon binding of the MDM2 RING domain peptide 8. I wanted to further 
investigate this change, to do this I used hydrogen deuterium exchange. 
 
In 1954 Linderstrom-Lang developed hydrogen exchange with the goal of identifying 
hydrogen bonded structures in proteins. Using deuterated solvent he observed rapid 
exchange of amide protons for deuterium in short unstructured peptides. The 
exchange for folded proteins such as insulin were complex and took place slowly
229
. 
Exposed hydrogens exchanged quickly, partially exposed hydrogens exchanged at a 
slower rate. 
 
Using mass spectrometry to determine the deuterium label content during hydrogen-
deuterium (HD) exchange has a number of advantages including the need for less 
sample
230
. Monitoring the presence or absence of label sites in the protein after initial 
exposure gives an instantaneous snapshot of protein conformation. Folded 
conformations with more amides buried or involved in hydrogen bonding will be 
observed at a lighter mass than less folded conformations that take on more label in 




In order to localise incorporated label to specific positions in the sequence a protein 
must be fragmented following HD exchange. Application of proteolysis following HD 
exchange is the most common fragmenting method, known as bottom up 
HXMS
231,232
. Following incubation in label for different lengths of time, an aliquot is 
drawn and subjected to conditions (low pH, 0 
o
C) that drastically slow exchange. It is 
then treated with acid stable, broad specificity protease(s) such as pepsin, to generate 
a set of fragments to obtain good sequence coverage for the protein
229
 (figure 4.14). 
 
HD exchange provides insight into three dimensional structures of proteins and 
complexes that are too disordered/flexible to meet the traditional requirements of X-
ray crystallography and NMR. 
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Figure 4.14: HD exchange linked to mass spectrometry. A schematic diagram showing the route 
that the deuterated sample takes, firstly they are digested on a pepsin column, followed by an analytical 














The HD exchange was carried out in collaboration with Dr Lenka Hernychova at 
RECAMO where I have made several visits to carry out experiments, observe 
procedures and learn the basics about MS sample preparation and instruments. The 
HD MS described in this thesis used an Orbitrap Elites MS combined with a robot 
from PALsystem. I wanted to use HD exchange to probe for a conformational change 
of UbcH5α upon the binding of peptide 8. To probe for a change in the complex first 
HD exchange had to be carried out on unliganded UbcH5α Initial experiment were 
carried out in the absence of deuterium in order to determine the coverage of the E2 
structure. The coverage of UbcH5α is not 100 % (figure 4.15) i.e. peptides for certain 
sites were not found. Residue 1 (methionine), residue 87, (aspartic acid) and residues 
106, 107 and 108 (isoleucine, cysteine and serine) of UbcH5α were not covered. 
Coverage of the His tag and linker were also not found, this is less of a concern. 
Although coverage of the E2 was not 100 % it was very good when compared to 
coverage seen of other proteins. 
 
My primary purpose of HD exchange was to probe for a conformational change of 
UbcH5α upon the binding of peptide 8. However HD exchange can tell us a great deal 
about UbcH5α by itself, it can tell us about the areas of the proteins that are flexible 
and the areas that are very stable and resistant to exchange in solution. Figures 4.16 
and 4.17 show the percentage of deuterium exchange for peptides from different 
areas of the E2. The majority of α helices and β sheets are most stable and the 
hydrogens in these regions do not exchange readily with deuterium, with the 
exception of a β stand (aa 23-27, figure 4.17) leading into a flexible loop. 
Interestingly the loops show no pattern, with some exchanging rapidly and other very 
resistant to exchange. There is an area of the E2 starting at residue 51 that is dark 
blue, indicating very low levels of exchange, in actual fact this area showed no 
exchange at all. Other areas of very low exchange did not show 0 % as this result did. 
We will be repeating this analysis prior to publication to validate the data in an 
independent experiment.       
 
With a baseline of HD exchange established for the unliganded UbcH5α and with 
coverage of the E2 sequence reasonably close to 100 % I was happy to go ahead with 










Figure 4.15: Screenshot showing the peptide coverage of UbcH5α. This screenshot shows the 
coverage of UbcH5α both as a schematic diagram and as a sequence. Residues highlighted in green are 












Figure 4.16: Model showing the level of HD exchange for free UbcH5α. These models show the 
level of hydrogen-deuterium exchange for different areas of UbCh5α. Dark blue indicates residues with 
<20 % HD exchange, light blue indicates residues with 21-35 % HD exchange,  pink indicates residues 
with 36-50 % HD exchange and red indicates residues with >50 % HD exchange. These models 













Figure 4.17: The sequence of UbcH5α showing the level of HD exchange for specific residues. 
This sequence shows the level of hydrogen-deuterium exchange for the different peptides of UbCh5α. 
The lines above the sequence are representative of the peptides obtained and analysed. The block areas 
under the sequence indicate secondary structures. H=α helix, β= β sheet and T= Turn. Dark blue 
indicates residues with <20 % HD exchange, light blue indicates residues with 21-35 % HD exchange,  
pink indicates residues with 36-50 % HD exchange and red indicates residues with >50 % HD 











Different molar ratios of E2 to peptide 8 were used (1:1, 1:10 and 1:100) and E2 and 
peptide were incubated for 30 minutes at room temperature to accommodate complex 
formation. Proton exchange with deuterium was then allowed to proceed for set time 
intervals (1, 2, 5, 10, 30, 60 and 180 min) before samples were quenched with acid. 
Results for molar ratios 1:1 and 1:100 protein to peptide were not successful, with the 
1:100 ratio leading to the precipitation of E2. Not long after HD exchange 
experiments had taken place a number of other experiments with peptide 8 did not 
proceed as expected. I discovered that the newly synthesised batch of peptide was not 
the concentration it should have been based on the information provided by 
mimotopes (commercial supplier), instead it was significantly (100x) less. I believe 
that this could explain the difficulty in obtaining significant information from some of 
the HD experiments. The hydrophobic nature of peptide 8 makes it very difficult to 
synthesis successfully. I have since had a new batch of peptide synthesised by peptide 
chemists who collaborate with RECAMO and a second round of HD MS experiments 
will take place to generate publishable HD MS data.   
 
However there was some change seen in the HD experiment carried out at the molar 
ratio 1:10, with two overlapping peptides displaying a significant change in the rate of 
deuteriation (see p values in figure 4.18).  
 
Peptide ALKRIQKELSDL shows supressed deuteriation after peptide 8 binding at 
early time intervals (figure 4.18a). The shorter version of this peptide KRIQKELSDL 
also displays supressed deuteriation after peptide 8 binding at early time intervals, as 
time progresses it shows increased deuteriation (figure 4.18b). The overlapping 
peptides correspond to the N-terminal α-helix of UbcH5α (figure 4.20a and b). My 
limited proteolysis linked to mass spectrometry indicated that part of the same α- 
helix is destabilised upon peptide 8 binding. Together the HD exchange and limited 
proteolysis suggest that the N-terminal helix of UbcH5αis initially stabilised 
following interaction with peptide 8 whereas prolonged binding may lead to an 
overall increase in flexibility.   
 
The residues that become more stable are in the centre of the peptides identified above 
(figure 4.20c and d). As our modelling of the N-terminus suggests that the N-
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terminus of UbcH5α is not directly involved in peptide 8 binding this is likely to 










































Figure 4.18: Screenshot showing UbcH5α peptides that display a change in HD exchange when 
UbcH5α is in complex with peptide 8. a) Peptide ALKRIQKELSDL shows supressed deuteriation 
after peptide 8 binding at early time intervals. b) Peptide KRIQKELSDL displays supressed 
deuteriation after peptide 8 binding at early time intervals, as time progresses it shows increased 
deuteriation. The red data points display deuteriation of the peptide from free UbcH5α, the blue data 

















Figure 4.19: Screenshot showing examples of UbcH5α peptides that display no change in HD 
exchange when UbcH5α is in complex with peptide 8. This screenshot shows just some of the 
peptides that showed no change in HD exchange when from free UbcH5α or UbcH5α in complex with 
peptide 8. The red data points display deuteriation of the peptide from free UbcH5α, the blue data 
points display deuteriation of the peptide from the UbcH5:peptide 8 complex. The data from all the 






















Figure 4.20: The overlapping peptides that display a difference in HD exchange correspond to 
the N-terminal α-helix of UbcH5α. a) Residues highlighted in turquoise correspond to peptide 
ALKRIQKELSDL that showed supressed deuteriation after peptide 8 binding at early time intervals. b) 
Residues highlighted in blue correspond to peptide KRIQKELSDL that displayed suppressed 
deuteriation after peptide 8 binding at early time intervals and as time progresses showed increased 
deuteriation. c + d) Residues in grey highlight the areas that limited proteolysis linked to MS showed to 
be less stable, the change in stabilisation suggests a conformational change. This correlates with the 







Initial HD exchange experiments show some promising data that corresponds with 
earlier results using limited proteolysis. Repeating this with the correct concentration 
of peptide and different molar ratios could provide further information regarding the 
conformational changes of UbcH5α upon peptide 8 binding. In addition I plan to 































The experiments in this chapter were carried out with the aim of discovering if the 
RING domain of MDM2 could allosterically activate its partner E2, UbcH5α.  
 
At the start of my PhD there was some evidence in the literature that E2s could be 
allosterically activated by their partner E3s
35
. If this is true then part of the mystery 
regarding how RING E3s facilitate the transfer of ubiquitin from the E2 to their target 
protein could be solved. Allosteric activation of the E2 has become the favoured 
hypothesis for ubiquitin transfer by RING domains, the simple orientation 
hypothesis
28,34
 i.e. RING E3s acting as a scaffold, bringing together ubiquitin bound 
E2 and substrate and orientating them in optimum positions for transfer, having fallen 
out of favour
39,227
 due to the distance between the E3 binding site and the active site 
cysteine on the E2. Should the RING be able to allosterically activate UbcH5α any 
conformational change is likely to be subtle as studies had shown no clear structural 
differences between free E2 and E2 in complex with E3 that would explain the 
enhanced activity of E2
34
.   
 
During the course of my PhD a study was published that suggested E2s could indeed 
be allosterically activated by their E3s
228
. Using NMR this study showed that some 
E2-ubiquitin conjugates (UbcH5c) favoured a more closed conformation upon E3 
binding (Bmi/Ring1b). A change in conformation is linked to the mechanism, in this 
case it would appear that the RING docks to the nucleosome positioning UbcH5c for 
ubiquitin transfer, following transfer of a ubiquitin UbcH5c-ubiquitin is no longer 
able to access both the E2 binding site on the RING and the nucleosome at the same 
time leading to a termination of the cycle after a single ubiquitination event.  
 
Based on this literature I wanted to test for a conformational change of UbcH5α, 
designing experiments to do so presented a number of considerations. There are a 
variety of spectroscopic techniques for monitoring conformational changes of proteins 
in solution. These include circular dichroism (CD), far-UV CD can evaluate the 
overall features of the secondary structure of the protein and near-UV CD can 
evaluate the tertiary structure. NMR spectroscopy is frequently used for the structural 
elucidation of proteins in solution. Disadvantages of NMR include the need for non-
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aggregating protein and it is of limited success in the detailed analysis of fluctuating 
states of proteins due to resonance broadening and/or lack of chemical shift 
dispersion. X-ray crystallography is another commonly used technique to study the 
structure of proteins, however MDM2 is not a protein that crystallises easily, so much 
so that a crystal structure of MDM2 in its entirety does not exist. Also previous report 
suggest that it is not easy to obtain stable MDM2 RING/E2 binding
220
 , this may have 
put others off attempting to crystallise this interaction. However I have shown a stable 
interaction using protein interaction assays and alpha screens (Chapter 1) suggesting 
crystallisation may be worth a second look. As well as protein suitability another 
disadvantage of X-ray crystallography is that subtle allosteric change may not be 
visible in a crystal. No one technique for structural analysis is superior, they all have 
their advantages and disadvantages. 
 
We also considered the fact that my earlier results showed that UbcH5α binds to 
peptide 8 (See Chapter 1) and that peptide 8 is able to mimic the majority of activity 
displayed by FL MDM2. It was therefore decided that I would use peptide 8 as a tool 
to study the activation of UbcH5α. Using peptide 8 instead of the RING domain or FL 
MDM2 opens up a range of biophysical techniques and allows the optimisation of 
assay conditions before potentially introducing full length protein. In an ideal 
situation I would want to use FL MDM2 as, by using just peptide, I cannot account 
for any reciprocal changes in the conformation of MDM2 itself upon interaction with 
UbCh5α. 
 
Limited proteolysis can provide important information on the structure and dynamics 
of a protein. An advantage of using limited proteolysis is that the technique is simple 
and modest amounts of sample are required. Another advantage is that it can provide 
data on the solution structure of a protein, even if the data does not provide the high 
resolution offered by NMR and X-ray crystallography
233
. This lack of resolution was 
solved here by development of a novel approach where I coupled limited proteolysis 
to MS in order to provide information of the topology of the proteases sensitive sites 
and how they changed on peptide binding. Limited proteolysis has been used for 
structural analysis of wild type and mutant proteins
234
, analysis of overall structure 
and structural domains of proteins
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I used limited proteolysis to probe for conformational differences between free 
UbcH5α and UbcH5α in complex with peptide 8. My results using trypsin showed 
that the Ubch5α:peptide 8 complex was protected from digestion by trypsin (figure 
4.3). One hypothesis for this result is that binding of peptide 8 to UbcH5α induces a 
conformation change of UbcH5α that results in the burial of a previously exposed 
trypsin recognition site. However this result cannot be used to definitively suggest a 
conformational change in UbcH5α as there is a second possible theory for the 
protection from digestion. It is possible that the trypsin recognition site is within the 
peptide 8 binding site, and that peptide 8 simply blocks the recognition site without 
inducing a conformational change. I therefore used a second protease to see if this 
provided a clearer picture. The theory was that if other proteases also protected 
Ubch5α from digestion then it would be unlikely that the peptide would block the 
digestion sites for all of them, suggesting that UbcH5α was undergoing a 
conformational change. 
 
The actual result seen when limited proteolysis was carried out by Glu-C was 
surprising, UbcH5α in complex with peptide 8 was not protected from digestion, 
instead the complex promoted digestion when compared to free UbcH5α (figure 4.5). 
This result suggests that binding of peptide 8 to UbCh5α results in a conformational 
change that exposes a previously buried recognition site for Glu-C. 
 
My limited proteolysis results show that a conformational change of UbcH5α upon 
peptide 8 binding is highly likely. Although allosteric activation of E2s by RING E3s 
has been suggested for certain pairings
228
 there is a lack of strong experimental 
evidence, especially in the case of MDM2,  and my study is probably the first direct 
evidence that MDM2 allosterically activates its E2, UbcH5α. Interestingly during a 
time course, in which digestion with Glu-C was allowed to proceed for up to 8 hours, 
no further digestion of either free UbcH5α or UbcH5α in complex was seen than the 
amount of digestion seen after 30 minutes. This suggests that UbcH5α has a stable 
core whether it is free or in complex, as my results suggest a conformational change, 
upon peptide 8 binding this stable core may be different in each scenario.  
 
My proteolysis results suggest that there is a conformational change of UbcH5α upon 
peptide 8 binding and that UbcH5α has a stable core, it cannot however provide 
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answers regarding the precise residues involved in these conformational changes or 
stable cores. For this reason I chose to combine limited proteolysis with mass 
spectrometry, this combination has been used previously to examine the dynamics of 
protein domains
236
 but not full length proteins like UbcH5α. 
 
Models were produced from the mass spectrometry data showing that UbcH5α and 
UbcH5α in complex with peptide 8 both had a stable core, interestingly the stable core 
for each differed. One main difference is that the site of ubiquitin binding appears to 
become much more stable when peptide 8 is bound. 
 
The stabilisation of the ubiquitin binding site could help to explain why the RING 
domain of MDM2 facilitates discharge of ubiquitin from UbcH5α (figure 3.6c). The 
stabilisation of the ubiquitin binding helix could result in it becoming less flexible 
and/or more rigid in such a way that it facilitates ubiquitin transfer by ‘ejecting’ the 
ubiquitin moiety. The RING without the tail is still able to bind UcH5α (figure 3.8c) 
but cannot facilitate the discharge of ubiquitin from UbcH5α (figure 3.6c). It would 
therefore be interesting to see if the RING without the tail affects the stability of 
UbcH5α in the same way as peptide 8. If the result is different it would imply that the 
tail of MDM2 plays a role in this allosteric change of UbcH5α. 
 
A study published in 2012 states that UbcH5c conjugated to ubiquitin is a highly 
dynamic structure that prefers an open conformation. It goes on to say that binding of 
the RINGS BRCA/BARD or E4B to this conjugate shifts the conjugate towards a 
closed conformation and it shows that this closed conformation is linked to E3 
enhancement of E2-ub reactivity (figure  4.21). The study also noted that leucine 104, 
a highly conserved residue throughout the E2 family was important for this closed 
conformation and that mutating it to glutamine decreased E3 ligase activity
228
. There 
is a leucine at position 104 in UbcH5α. If this study is correct then perhaps the 
stabilisation of the ubiquitin binding domain that I show in my results could facilitate 
a closed formation of the UbcH5α and ubiquitin conjugate, the stabilisation of the 
domain could correspond to the decreased flexibility of the conjugate. It would be 
very interesting to repeat this experiment with a UbcH5α ubiquitin conjugate and then 












Figure 4.21: Schematic diagram showing how a ‘closed conformation’ of the E2-ubiquitin 
conjugate upon RING binding contributes to the overall mechanism. When the RING binds to the 
E2 the  E2-ubiquitin conjugate adopts a ‘closed’ formation. This orientates the conjugate in such a way 
that is optimum for transfer of ubiquitin to the substrate. 
 
Figure adapted from   Pruneda JN, Littlefield PJ, Soss SE, Nordquist KA, Chazin WJ, Brzovic PS, 
Klevit RE. Structure of an E3:E2~Ub complex reveals an allosteric mechanism shared among RING/U-



















I did not carry this out, as previously discussed in Chapter 1 creating a stable E2- 
ubiquitin conjugate is an extremely tricky task. I describe the new method of click 
chemistry as an alternative way to create a stable E2-ubiquitin conjugate. If this 
method were to produce a stable conjugate then this would certainly be an experiment 
worth repeating.     
 
My previous results show that the RING binds to UbcH5α (figure 3.8c) and that of all 
the RING peptides, peptide 8 has the greatest affinity for UbcH5α though Peptide 2 
also showed some affinity for UbcH5α (figure 3.1c). From the model (figure 4.13) it 
looks like residues in peptide 1 and 2 contact the N-terminal helix of UbcH5α, other 
RING E3 have also been shown to contact this α helix
228
, part of this very same helix 
changes upon peptide 8 binding to UbcH5α as demonstrated by HD exchange and 
limited proteolysis. Therefore it is likely that the change in flexibility of the N-
terminal helix on peptide 8 binding contributes to the binding of the E to the FL RING 
and that binding of the peptide 8 region of the RING then facilitates (or potentially 
disfavours) subsequent formation of additional interfaces.   
 
The limited proteolysis and mass spectrometry experiments could be developed 
further; it could potentially be used to study the change of UbcH5α, upon peptide 8 
binding, over time. As mentioned above it could also be used to look at the affect that 
peptide 8 has on the UbcH5α:ubiquitin conjugate.         
 
I used HD exchange as it is a very useful tool for studying three dimensional protein 
structure and allosteric changes that may not be detected by X-ray crystallography. I 
thought that using HD exchange would complement my limited proteolysis and mass 
spectrometry results and possibly provide more information regarding the allosteric 
activation of UbcH5α upon peptide 8 binding. 
 
For the most part my HD exchange assays were unsuccessful. Although I had nearly 
100 % primary amino acid coverage the main problem lay in the concentration of the 
peptide. Initially the concentration of the peptide was 5 mg/ml, and this was used in 
all earlier experiments. We carried out calculations and the HD exchange based on 
this. However a couple of later experiments using the peptide did not proceed as 
planned and so I re-tested the peptide concentration and found that it was 100x less 
181 
 
concentrated than suggested by the manufactures. Consequently the molar ratios of 
1:1 , 1:10 and 1:100 (E2 to peptide) that we thought we used for HD exchange were 
actually molar ratios 100:1, 10:1, 1:1 (E2 to peptide). It is highly unlikely that 
complexes would have formed at this molar ratio and any complexes that did form 
would not be detected by the mass spectrometer due to the excess of protein not in 
complex. This explains the minimal change or no complex formation that is seen in 
the results. I aim to repeat this with new peptide at the original molar concentration 
planned (1:1, 1:10, 1:100, E2 to peptide), the hope is that one or more of these ratios 
is optimal for complex formation and that we therefore may be able to detect 
conformational changes of UbcH5α due to this complex formation. 
 
The HD exchange did provide one result; there was a change in the rate of 
deuteriation of two peptides (figure 4.18) that correspond to the N-terminal α-helix of 
UbcH5α. This is the same α-helix that is destabilised upon peptide 8 binding in my 
limited proteolysis assay (figure 4.20). It is a promising sign that the results from 
these two approaches reach complimentary conclusions and it provides hope that 
repeating the HD exchange may provide us with further information. 
 
In conclusion my results show that peptide 8 binding to UbcH5α induces an allosteric 
change and that this activation may play a part in the transfer of ubiquitin from the E2 
to the target.         













Chapter 5: Results 
 




A bacteriophage is a DNA containing virus that infects bacteria and produces many 
copies within a short space of time.  In 1985 it was reported that a ‘foreign’ peptide 
could be displayed on the surface of a filamentous bacteriophage
237
, following this 
phage display technology was developed.  
 
Peptide phage display describes a selection technique in which a library of peptides 
are expressed on the outside of phage, while the genetic material encoding the peptide 
is contained within the phage. This physical linkage between the peptide and genetic 
material encoding it allows rapid partitioning based on a binding affinity to a given 
target molecule by an in vitro process known as panning. Panning is carried out by 
incubating a library of phage displayed peptides on a plate, or bead, coated with the 
target, washing away the unbound phage and eluting the specifically bound phage. 
The eluted phage are then amplified and put through additional binding and 
amplification cycles to enrich the phage pool in favour of binding sequences (figure 
5.1). After multiple rounds the individual clones are characterised by DNA 
sequencing. Next generation sequencing (NGS) is a novel technique developed by the 
Hupp/Ball labs, with NGS it is possible to sequence millions of inserts in parallel, 
previously peptide phage display data was limited by conventional DNA sequencing 
and only obtained 20-50 sequences.   
 
Commercially available phage display systems can be obtained from New England 
Biolabs, their Ph.D.™ system is based on a simple M13 phage vector , modified for 
pentavalent display of peptides as N-terminal fusions to the minor coat protein pIII. 
The phage-peptide combination has been optimised so that there is no effect on the 




















Figure 5.1: Schematic diagram showing simplistic phage display method. Panning is carried out by 
incubating a library of phage-displayed peptides on a plate (or bead) coated with the target, washing 
away the unbound phage, and eluting the specifically bound phage. The eluted phage are amplified and 
taken through additional binding/elution/amplification cycles to enrich the pool in favour of binding 
sequences. Individual clones are characterised by DNA sequencing.   
 







NEB currently provide three premade random peptide libraries, all the libraries are 
claimed to have complexities in the order of 10
9
 independent clones. I used the linear 
dodecapeptide (Ph.D.-12) library.    
Advantages of peptide phage display technology over other methods include its 
relative inexpensiveness and the short time required for the selection and 
amplification process.  
This system can be used in a diverse range of applications including the identification 
of small molecule binders, novel enzyme substrates, cell targeting peptides and 
epitope mapping. A dramatic application of peptide phage display involved the Ph.D.-
12 library being panned against taxol to identify the natural target for the drug, Bcl-
2
241
. This application demonstrated that short peptides from an unstructured peptide 
library can mimic a 3-dimensional ligand binding site, greatly increasing the potential 
for peptide phage display applications.  
I am involved in the developing of a novel use for phage display to use it to probe 
protein conformation. My goal was to determine if peptide phage display could 
provide a tool to probe the UbcH5α conformations defined in Chapter 2.  
 
Questions 
1) Can I confirm the biophysical data?  
a. Is there a conformational change in UbcH5α plus peptide 8 compared 
to free UbcH5α that can be detected as a difference in binding activity? 
b. If there is a difference in peptide binding than what implications could 
this hold for the activity of UbCh5α in ubiquitination? 
2) Can I identify peptide motifs that bind UbcH5α that could be important for 
a. activity? 
b. designing of therapeutics towards UbcH5α?    
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5.1.2 Peptide phage display utilising NGS for a novel application 
 
As described in the introduction peptide phage display has been utilised for a number 
of different applications. I wanted to use it to probe for a conformational change of 
UbcH5α upon binding of peptide 8. My hypothesis was, if UbcH5α were to undergo a 
conformational change upon peptide 8 binding this may be accompanied by a change 
in the binding specificity of the E2. As such I set up the peptide phage display assay 
to isolate those phage peptides that bound to UbcH5α and those that bound to 
UbcH5α in complex with peptide 8. I also used an empty well as a control to assay 
whether any of the phage were particularly sticky. 
 
It should be noted for my results that using peptide phage display to probe for 
conformational change is a novel idea and as such the assay protocol and 
interpretation of the results are still emerging methods. Further experimental work 
would have to be carried out in order to establish standard experimental methods and 
result analysis.  
 
The first thing to consider when carrying out peptide phage display, for any 
application, is the diversity, the proportion of possible sequence present in the library, 
of the peptide library. The more diverse the peptide library is the higher the quality of 
the library. Should a peptide library be less diverse the final results may be biased in 
favour of certain peptides and other valid peptides could be incorrectly discounted. 
 
Prior to the availability of NGS it was hard to determine the diversity of a commercial 
peptide library in the laboratory and we were obliged to go with the quality control of 
NEB. However with the advent of NGS we are now able to make or own assessment 
of library quality and diversity. Figure 5.2a is an example of a poorly diverse library, 
there are a number of clone with an exceedingly high copy number (234301) and a 
large number of clones with copy numbers in the hundreds. In a more diverse library 
there would be more clones with a lower copy number, ideally one, and no clones 
with exceedingly high copy numbers as in this library. Figure 5.2b shows the peptide 


































Figure 5.2: The diversity of phage libraries. a) Graph showing the diversity of a commercial peptide 
library, the diversity of this library is poor. b) Graph showing the diversity of a commercial peptide 
library, the diversity of this library is good. The Y axis represents the number of unique peptides with 
at least the number of copies displayed on the X axis. NGS makes it possible to test the diversity of 
commercial peptide libraries.   
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A large number of the clones have only one copy, there are much fewer clones with 
multiple copies and the highest copy number is (2574), this is 100x times less than the 
highest copy number of the less diverse library. 
 
I followed the peptide phage display protocol as described in detail in the methods 
section of this thesis. Briefly, free and ligand bound UbcH5α were captured onto a 
microtitre well, they were incubated with the phage library followed by the removal 
of unbound phage via washing, either 10 fast washes of 6 slow washes. The bound 
phage was eluted and the process was repeated again, this time adding the eluted 
phage from round one as opposed to the entire phage library. Subsequently the 
amplified and eluted phage for free and ligand bound E2 in rounds one and two, were 
sent for deep sequencing. In this method the peptide sequences are mixed prior to 
sequencing, each set of peptides from each sample are identified by a ‘bar-code’ 
introduced to the peptides during the PCR step (figure 5.3).  
 
For demultiplexing of sample, barcodes located upstream of the sequencing primer 
were read independently through  Illumina sequencing (Otogenetics, GA, USA) and 
provided as fastq files. Fastq files were then captured using a custom tool 
programmed in Java language that was used to extract amino acid sequences from raw 
NGS reads. Only forward reads were processed (as reverse reads do not capture the 
bar code).  Barcode and mimotope DNA sequences were extracted from reads that 
passed quality control. All sequences having nonsense (not in list) bar code were 
filtered out. Mimotope sequences having inappropriate length or containing nonsense 
codons (stop codons as well as some other "forbidden" codons that should not be 
present according to New England BioLabs phage library manual) were filtered out. 
Sequences passing these filters were translated, grouped by resulting peptide sequence 












Figure 5.3:  PCR primers for peptide phage display. The PCR step incorporates a bar code to the 
PHAGE peptides. The bar code differes for each of the conditions e.g the peptides that bind to free 
UbcH5α in round 1. This bar code allows the peptides for each condition to be seperated after NGS. 






















The general flow of the custom Java tool is as follows-  for each read in .fastq file: (i)) 
check quality (no "N" signs for unknown nucleotides etc.) and discard reads with low 
quality; (ii) read first 3 nucleotides which is the barcode; (iii) if nucleotides (X)n + 1 
to (X)n + 36  this is a insert sequence.  Nucleotides 1 to 36 are taken as peptide 
sequence, and translated to 12 AAs. If none of these two conditions is satisfied, read 
is discarded; (v) Sequences with barcodes are sorted so that for each unique sequence 
one line contains counts with all barcodes. Lines are sorted and top 50,000 (in terms 
of sum of all barcodes) are outputted. 
 
5.1.3 Analysis of raw data 
 
The list of peptides provided by Adam Krejci at RECAMO contains hundreds of 
thousands of peptides and so I had to try and find the best way to sort them. As 
previously mentioned this is an emerging method, therefore there was no standard 
analysis route to follow. 
 
I first sorted the results to analyse those peptides that bound preferentially to free 
UbcH5α. To do this I selected peptides that were found to bind to free UbcH5α at 
least 4x more than UbcH5α in complex. I also introduced a cut off point for analysing 
peptides, I did not analyse any peptides that were found to bind to free UbcH5α less 
than 8 times in the sample. Following this analysis I ended up with four tables that 
show the peptides that preferentially bind to free UbcH5α in round 1, for the quick 
wash (table 5.1) and slow wash (table 5.2) method and round 2, for the quick (table 
5.3) and slow wash (table 5.4) method. 
 
The data shows that there are a large number of peptides that bind preferentially to 
free UbcH5α. It could also be argued that when peptide 8 is present in the complex it 
physically blocks the binding of peptides that bind to the same site of UbcH5α as 
peptide 8. Whilst this argument may be valid for a number of the differences it seems 
unlikely that it would account for all the differences seen in the tables leading to the 







seq sum QW C QW E2   QW E2 + 8  
DSDIGPTRNHRV 393 28 28 6 
HTWHEDVNVQRP 470 21 26 6 
DLVTVSRMVVNR 169 10 25 4 
RTPEMTSLMAWG 1060 15 21 5 
VFSLTPDWRISL 54 11 19 5 
LEGDTETIVRKI 270 13 18 5 
YDSSLTMPPQAT 19 10 15 4 
SAYVRHVSGGPR 189 7 15 4 
ATSSDRHNRYVS 16 15 15 3 
TWTYDSSTMQLV 105 13 14 4 
VLSRVGHFNIPS 33 13 14 4 
GSNNVSWSTNLH 218 13 14 2 
KPQPHGIDVWLT 34 8 13 3 
DYKVTRTQVWTF 63 10 13 3 
SHSIRWDPQGAC 32 8 13 3 
KIMSQGQEPQGY 66 16 13 2 
TETFGSGLNFRG 43 3 13 1 
VSHSRAFIVSGG 84 14 12 3 
TSSIVHKIVHAR 38 9 12 3 
EVHSGRPWLRTG 52 15 12 2 
TMKPSMTRTHLL 43 11 12 2 
GNFSDTHRGLPV 47 10 12 2 
GGHFAVTVRSEL 5 10 12 2 
EGRLLWYGSPAT 23 6 12 1 
QVAVLDEKTFLR 74 12 11 3 
GFAAALAANNAQ 30 6 11 3 
DVDHSADSSLMS 56 5 11 3 
YPPYFTPPFQLM 34 8 11 3 
MPSMSTNHLNTR 373 8 11 2 
TQMRLNSYFYDS 6 11 11 2 
TLRIRCLADHTK 8 5 11 2 
SEPRAIQNLDRW 4 5 11 1 
DDFRVWWPNFPR 1546 7 10 2 
IDGNGGVQQRGL 49 7 10 2 
LTCCHVDLSANS 4 1 10 1 
SLGQSNNVSPIV 97 9 10 0 
KYATPIPYDRLA 73 4 10 0 
HGTAYSFHGPAV 100 9 9 2 
IHRYTPNEIDRA 18 6 9 2 
GKAADLAPFTRA 78 11 9 2 
RAFYSDPMLYDA 30 8 9 2 
ETLIQHIQVFAV 5 6 9 2 
TPTHYSDDGPNN 87 7 9 2 
SYIPTFPPGLSR 30 3 9 2 
DDLRPVSRIFVT 5 8 9 2 
RPEINFTQSLSS 19 3 9 2 
IDSPSLTPMKLM 7 3 9 2 
KLLHVTPSSASK 6 7 9 1 
TRRILDQGLGTT 60 7 9 1 
TTRILDQVLGTT 208 5 9 1 
SVHGTKHLSSEL 688 4 8 2 
YDAEAAAVSRRN 9 7 8 2 
191 
 
KAPPDAEPNFRH 28 3 8 2 
GQAVDLAPFIRA 3 3 8 2 
KSYNPTDYHASR 4 7 8 2 
SVNTTVTLMPTT 35 8 8 2 
GCCGPSRALLPI 16 8 8 2 
SQGPVRTHIARL 11 7 8 2 
GKHGTEKVPAHQ 3 4 8 2 
YGTRDHSVLIRQ 14 4 8 2 
YSQPDGPLWYIR 11 3 8 2 
FAFPVIPYFTHT 60 6 8 2 
GIGASPNTFRLP 23 5 8 2 
YPWLDAARHLMR 55 3 8 2 
AGAWNRDATPEP 15 8 8 2 
GSYAVVVPEGVD 4 6 8 2 
WKAADLAPFIRA 429 6 8 1 
ELGEVNTLGRVT 33 5 8 1 
GMASDGRVDSAS 15 1 8 1 
YNTHLIVSESAH 26 8 8 1 
ADANTWFPGRTK 44 5 8 1 
ALPANMGRLMEL 81 6 8 0 
NPSRVAGVNLAF 150 2 8 0 
SGILNPSQRQDL 32 3 8 0 
 
Table 5.1: Peptides that preferentially bind to free UbcH5α compared to UbcH5α in complex, in 
round one with the quick wash method. Seq= peptide sequence, sum= number of times peptide was 




















seq sum SW C  SW E2  SW E2 + 8  
NYKVTRSQVWTF 281 27 34 5 
NYKVTRIQVWTF 133 10 17 4 
QSSHSARLIQYG 371 5 16 4 
SAPPDAVPGYVH 354 20 16 4 
QSGMLRLDENHD 107 3 15 3 
GDGNSVLKPGNW 901 2 14 3 
LSIGASNISLVQ 567 11 13 3 
QGSWSPSSSHSL 169 7 13 3 
AYITKRDPHASP 108 10 12 3 
SHGEMSNIAIAS 109 8 12 2 
FSELPKQSGYFL 199 10 11 3 
STLAPTPEELHT 157 7 11 3 
STDSHYGRWVND 113 6 11 2 
SVFPKPGYNSNL 103 4 11 2 
NSVHDLMLSPPP 99 6 11 2 
DALEESNVNSAH 63 2 11 2 
TFNMKAFGTNAM 115 4 11 1 
SFHPMGLPSTSF 123 6 11 0 
FDMYPTNRNPGR 66 1 11 0 
SQSGPPMWSTFW 104 8 10 2 
TTRIFDQGLGTT 80 6 10 2 
QPDVCSIRGCTY 78 10 10 2 
YTKHLIVSESAH 49 3 10 2 
INNVPNEMPLGL 44 2 10 2 
TNSPKTFTNTSS 40 1 10 2 
DSERNTLNPYRS 82 6 10 0 
SPLLMPRMPGIG 91 4 9 2 
TLGSPSDLPISE 59 1 9 2 
EVHSGRPWLRTG 52 3 9 2 
TDTSAALSFSAR 614 2 9 1 
SLASEDTPNVLA 144 2 9 1 
LPRGTYLIYPDQ 78 5 9 1 
NKVGLVPHMSAI 65 2 9 1 
LPAWSGWGYRVL 310 5 8 2 
SIWDRYGAVSHG 72 1 8 2 
EVHSWSPWLRTG 62 7 8 2 
TFAERNVLPDLQ 59 0 8 2 
WEGSYGNAARHR 59 2 8 2 
TRITNGIDVALT 49 0 8 2 
HDTLPRASVTRQ 44 3 8 2 
HPHEMRTDGLRR 41 2 8 2 
DIASHSSQMTAL 39 0 8 2 
HHRNYLPTSGTK 36 4 8 2 
NANSSVDTATIL 68 3 8 1 
AVHADHMCSIHI 55 2 8 1 
DLKQSILSPAPG 54 2 8 1 
TELLQIDSLKGQ 54 5 8 0 
 
Table 5.2: Peptides that preferentially bind to free UbcH5α compared to UbcH5α in complex, in 
round one with the slow wash method. Seq= peptide sequence, sum= number of times peptide was 




seq sum QW C  2  QW E2  2 
 QW E2 + 8  
2 
SVPPSTNSPFSH 681 30 218 36 
KVPTVCANPEWC 769 120 205 35 
LPYKIPSTFFNI 414 12 133 11 
AVGIYHAAEHPY 264 11 118 12 
CFAIAPTRLMYS 276 25 107 6 
ALKPWDLSSNLS 284 22 100 23 
DSDIGPTRNHRV 393 26 93 20 
DSQFNKYSIATV 552 10 89 11 
DLQLPRSGPRAS 453 46 88 17 
RILPMVDTQILT 130 0 80 1 
HVADTGSLISKR 253 9 76 8 
ARSASNPSWIAP 242 14 66 7 
TDLYFESWRMTG 100 1 55 2 
MQPRSVNTIDIL 187 10 49 8 
LTAGYDHRFRQP 131 1 46 11 
HPDAEDITNTLQ 105 0 42 0 
DWSIREGHQTYP 46 3 39 0 
HIHVRTTSALVA 78 0 38 1 
VTVTDMNHDRDF 47 0 38 0 
VWAMENSIRMTL 140 6 37 7 
TDNYGGRSTQAA 483 14 37 4 
TYTSRMFIEHVR 180 10 37 2 
VPGALSKANTLG 177 9 36 5 
WAYDGDQKFRRL 183 5 35 4 
GEVAQLRSAEPY 99 44 35 1 
SSHPSNATLKTN 45 0 35 1 
ASSSLCCTRGLM 114 3 34 5 
FSLSRYPSSASI 59 0 34 0 
NYHLSEQVPRHR 325 19 32 5 
DRNLPSNQFQRS 103 0 32 0 
VKDIRGTAMRWA 37 0 32 0 
SATFPGPYHSTP 175 3 30 1 
IGSRNAPSFLLH 120 1 30 1 
RKAPETSLSIPL 101 7 29 6 
GSEPAQRLEDRK 108 6 29 4 
GGTVTNQVVTLR 134 1 29 3 
YLPYDALRKAWG 74 1 29 3 
GFARPDGSLLTS 199 6 28 7 
FPLREGHHWDAG 189 41 28 6 
NSVAWWGDFSSS 57 0 28 6 
DVVSSGHTIASI 113 8 27 6 
SSILDYIDSYPF 84 16 27 6 
194 
 
AGTHHPLYFRQV 80 18 27 3 
VHCKMPMRLLYG 44 1 27 3 
RKQHAIPLIWPA 59 4 27 2 
RIDFLSNSWSAR 61 0 26 5 
SPVSAGARNLPY 57 1 26 1 
NSSPFTTPGSSK 77 15 26 0 
AEIVPMSHRGFS 43 4 26 0 
SHAEWAMASTSS 335 12 25 6 
HHPLGWNDTVEA 107 8 25 5 
SQFATVWERMRN 158 15 25 2 
NTYIPANLHHMP 264 18 24 6 
HDSPNALTTKLN 63 1 24 0 
SLINFLAHPTQN 37 7 24 0 
AFNMTRFPERYA 30 0 24 0 
SGPSNYGASHRN 27 0 24 0 
GQSEHHMRVASF 87 0 23 6 
SHTAYSISSGGH 382 18 23 5 
ASYVKAASAVFD 129 8 23 4 
VAAAGCSRCHSG 133 7 23 1 
YSCPSSGLYSGC 92 0 22 1 
SLQWTVDLGMPP 56 4 21 5 
ASVLDYKGFFQR 79 1 21 3 
RPAVLDFHWAKI 64 0 21 1 
GGFHVSDPVMSY 55 0 20 0 
VRFPDPQVTHRL 62 2 19 4 
TVSMVNYGGSTV 276 7 19 3 
SQSGLPPATGLE 117 0 19 3 
ATARFSLTMVGF 287 4 19 2 
IVGEPRMSRSYS 138 1 19 2 
YVEPGTPLSYTH 60 0 19 1 
YPWLDAARHLMR 55 0 19 1 
TTIVQPPSKDST 80 0 19 0 
QYYGAWWHTPAA 35 0 19 0 
HTHLRDALWVHS 30 0 19 0 
KTPFNHVNQFSL 21 0 19 0 
TYITGPYRSSAP 292 25 18 3 
SPNPLPWSSRVP 191 9 18 3 
GYCMNKQHSTLD 91 1 18 2 
HESWLPAYVLGS 42 0 18 2 
GTDLYNAFKTFS 121 1 18 0 
VPSGLPSTGHRI 59 4 18 0 
EYQRSVAWLKEH 27 0 18 0 
FPTSLWSPEQDV 23 1 18 0 
SGVYKVAYYWQH 92 13 17 4 
195 
 
EPYSKRVFDPVP 70 0 17 4 
IALPNESNIHLP 175 7 17 2 
YTPSSIATPLRL 144 13 17 2 
VRSADRPNVVFE 46 0 17 1 
IAHDAVPWPASP 111 9 17 0 
GKAAGLAPFIRA 277 11 16 4 
NTNYVTWSPSSR 64 0 16 4 
ALVTSLMENEST 107 3 16 3 
QLNPTRFTPLAW 79 0 16 3 
EHWYSLVKAIPF 209 21 16 1 
GALLPSMNKGHW 192 3 16 0 
YHVPRSVFYAMH 31 1 16 0 
RAYESVSVYRAW 28 1 15 4 
DSTAKVSTLKDT 198 18 15 3 
SYAERPIQKFST 123 8 15 3 
NGPASLLQLWVA 34 0 15 3 
IPHESNALSHDE 129 1 15 1 
YSRHPSSQPVHY 82 1 15 1 
GASAVPWRTINH 70 1 15 1 
IGRQGTTDFLFS 34 0 15 1 
TVQRTDFYGSQY 17 0 15 1 
GDVMDKRNQFLF 52 0 15 0 
QQRPYVQDLRLI 48 1 15 0 
WVLSPNSFPRAK 38 1 15 0 
INTDFEKAPTPH 19 0 15 0 
NYKVTGTQVWTF 155 4 14 2 
GPSFSMLDDPSG 65 0 14 2 
TITWMWTGTPRG 187 10 14 1 
WNAPSVANGPRM 176 1 14 1 
HKLDRTWFHHTP 106 29 14 1 
FQNKVSGDSGVR 51 5 14 1 
AGTHLLNIPIDG 35 0 14 1 
AMIGNQRAWEPN 19 1 14 1 
SVAVLSKTFEVY 58 0 14 0 
SIRMSYFEFAGN 45 0 14 0 
LTVNHNLRNDSR 35 1 14 0 
VSAGERTLLLMP 34 1 14 0 
SLRSVSYNPSTL 128 11 13 3 
HPHRLWDIHQGT 69 3 13 3 
DRVHDASKLYGH 77 10 13 2 
MDENVATNQLMI 71 1 13 2 
GWNDMSSNDSNG 52 0 13 1 
GHIDHSRALGAR 17 0 13 1 
TVTSAQPSSHTR 95 11 13 0 
196 
 
FPTLSVHASAST 57 2 13 0 
RLPFSFGAPHMP 20 0 13 0 
VNNESWSWSADS 20 1 13 0 
SLPDTLNMLMLA 17 0 13 0 
QVSNSEYMRITQ 14 0 13 0 
GKAADLGPFIRA 179 8 12 4 
KLARNNDWSYMQ 124 1 12 4 
GNVHENVNTTRS 78 4 12 4 
SGNTTVTLIPTT 40 4 12 4 
SMLRVFSELREP 327 20 12 3 
STNGAVIANSKP 246 4 12 3 
GKSADLAPFIRA 181 6 12 3 
DYVSAITRIRMV 173 12 12 3 
GKAADLATFIRA 165 3 12 3 
SFWLPPQPYHPV 147 32 12 2 
DFTLLSSNGRSK 98 2 12 2 
FVDPETDLFLDD 48 10 12 0 
ASPQCCDWQAIG 41 1 12 0 
EAAYTTLDPRNQ 35 0 12 0 
QNDMLNLRVSQV 35 14 12 0 
VEASSQDERNTQ 34 0 12 0 
AADAGTQDHTLV 22 0 12 0 
SDPCGRCSITFD 16 0 12 0 
GVATGSRVETFL 12 0 12 0 
VGQLSWYTPQKT 175 9 11 2 
SSLWSELYGGSM 167 0 11 2 
SLHTSFFRTPEF 158 13 11 2 
MSGLKPVKGDLS 59 0 11 2 
NLITQAPNPSRS 242 9 11 1 
GYEDFAERVSHG 161 2 11 1 
YLVPSPPWSQTF 100 7 11 1 
GMLQHALVPKVW 18 0 11 1 
WMATTTEQLVVR 86 5 11 0 
NADPAMVTRLSA 78 1 11 0 
SPRMAAEEHSHG 60 0 11 0 
KWWSAAEGALLS 29 1 11 0 
VIAKSSPVMDYH 22 0 11 0 
TPRMAQDRAVHQ 191 27 10 2 
NSVFIPLTKPDT 154 4 10 2 
ARSTEVLFLSSS 136 12 10 2 
LLSSPRQPAMPG 133 5 10 2 
TTMRMDSMTRNP 131 7 10 2 
STIWGWSNNSHF 129 5 10 2 
DRDEGFASGWSL 59 11 10 2 
197 
 
GAETTPLSLSPP 136 7 10 1 
SGDNDTQLEYIA 117 9 10 1 
SNMHLLQPTKPR 68 4 10 1 
AMFHTRPLTSQT 58 2 10 1 
HEMDGFIVVSSY 167 1 10 0 
VFSLTPDWRISL 54 1 10 0 
LTTEVAQIMRYE 50 0 10 0 
ASLTPLVRTPSA 25 0 10 0 
ATFRPTGVPVVH 23 0 10 0 
GHRHHTIHNMNL 23 0 10 0 
SSYRPTHDTWML 22 0 10 0 
KTLNGLSLDRPY 20 0 10 0 
YAKSAQQISPMY 19 0 10 0 
TPDQSRRIGSVW 15 0 10 0 
SHPRAISAASVG 14 2 10 0 
HQVGLVPHRSMP 13 0 10 0 
SLPHPINSTYNN 10 0 10 0 
TTRILDQVLGTT 208 10 9 2 
YAIVPQRHDKHH 180 0 9 2 
KGGLEVHSRNLQ 118 12 9 2 
ASSLPQGNFARA 95 8 9 2 
TLSLDCTSHPNN 86 8 9 2 
TPIRPLESVVRH 424 19 9 1 
FPHASTLNSYGG 131 4 9 1 
FSSRASSAPHTD 95 3 9 1 
GGLQMSRHTTYT 77 0 9 1 
VHNSGLDSVIRV 66 4 9 1 
FSDDWLVNTSLK 65 3 9 1 
LVAQRTPEVEKL 61 13 9 1 
ICSSCFVQKSIV 56 1 9 1 
LTHTQHGRSATL 48 0 9 1 
GATQIQSTNRIG 26 2 9 1 
HVTSAFRFGLSA 24 0 9 1 
NPSNVHRSSANN 158 3 9 0 
TDLPIPASFGKF 105 10 9 0 
MFGPSQSIRTKV 64 8 9 0 
TMWSAHFGPLVR 57 0 9 0 
TFTAPHYPVILA 43 19 9 0 
FVERSTDNKLVG 29 2 9 0 
VASLHIPMTDHP 10 0 9 0 
NLMTASTISLWG 9 0 9 0 
AFHADHMGSIHI 185 3 8 2 
DSALPSRGFRIS 182 24 8 2 
NVARDMYRNGAD 149 8 8 2 
198 
 
SWLGLTGSGTLF 95 17 8 2 
GKAADLASFIRA 84 6 8 2 
ASATVSKPWPTG 63 1 8 2 
FAFPVIPYFTHT 60 4 8 2 
SNGSSYLFATNS 55 0 8 2 
FSDPDMRAWAFS 49 9 8 2 
ACNGRDCIPKGH 46 2 8 2 
NYPMKSLRGVHS 39 12 8 2 
ATEERSRIWMFL 34 0 8 2 
HSTHDYGTFLTR 23 0 8 2 
DLVTVSRMVVNR 169 4 8 1 
GFYQHWRVGASA 128 0 8 1 
YYPAYAHGPRGT 50 8 8 1 
SGVYKGAYDWQH 39 5 8 1 
SDAWPTKNLLIS 13 0 8 1 
GPESAMQKQMAG 111 0 8 0 
FNTVNSPNVQNN 74 17 8 0 
SDEASKTFSLGH 69 0 8 0 
QHAQRHITLGSE 62 5 8 0 
TNEPIRGTMRLS 60 1 8 0 
LTPNASRSLTSD 55 7 8 0 
APARVVTDCSRC 54 0 8 0 
SLADAGHPKGSL 49 0 8 0 
GYNLYPVVGPDE 48 7 8 0 
QAPTEIREQGLQ 35 1 8 0 
HYKQDYDWRPGK 30 0 8 0 
SHALQGPEGTAT 26 0 8 0 
SVWQGASILWRL 22 1 8 0 
NLWSYSMPNRDI 17 0 8 0 
GRIDEQARGPVM 14 0 8 0 
WTWPLPAAKMKR 13 0 8 0 
QFHHWRQNNAHQ 10 0 8 0 
NSCWVGDCERLR 9 0 8 0 
 
Table 5.3: Peptides that preferentially bind to free UbcH5α compared to UbcH5α in complex, in 
round two with the quick wash method. Seq= peptide sequence, sum= number of times peptide was 
identified in sequencing. QW= quick wash, 2= Round two C= Control, E2= free UbcH5α, E2+8= 







seq sum SW C  2 SW E2 2  SW E2+ 8  2 
TSIQISNAHPKS 1082 48 165 40 
GSGASYQVWRPM 183 5 58 3 
GLMESRPVSTPV 213 32 40 9 
ARSASNPSWIAP 242 18 36 9 
DRNLPSNQFQRS 103 1 36 2 
NYKVTRTQAWTF 336 17 35 7 
VVASAKGHIQVT 165 21 35 7 
SSVMTAAQEAWS 68 2 34 7 
NTHREVRYLTEM 148 10 31 4 
GGLHTDHFKPIL 101 15 31 1 
NHLSTPVWSITG 212 31 29 6 
GNKHVSGLDIHW 133 6 29 7 
VQFPQGRQFGAL 314 17 28 4 
HPTNVSIASTKK 87 7 28 5 
GTDTRWELLYRP 79 2 28 2 
ADPLGISYLRSS 112 28 27 6 
DVIVPPIAQTAD 100 18 27 7 
NWSHNVRLNYTY 46 0 26 2 
HYSWSWIAYSPG 186 0 25 4 
TQGYDNRVVSSK 198 13 24 4 
ALADSIHHYRFI 158 11 24 5 
SWYRPSDGPGPQ 45 2 23 4 
SVDSRVAPRLLS 135 5 22 5 
YSAAIPNWLSNW 121 8 22 5 
DRMPPFTSLELQ 62 1 22 1 
VTLHTPAPSTRA 61 2 22 2 
APLHQVSSIWQS 47 1 22 1 
SLHTSFFRTPEF 158 2 21 3 
GHDFGGKPMIWW 111 46 21 3 
AKPTAMLYPSAT 31 0 21 0 
ALKSNAWGPWMT 167 28 20 4 
FSISLIDSESHT 152 5 20 3 
YISPWHSLDLKG 107 10 20 1 
HTFHGENSHPTS 78 0 20 2 
CFAYDIVSDEMW 72 2 20 1 
VETSNGFGWPNG 25 0 20 0 
ALKPWDLSSNLS 284 47 19 1 
VSIPKNSQHHLL 165 20 19 4 
TVGLPMTYYMDT 115 0 19 2 
TLTSETPWSLNR 50 0 19 0 
GTVTGHIMRLDQ 33 1 19 1 
200 
 
GYFRVSVSEDSR 30 0 19 0 
VFAYDLPIYSKV 137 26 18 4 
GHSARTMGVLTP 41 2 18 2 
IDAHFGLRLVND 221 3 17 2 
ASTSHVSSGGSN 146 26 17 3 
QWNWPVRSVANV 130 1 17 0 
SSILDYIDSYPF 84 0 17 3 
QSVDSAPLDLRR 65 0 17 3 
DMTNVPPQRVSL 62 25 17 2 
VPWPVGSLWWDH 24 0 17 2 
QRTLSSDSTSVV 214 6 16 3 
SLGPYGLAAPIS 168 53 16 2 
KVPVGVLPLSHS 117 7 16 4 
FGPPYWSSNGQN 70 1 16 3 
WDSSDFHWIDTQ 22 0 16 0 
HIPNNGVQTYLP 21 0 16 0 
IPQIALDAQRWV 20 0 16 0 
TVFPNTQAVSMT 117 24 15 3 
LHTSIAPTDGWQ 71 14 15 3 
GTLSRDHNIVGW 70 8 15 3 
FGNRATPSSYPG 58 10 15 1 
LGLPDRRPNLLH 58 2 15 1 
AVARVLYTDDPG 53 0 15 0 
SEGHAPPVQHRI 44 0 15 0 
SALTDARTENKL 27 3 15 0 
DNGQHLWSTTTV 22 0 15 1 
TRPPVISMHSWH 22 0 15 2 
QLPFYTQRNAAS 166 11 14 3 
AQHNITAYSTTF 124 1 14 3 
LPADPVQKHRIN 105 2 14 3 
YWRPHPGHSTVG 103 9 14 1 
KLAVTTHDTSSM 74 2 14 2 
DNGHFKLSEVWA 60 0 14 2 
TNHQMSNHTEKP 55 0 14 2 
SPNLIKRMPSLS 37 0 14 1 
NGDGCRYNACAT 219 7 13 3 
SLASEDTPNVLA 144 9 13 3 
IPHESNALSHDE 129 2 13 1 
DVVSSGHTIASI 113 4 13 1 
AHDILHAMKTPR 86 2 13 1 
YVTTWTPDQRVV 57 3 13 0 
QGMGYGSNWPSI 51 10 13 1 
201 
 
ELVRTTPRMLYL 34 0 13 0 
TMPRHGSAVTTM 33 1 13 2 
IRFDTPSHLPPP 112 7 12 2 
SAVFNSYDQDVT 107 20 12 3 
HTAHVQADRPTQ 75 1 12 1 
HVANRGLTENTL 74 0 12 2 
SFADPFAQMRFV 53 1 12 2 
HAGQAHMADLTQ 40 1 12 3 
DYLRDRMSHSRP 32 0 12 1 
GFPRLSTLPAPN 30 0 12 2 
HGPTHGYFLHLR 30 2 12 2 
KPIYDGMRNSFY 28 0 12 0 
SVPTNWHTLDSL 27 0 12 0 
DSSIYYNWWMVG 26 0 12 3 
RLDFIDVFRSSF 26 0 12 0 
DWSPLANLQQNK 25 0 12 1 
VSSSEFPHRAVL 25 2 12 0 
LPPPAPWGHARE 16 0 12 0 
LLSSPRQPAMPG 133 6 11 1 
DMRALHQGTTLD 109 7 11 1 
ITGLKATDYKDW 101 10 11 2 
AKAQLMSQTWYL 86 29 11 2 
AGTHHPLYFRQV 80 2 11 2 
FGLSTENRGQYR 80 0 11 1 
VADLGAYNYPVP 76 11 11 2 
GHDLTRNTGRIS 73 1 11 2 
YPHTYSPSSWSL 65 2 11 1 
GGAVYFGQVKVA 54 0 11 1 
AHFSLKYTFTRT 53 2 11 3 
GSSSLMNPASVM 49 2 11 0 
SSDFLWNYRLLG 40 1 11 1 
ATEERSRIWMFL 34 2 11 0 
SPTYTFISTSVA 29 0 11 3 
SEMNNFSWLTVI 25 0 11 0 
SNGHSLGIKADT 22 0 11 0 
GLHDMTRPPHHG 21 1 11 0 
SQTPTTSPSTSF 21 1 11 0 
SHQFLPMGGPLP 14 0 11 0 
WTTQSTGSAARF 11 0 11 0 
AYITKRDPHASP 108 2 10 2 
DGPKYTPPIQGQ 64 0 10 0 
SLTAWKTNEMAY 63 2 10 1 
202 
 
WNDTMSHYHTRP 58 1 10 2 
SPQMWITNPGNI 55 1 10 0 
HVSWKITTIDSI 52 0 10 2 
RLDAPLNTGEYS 52 7 10 2 
NPDWFVFYDKGR 51 0 10 2 
VADSENRYKEPQ 49 0 10 0 
VNASNGESLGRR 39 2 10 0 
AFNSKIEKLDLA 36 3 10 0 
EAAYTTLDPRNQ 35 1 10 0 
WQDFGAVRSTRS 35 5 10 1 
DVWEPKFREDRT 34 0 10 0 
HHNMVPVMYSVR 34 0 10 1 
SSSHLISAEMYG 33 0 10 2 
HSVANTYPYARS 27 0 10 0 
NWHRLDGFQTLV 25 0 10 1 
VPNMRDEPAINN 18 0 10 0 
SVIQTVPMSLGL 17 0 10 2 
HVDFRRDTNSFN 13 0 10 0 
SSHLMLVESKEF 11 0 10 0 
LVGNHYGFQGGW 123 21 9 1 
CVASARGAQIGM 115 4 9 2 
LPRAPERASLAS 99 6 9 1 
TTGILDQGLGTT 97 4 9 2 
FPHDSTLNSYGA 89 4 9 0 
HSGLARNSAYWY 86 1 9 2 
GQDRMPKWPANS 81 2 9 0 
WPQRLEMGRSSA 73 1 9 0 
SAMTMNQVQTKV 69 0 9 2 
SGGAQMVASSNH 69 5 9 1 
THAKDNREPFAG 69 0 9 2 
SHEGRYIVSTVV 58 6 9 2 
GFDVRNPPRDDR 56 0 9 0 
AQFERQTQPAYE 55 3 9 1 
DRNWAYNLLQDI 50 3 9 1 
VVSPDINLLLTN 42 5 9 2 
HFDYIRLAMVSN 38 1 9 1 
VPLTGRPLSPLT 36 0 9 2 
YRLPHVPYNYAE 35 0 9 1 
GPTAYPQALTNR 30 0 9 1 
ALNSLAPSSVMT 29 1 9 1 
ANLTHHSSHLIF 29 0 9 0 
DLRFQPRMASYV 29 3 9 0 
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RPLDSPDRLNAR 28 0 9 1 
VNRDPYAGNWQM 28 9 9 0 
RCVETHVLCADM 25 0 9 1 
SVRPPSDIRSPT 24 1 9 0 
NHQTAMLGVVGD 22 0 9 1 
DSENGDSIRRFI 17 0 9 1 
YTPNAVNNVGSD 15 0 9 2 
APHPADSMMNLP 14 3 9 0 
TDVHVHPNHNHG 14 0 9 0 
NPLVHRHATLKV 9 0 9 0 
STSTFEIYRLRG 9 0 9 0 
ISMPEMLLSPLL 221 1 8 1 
SVWEPGVGNQHW 152 4 8 1 
SLDRKILRAYEE 140 9 8 0 
SNTQSERHPLSM 126 0 8 1 
KPLVGYGQMPEQ 122 3 8 1 
SHRPVEMWVAAV 110 4 8 2 
NYKFTRTQVWTF 100 2 8 2 
AGSSHYAALGWT 94 1 8 1 
VSHEGAFSGFAI 92 8 8 0 
TQPAATAIMWLQ 88 1 8 1 
LCTDPSPYCPRF 86 5 8 2 
TWRDSVHPIWRD 84 7 8 1 
YEPVGIGNMMAM 68 18 8 2 
DTHQYVHSTSIN 56 4 8 2 
YQAANTMGHVKT 56 5 8 1 
QVSVSVQNVLHR 54 7 8 2 
TAYWTTAYQQGY 54 7 8 1 
TVNSEEEIHQRI 53 0 8 1 
AVMHQSYNYYHR 52 0 8 2 
NDMTPRRAIAMS 51 0 8 1 
YIFKPDHRTNNV 49 3 8 0 
CYAGHDLYVAAD 46 0 8 2 
VGPNLEFHFDKG 45 0 8 0 
VPMQDLSTNHVT 42 0 8 2 
IPVKSWPIRPSS 41 0 8 2 
EHGTLSNIFHAR 39 12 8 2 
DLFGSVQLVRGA 35 2 8 1 
WNDYSSRPGHFD 35 1 8 2 
GSVASLSSLRGL 34 0 8 2 
NAVLPAWVPRVV 34 0 8 0 
GPPTSTPTSRNA 25 0 8 1 
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SEIGYGLMASEL 25 0 8 1 
QSHMTRGSMAPS 24 0 8 0 
QDEEFKEFAKYY 21 0 8 1 
GAGVTVTNDRDV 19 0 8 0 
SLAHDPNRFTLT 19 0 8 0 
YLNKVYPSPILL 19 1 8 0 
TWRVGHDQAYTR 18 0 8 0 
GTDKGSTYWKYN 16 0 8 0 
SYKNLSLPGAPY 14 0 8 0 
TFVFNPSITPLI 14 0 8 1 
NLDTNSDHLFMK 11 1 8 0 
YSQPDGPLWYIR 11 0 8 0 
GPFMLSYHRHPY 10 0 8 0 
SESSLVRSQTFH 10 0 8 0 
GVLISDTTYLDT 9 0 8 0 
 
Table 5.4: Peptides that preferentially bind to free UbcH5α compared to UbcH5α in complex, in 
round two with the slow wash method. Seq= peptide sequence, sum= number of times peptide was 
identified in sequencing. SW= slow wash, 2= Round two C= Control, E2= free UbcH5α, E2+8= 

















I then sorted the results to analyse those peptides that bound preferentially to ligand 
bound UbcH5α. As before I selected peptides that were found to bind to ligand bound 
UbcH5α at least 4x more than free UbcH5α and I did not analyse any peptides that 
were found to bind to ligand bound UbcH5α less than 8 times in the sample. 
Following this analysis I ended up with four tables that show the peptides that 
preferentially bind to ligand bound UbcH5α in round 1, for the quick (table 5.5) and 
slow wash (table 5.6) method and round 2, for the quick (table 5.7) and slow wash 
(table 5.8) method. 
 
The data shows that there are peptides that bind preferentially to UbcH5α in a ligand 
bound conformation. It could also be argued that when peptide 8 is present it itself 
attracts peptide binding partners and that some of the differences are simply due to its 
presence in the assay. Whilst this argument may be valid for a number of the 
differences it seems unlikely that it would account for all the differences seen in 
tables, also if this were the case I would think that this would give more not fewer 
overall binders, leading to the conclusion that there is a conformational change of 
UbcH5α upon peptide 8 binding. Interestingly there are many less peptides that 
preferentially bind to ligand bound UbcH5α compared to the amount that 
preferentially bind to free UbcH5α. This could be due to the nature of the 
conformational change, if UbcH5α were to become more ridged/less flexible upon 
peptide 8 binding, then it could be that it is less receptive to interactions with peptide 
















seq sum QW C  QW E2   QW E2 + 8  
NRDFLNLKPWDI 71 11 2 10 
TFNMKAFGTNAM 115 5 0 9 
NYKVTRIQVWTF 133 9 2 8 
 
Table 5.5: Peptides that preferentially bind to UbcH5α in complex compared to free UbcH5α, in 
round one with the quick wash method. Seq= peptide sequence, sum= number of times peptide was 


























seq sum SW C  SW E2  SW E2 + 8  
NPSRVAGVNLAF 150 5 4 14 
AHVKLYHRNGAT 101 6 4 14 
TRRILDQGLGTT 60 5 2 11 
DRMASTVLSMGS 90 3 2 10 
KNLRDDRFEMSA 73 1 2 10 
DSSIVYKPLHSP 97 5 2 9 
QKVEYSRWHQPL 65 3 2 9 
SSVAVAHSMRDN 102 13 2 8 
 
Table 5.6: Peptides that preferentially bind to UbcH5α in complex compared to free UbcH5α, in 
round one with the slow wash method. Seq= peptide sequence, sum= number of times peptide was 























seq sum QW C  2  QW E2  2  E2 + 8  2 
IGLPHSANSTKP 428 102 14 58 
EDLRKESSRLVD 298 3 9 55 
VTSPIDSGARQL 344 2 5 54 
GDGNSVLKPGNW 901 6 6 48 
SSAFDSRMNVHW 57 0 0 47 
VFAYDLPIYSKV 137 1 6 33 
WNLDYAPSGVPT 191 16 5 30 
TNDPSHRYEMLM 203 6 3 30 
SLASEDTPNVLA 144 1 6 25 
SPSWVPSAPNER 142 0 3 22 
YSLPYQMYAYHT 218 7 2 21 
KMPKENPSSWLS 64 1 0 21 
FVTHASANPWIP 45 1 0 21 
LSVSGGNSYVTT 81 0 4 19 
LQTTTNSLSELV 101 1 2 19 
LRLDSHVNMSRD 89 8 0 18 
TVISSVSTPANS 138 25 3 17 
WTEGWRWINFHP 103 19 2 17 
SHGELMQGLAMQ 119 4 1 17 
WSAKDVINFIRV 19 0 0 17 
SIQLERVSKWSL 18 0 0 17 
NLHDASSFPYHW 535 3 4 16 
ELLAYDSPPAVG 92 3 4 16 
VSPAKYKPLILA 247 63 2 16 
HSGQPFTKVVSH 51 0 2 16 
MYPTNPNPFNTR 40 0 0 16 
TVGLPMTYYMDT 115 23 1 15 
HHSNTWTGPLRS 39 1 0 15 
SNTQSERHPLSM 126 4 4 14 
LVPDVHLLLSYA 75 0 2 14 
SSRDAAFSWTMT 31 0 1 14 
HYAQMSIVGRTS 121 41 1 13 
TLGGLYQFEYAL 25 0 0 13 
TIYTSGLAAFNR 183 69 3 12 
DRMPPFTSLELQ 62 1 2 12 
IPLNTALFATRN 47 0 2 12 
AGESFEGAAEPF 44 1 2 12 
SPLQLDVGGPKP 37 12 2 12 
HTPLAWHWAVQN 52 27 1 12 
HSSIALEAQTDS 74 2 0 12 
ASHVLWSTVTYM 16 0 0 12 
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SHYFPPSNQTSR 25 0 3 11 
DNGHFKLSEVWA 60 15 2 11 
LVGNHYGFQGGW 123 31 1 11 
DYDRIPDIPMLG 109 21 1 11 
LGHSGGPTRPSW 45 11 1 11 
YEGRWAELDSLK 16 0 1 11 
HPTNVSIASTKK 87 11 0 11 
CFAYDIVSDEMW 72 1 0 11 
TNMPSPSLTNHY 39 2 0 11 
QFDSQGYVSYNP 36 0 0 11 
GGARTMYQAIGI 14 0 0 11 
IETSHYRGYPPN 14 0 0 11 
STVSRDFMHMHG 14 0 0 11 
TTPDGSPEPNSL 14 0 1 10 
YGEVMDAMQANG 81 1 0 10 
FTVARPLQWSLT 52 0 0 10 
SWSLPSVWRLHA 47 17 0 10 
ELVRTTPRMLYL 34 1 0 10 
LQPSGSSPVAPF 26 0 0 10 
TSSWQEVIRMSV 23 0 0 10 
STYHSTRDSLPQ 15 0 0 10 
NYKVTRTQVLTF 228 4 2 9 
LSVHLPVVDSPN 205 7 2 9 
TLSWYDSTYAHH 191 62 2 9 
FTADVLSERSEY 154 1 2 9 
CVASARGAQIGM 115 6 2 9 
KVLPPLWVQAYE 74 1 2 9 
KVPVGVLPLSHS 117 0 1 9 
SMEEAVVSPTST 71 1 1 9 
RIQELSPIRTWA 43 4 1 9 
SEVSNSVAGNWR 12 0 1 9 
GEHMHAVLMIEG 23 0 0 9 
FCLDRSHCVIGG 16 4 0 9 
MADARMTGEHIL 12 0 0 9 
YIWPFSAVWETP 126 59 2 8 
VIGKGHPMIVTV 95 0 2 8 
MHEGILIEPMTA 93 0 2 8 
FAASDMAGFKWV 79 0 1 8 
FNMTGRGLFPPF 71 0 1 8 
STTANEVAKITT 60 1 1 8 
QIAGGSPSKVER 134 1 0 8 
SPNLLFPISTRN 69 17 0 8 
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SSVMTAAQEAWS 68 2 0 8 
GLPSEHQMLPAR 46 0 0 8 
TIRLNKAPSPDV 29 1 0 8 
SWVPMSQIVELR 12 0 0 8 
AEMGALVTHFSL 11 0 0 8 
HHPRLSMDAMDH 8 0 0 8 
 
Table 5.7: Peptides that preferentially bind to UbcH5α in complex compared to free UbcH5α, in 
round two with the quick wash method. Seq= peptide sequence, sum= number of times peptide was 
identified in sequencing. QW= quick wash, 2= Round two C= Control, E2= free UbcH5α, E2+8= 
























seq sum  SW C  2  SW E2 2 SW E2 +8  2 
TPAGGWLAWLSH 183 9 11 55 
ELFTTNNVRPEN 393 34 9 41 
HSDATVRFAHRE 428 49 5 28 
WNKPLSDRDAPI 89 6 5 28 
FTADVLSERSEY 154 2 5 25 
IGTLPLKIENRR 98 2 2 24 
YIWPFSAVWETP 126 11 0 20 
ASTAGYPGGALS 30 0 1 20 
GFIHDYSGSHRS 29 0 1 19 
ALLANHEELFQT 117 43 1 18 
MLSKLPVSIDET 23 0 1 18 
GHLTVVGTNYHR 188 14 6 17 
SPSWVPSAPNER 142 27 3 17 
GHYHKSRDQLLL 79 1 0 17 
MDNKTTRWRDPL 36 1 0 17 
STQSAVCMNCHD 76 0 1 15 
VSLSGVSSNSRV 222 15 1 14 
DSSIVYKPLHSP 97 6 1 14 
NNANPHLPKQWL 94 13 2 14 
SGDVPVTSTYTS 91 1 2 14 
EHPNTSGNSVVD 46 0 1 14 
WNAPSVANGPRM 176 29 3 13 
SLFNPLQMLPYP 95 3 3 12 
ELLAYDSPPAVG 92 1 2 12 
ALAADTPQSARR 90 7 1 12 
LGVREYGMRGLG 84 22 2 12 
FPALSEFGSSLR 73 4 2 12 
FGVERDDAAHRW 37 3 0 12 
SQFATVWERMRN 158 39 2 11 
FSWSMVMPWPTA 143 1 2 11 
LVPGAMKLLSDT 115 0 3 11 
STDSHYGRWVND 113 4 3 11 
NSVHDLMLSPPP 99 1 1 11 
HDLTSYVTLKAQ 74 5 0 11 
VARATSHGPSTT 74 2 1 11 
NTNYVTWSPSSR 64 0 0 11 
GPSWLFIHSWQS 55 0 0 11 
NDAAEMTWASLV 37 0 0 11 
HDASWRDVTAMV 24 0 1 11 
TVPRSSSVPTQW 153 7 1 10 
VAPVSFQPWVHS 112 1 2 10 
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HMRFDHMRPQTG 63 6 2 10 
MGLESTSLMADS 59 0 0 10 
GDVMDKRNQFLF 52 0 0 10 
NYPATNTHRYTP 32 7 0 10 
GYHTTYSAGPKW 12 0 0 10 
VEHMAYWDQVLD 148 4 1 9 
FPFTFAHATGAS 113 15 2 9 
GKAADLTPFIRA 110 8 6 9 
TDLYFESWRMTG 100 8 0 9 
YQKYDPAMVSVT 74 11 0 9 
LQVGTLNIQLTN 54 1 0 9 
RLDLATSNWPSR 36 0 1 9 
YGHAGARPATAT 34 1 0 9 
YSYPPTKLALAN 31 4 0 9 
SKFMDSQSRMWR 27 0 0 9 
TLQGYAIDSDYL 18 2 1 9 
AVPTPFAHGSNL 17 0 0 9 
NLPIPPHIPLPQ 12 0 0 9 
SLLSSGQASITG 154 2 1 8 
VIGKGHPMIVTV 95 1 1 8 
DSYTRATNWSPH 65 2 2 8 
YTTHLIVSEPAH 65 1 2 8 
TLSLDWTIHPNN 58 1 2 8 
HHLPFVRDGLRP 50 0 1 8 
YPAVNLRTPVYF 50 5 5 8 
AVWRTQASPQSL 48 1 0 8 
EYWSLGSHQTIY 48 11 2 8 
SPGHAHLRLDKR 40 0 0 8 
DSTNSSMSLTGM 31 0 1 8 
KNLYSEHYRGPA 31 2 0 8 
DMGLHYVQFDHV 30 0 1 8 
APYHPLDSLTPN 21 0 0 8 
FPTPLTETSFED 19 0 0 8 
GVTHNSTNWLYR 19 4 0 8 
SQPHMQNAPSKT 17 0 1 8 
TGTMPNSFPQSG 11 0 0 8 
FSISYFPQYPVQ 8 0 0 8 
 
Table 5.8: Peptides that preferentially bind to UbcH5α in complex compared to free UbcH5α, in 
round two with the slow wash method. Seq= peptide sequence, sum= number of times peptide was 
identified in sequencing. SW= slow wash, 2= Round two C= Control, E2= free UbcH5α, E2+8= 
UbcH5α in complex   
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I have used peptide phage display to demonstrate a likely conformational change of 
UbcH5α upon peptide 8 binding. I came to this conclusion based on the fact that 
different peptides bind to free UbcH5α than to UbcH5α in complex with peptide 8. 
 
The results gathered are what I had primarily set out to achieve, however this is just 
one way to analyse that data that I have obtained. There are a number of ways that the 
peptides could be analysed to provide various information, such as consensus sites in 
the binding peptides, protein binding partners of UbcH5α, families of proteins that 
bind UbcH5α and the roles binding proteins may play in UbcH5α function. I have not 
analysed my data in this much detail, this is something I would like to pursue and is 
highlighted in ‘Further Work’. I have however provided examples of how my data 
could be analysed to obtain further information. 
 
The peptides listed in the previous tables could be analysed to identify consensus 
sequences. A consensus sequence is a genetic sequence found with minor variations 
and similar functions in different genetic locations. The consensus sequence may 
consist of DNA nucleotides or amino acids. In a consensus sequence some residues 
are absolute and others can be variable, with either any other residue viable or only a 
certain subset viable. Software can be used to identify consensus sequence within 
peptides, one of these programs is MEME. In figure 5.4 is the consensus sequences 
identified by MEME from the list of peptides that preferentially bind to free UbcH5α 
or ligand bound UbcH5α after two rounds of panning, using the slow wash method. 
Each sequence was identified twice within the list of peptides. Further analysis would 
be required to assess whether these sequences.  
 
Although computer software is an extremely useful tool for the analysis of peptide 
phage display data any peptides that appear to be interesting need to be validated. It 
would be an extremely time consuming and expensive task to validate all the peptides 
displayed in the above tables. I would further narrow down the peptides for validation 
by sorting the round 2 fast and slow wash tables into a top ten, based on the difference 
of a peptide binding to UbcH5α over UbcH5α in complex (figure 5.5). I would then 








Figure 5.4: Peptides that preferentially bind to free UbcH5α or  ligand bound Ubch5α, in round 
two of panning with slow wash method, analysed by MEME. a) The top five consensus sites in 
peptides that preferentially bind free UbcH5α as determined by MEME, each site was identified twice. 
b) The top five consensus sites in peptides that preferentially bind ligand bound UbcH5α c) Key 















Figure 5.5: Top Ten peptides that preferentially bind to free UbcH5α in varied conditions. 
a)Round one, quick wash method b) Round one, slow wash method, c) Round two, quick wash method 
d) Round two slow wash method. Seq= peptide sequence, sum= number of times peptide was detected 
in sequencing, QW= quick wash, SW= slow wash, 2= round two, E2= free Ubch5α, E2+8= UbcH5α in 




















Figure 5.6: Top Ten peptides that preferentially bind to UbcH5α in complex with peptide 8 in 
varied conditions. a)Round one, quick wash method, it should be noted there is not 10 peptides that 
bind hence the reduced top ten b) Round one, slow wash method, c) Round two, quick wash method d) 
Round two slow wash method. Seq= peptide sequence, sum= number of times peptide was detected in 
sequencing, QW= quick wash, SW= slow wash, 2= round two, E2= free Ubch5α, E2+8= UbcH5α in 
















Forty is still a large number of peptides to validate and so I would probably narrow it 
down further and validate the top 5 peptides in each of these tables. There are 
instances in which I may not select one of the peptides should the control be very 
high, I would be suspicious of the result if the peptide bound with high affinity to the 
empty control well, an example of this can be seen below: 
  
 SUM C E2 E2 + 8  
ALLANHEELFQT 117 43 1 18 
 
A second way of narrowing down the peptides to validate is to take the peptides 
obtained in the ‘top ten’ tables above or alternatively the consensus sites identified by 
MEME and BLAST them. Basic Local Alignment Search Tool (BLAST) is an 
algorithm that compares primary biological sequence information. During a BLAST 
search a query sequence is compared with a database of known sequences and 
database sequences that resemble the query sequence are identified. BLAST could be 
used on the peptides in the top ten tables or MEME consensus sites to see if the 
peptides are present in any proteins that may be important in relation to UbcH5α, then 
these peptides could be chosen for validation. For example I ran the top consensus 
motif, identified by MEME, for peptides that bind to free UBCh5α and the top hit was   
a deubiquitinating enzyme. It is very interesting that a deubiquitinating enzyme would 
bind to UbcH5α only when it is not bound to the RING. This peptide is one that I 
would choose to validate.  
 
Once selected there are a number of ways in which the peptides could be validated to 
bind to UbcH5α or UbcH5α in complex, these include ELISAs, α screens and pull 
down assays.  
 
Finally BLAST could be used on all the peptides generated in tables 5.1-5.4, they 
could be run through BLAST and the protein hits gained from this could be put into a 
program such as Cytoscape. In Cytoscape the proteins could be analysed and sorted 




In conclusion peptide phage display has further provided evidence for a 
conformational change of UbcH5α upon peptide 8 binding and yet has also shown 




































We now appreciate that proteins can be regulated through their interaction with short 
linear peptide motifs in binding partners. Such peptide motifs are predominantly 
found in disordered regions, and are characterised by low binding affinities which are 
crucial for reversible signal transduction events. These linear motifs are typically very 
short and their specificity, on average, can be determined by as few as 3-4 residues
242
. 
Peptide phage display is a relatively new technique which exploits short linear 
interaction motifs and which can be applied to many experimental situations to 
analyse large numbers of linear motifs in a high-throughput format. The applications 
of peptide phage display are constantly evolving and developing. It has previously 
been used in a diverse range of applications including the identification of novel 
enzyme substrates and cell targeting peptides as well as epitope mapping. I used 
peptide phage display in an attempt to further confirm the conformational change of 
UbcH5α upon peptide 8 binding that I had previously identified using limited 
proteolysis and mass spectrometry (Chapter 2). My hypothesis reasoned that if there 
was a conformational difference between free UbcH5α and UbcH5α in complex then 
there would be a difference in the peptides that it could bind i.e. the unliganded form 
of the UbcH5 may have a different binding specificity than the E2 in its bond 
conformation.  
 
There are certain drawbacks when using an emerging method for a novel function. 
Firstly I had issues with the method itself; I used two methods which were for the 
most part identical apart from the wash step. In one method the washes were quick 
and in the other method they were slow, by this I mean that the unbound ligand was 
either washed away from the well 10x, with the wash immediately discarded or 6x 
with the wash left on the well for 5 minutes. The length of the washes clearly makes a 
difference as when examining the results there are differences in the peptides obtained 
depending on the length of the wash. It should be noted that not all the peptides are 
different just that there are some differences. I do not know which results I should 
use, as of yet I am analysing both. I currently do not know if one method holds more 
advantages than the other; it would take further experimental work and validation to 




I am also not entirely sure if the controls that I have used are relevant or used 
correctly. I used a blank well to test for ‘stickiness’ of any of the peptides. In some 
cases the number of copies of peptide eluted from the control, free UbcH5α and 
UbcH5α in complex were all of a similar value and very high, in these cases I 
assumed that the peptide was sticky. There are other results however that show a high 
value for the control and then a lower value for binding UbcH5α, an example of such 
a result is displayed below: 
 
seq sum 




 SW E2+ 8 
AMP 2 
ALKPWDLSSNLS 284 47 19 1 
 
In a case such as this I am uncertain if it is a true result, the peptide does not appear to 
be sticky as the result value with protein is low but I am still unsure as to why the 
control is so high. 
 
The results of the peptide phage display are generated as a numerical value. When a 
result is numerical the natural questions that follow are regarding statistics. Statistics 
do not apply to the results of peptide phage display, just because there are numbers 
present does not mean that a p value can be applied to them. The peptides in this assay 
are not neutral and so they could potentially provide the bacteria with a growth 
advantage or disadvantage and as such the actual number is not significant. I look at 
the peptide phage display as an enrichment assay and therefore analyse the results as 
such. I chose to analyse results that were 4x higher than that of their counterpart, I do 
not know if this is significant until I validate my results by carrying out further 
experiments. As mentioned previously I could validate the peptides by ELISA, α-
screen or pull down assays. If this assay were repeated and enough validations were 
confirmed then it may in the future be possible to make statistical rules for analysing 
peptide phage display data for conformational changes of a protein.  
 
I wanted to use peptide phage display to confirm a conformational change in UbcH5α 
upon binding to peptide 8. My results show that there is a difference in peptides that 
bind to free UbcH5α and UbcH5α in complex with peptide 8, this difference may 
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suggest a conformational change, though there are other arguments for this difference. 
For example it could be argued that when peptide 8 is present in the complex it 
physically blocks the binding of peptides that were previously able to bind free 
UbcH5α. Secondly it could be argued that when peptide 8 is present it can bind some 
peptide phage.  These are two valid arguments and it is likely that some of the 
differences in peptide binding are simply down to the presence of the peptide. It does 
however seem unlikely that all the differences a simply due to the presence of the 
peptide.  
 
My previous limited proteolysis and mass spectrometry data indicated a 
conformational change of UbcH5α upon peptide 8 binding and in combination with 
the peptide phage display data I believe that there is a strong argument for the 
conformational change of UbcH5α upon peptide 8 binding. 
 
The mass spectrometry data suggested that upon peptide 8 binding a very stable core 
of UbcH5α was formed. It is possible that when peptide 8 binds to UbcH5α the 
complex is very ridged and less flexible than free UbcH5α. In the peptide phage 
display data less peptides bind preferentially to UbcH5α in complex than free 
UbcH5α, this  could be because the complex is less flexible and less receptive to 
binding partners than free UbcH5α. 
 
As well as being used to probe for changes in E2 specificity and conformation the 
data I have obtained using phage display can also be analysed in other ways to extend 
its utility.  For example to identify lead molecules or to define novel members of the 
E2-interactome.  
 
I have outlined how next generation sequencing data from phage peptide display can 
be analysed by MEME to provide consensus sequences. An application of the MEME 
sequences is to use them as the basis of a bioinformatics screen for open reading 
frames which contain similar motifs. For example, when I BLAST the top two 
consensus sequences provide by MEME analysis for peptides which bind to 
unliganded UbcH5 I can identify consensus sequences in proteins which are known 
to be involved in ubiquitination, such as and TRABID/ZRANBI and UCHL5/UCH37 
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(Figure 5.7). The next step in this type of approach would be to synthesise both the 
MEME peptides and the homologues region from TRABID/ZRANBI and 
UCHL5/UCH37 to see if the sequences bind to UbcH5. Following on from this you 
could begin by determining if the two proteins interact in cells, for example using 
proximity ligation assays and/or co-immunoprecipitation analysis. Based on the 
output from this type of experimental approach you could subsequently undertake a 
detailed molecular analysis on the role of complex formation on the function of the E2 
partner proteins. This type of approach could therefore help to further decipher the 
role and mechanism of UbcH5 in ubiquitin mediated signalling.  
 
UbcH5α was originally thought to be an undruggable target of the ubiquitination 
pathway, as it was characterised as very ‘flat’ protein with no obvious binding pockets 
or crevices. However, a recent study has suggested that small molecules can be 
identified which bind to the E2 and inhibit its function. Using this study as a proof of 
concept peptides identified using phage display may provide binding motifs that can 
be utilised as a lead biologic molecule for use in structure based drug design 
strategies
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.   
 














Figure 59: BLAST of MEME consensus sites. BLAST data of the top two consensus sequences 
provided by MEME analysis of peptides which bind to unliganded UbcH5a identify consensus 
sequences in proteins which are known to be involved in ubiquitination, such as the deubiquitinating 




Chapter 6: RESULTS 
 




At the start of this project information regarding the dimerisation of MDM2 provided 
more questions than answers. It is true that MDM2 is able to form a dimer, the 
solution structure shows that MDM2 can form a stable homodimer
130,139
 or 
heterodimer with its homologue MDM4
130





The solution structure shows that the homodimer interface primarily includes residues 
Val451, Lys453, Thr455, Gly456, Leu458, Met459, Val486, Leu487, Thr488, 
Tyr489, Phe490, Pro491
130
. Six of these residues reside within the C-terminal 12 
amino acid tail of MDM2. The tail of MDM2 has been implicated as necessary for 
dimer formation with tail mutants running on an polyacrylamide gel at a size 
depicting monomeric structure
141
. Conversely a student with Professor Malcolm 
Walkinshaw, working on MDM2 prior to my PhD had shown, via gel filtration, that 
MDM2 without the tail could still form a dimer (‘Biochemical and Biophysical 
studies of MDM2-ligand interactions.’). So the first question raised was ‘Is the tail of 
MDM2 involved in dimer formation?’ 
 
There is also controversy regarding whether MDM2 must be present as a monomer or 
dimer to be active as an E3 ligase. There are in vitro studies that report that MDM2 is 
active as an E3 ligase towards p53 regardless of whether it is in monomeric or dimeric 
form
141
 and there are opposing in vivo studies that report that MDM2 must be dimeric 
to be active as an E3 ligase
102
. This raises the questions ‘Is MDM2 active as an E3 
ligase as a monomer, dimer or both?’ and ‘If active as both is there a preferred form?’. 
 
If we assume that MDM2 is active as an E3 ligase when a dimer, whether or not it is 
also active as an E3 ligase when a monomer, then the questions arise of whether or 
not it is active as a homodimer, heterodimer or both, and if both, is one preferred. 
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Heterodimers of MDM4 and MDM2 have been shown to be highly stable 
130,139
 this 
does not necessarily mean that in the cells the heterodimer is the preferred dimer 
required for E3 activity of MDM2. There are functions other than E3 ligase activity 
that could be the sole reasons that MDM2 and MDM4 form a dimer. Experiments 
show that when MDM4 is not present in cells MDM2 is inefficient at down regulating 
p53 due to its very short half-life. Association of MDM2 with MDM4 leads to an 
increase in steady state levels of MDM2
185
. MDM4 is present in the cytoplasm and 





My results so far would suggest that MDM2 is active as an E3 ligase, independent of 
its association with MDM4 in vitro, as my ubiquitination assays contain no MDM4 
and ubiquitination of p53 is seen. This of course does not mean the heterodimer is 
inactive as an E3 ligase or that it is not the preferred dimer for E3 activity, the results 




1) Does MDM2 form a homodimer in solution? 
 

















6.1.2 Full length MDM2 dimerises in solution as detected by SERS. 
 
During my PhD I had the opportunity to contribute to a publication investigating how 
surface-enhanced Raman scattering could be used to study protein interactions, and in 
particular MDM2. 
 
Current techniques used to probe interactions in biological systems commonly use 
read out tools such as fluorescence
244
. Disadvantages of these methods include a high 
background from biological media, limitations due to broad emission bands and the 
inability to probe interactions over distances greater than 10nm. Surface-enhanced 
Raman scattering (SERS) is a vibrational spectroscopy that provides a similar 
sensitivity to fluorescent methods but narrower spectral peaks allow for the detection 
of multiple species simultaneously
245
. SERS interrogates an analyte adsorbed onto a 
roughened metal surface and can be enhanced by the aggregation of nanoparticles 
(NP). NP and SERS have been used for proteomic investigation
246
 and a number of 




Our collaborative study with the group of Professor Duncan Graham (Strathclyde) 
and Professor Ted Hupp (Edinburgh) began with a solution based approach to 
investigate the interaction of full length MDM2 with a p53 peptide mimic using the 
selectivity and sensitivity of SERS. Cell based studies suggest that MDM2 is dimeric 
in solution
141
. So the theory behind this investigation was that putative dimerisation of 
FL MDM2 , through its RING domain would present two N-terminal hydrophobic 
pockets, per dimer, to interact with ligands, in this case the p53 Box-1 mimic peptide, 
12.1. N-terminal interactions of 12.1 would therefore bring together two peptide 12.1 
functionalised nanoparticles (PSN-12.1) in solution. PSN aggregation from MDM2 








Figure 6.1: a) Schematic of the proposed assemble of PSN through specific interactions between 
peptide 1.1 and MDM2. Inset i) and ii) show two proposed models for MDM2 binding resulting in 
PSN aggregation from MDM2 dimerisation. b) Sequence (C-N) of peptide 12.1 
Figure adapted from Robson AF, Hupp TR, Lickiss F, Ball KL, Faulds K, Graham D. Nanosensing 
protein allostery using a bivalent mouse double minute two (MDM2) assay. Proc Natl Acad 








Peptide 12.1 and the negative control mutant, 12.1WΔA, were modified with 
benzotriazole and directly conjugated to EDTA reduced silver NP in a one-step 
reaction. I showed that benzotriazole modified peptide 12.1 and mutant peptide 12.1 
displayed high level and low level binding, respectively to MDM2 protein, in peptide 
competition assays. I carried out a competition assay in which biotinylated p53 Box-1 
peptide was adsorbed onto a streptavidin coated microtitre well and fixed levels of 
MDM2 (100ng) were titrated in with increasing amounts of indicated peptide, 12.1, 
12.1WΔA and Nutlin-3. Nutlin-3 is a small molecule that binds to the hydrophobic 
pocket of MDM2 and competes with p53, or biotinylated p53 Box-1 peptide for 
MDM2 binding. Unbound protein and or peptide were removed by extensive washing 
and binding of MDM2 was quantified by monoclonal antibody 4B2. My result shows 
that peptide 12.1 is almost as potent as Nutlin-3 in displacing MDM2 from p53 
(figure 6.3) 
 
Unlabelled MDM2 was added to PSN solutions at various concentrations based on 
molar excess of protein to PSN and was shown to induce PSN aggregation (figure 
6.2). There is the remote possibility that 12.1 can bind elsewhere in MDM2 other than 
the N-terminal hydrophobic pocket, and that this is causing the aggregation of the 
PSN. There is no evidence for this model in the literature so it is assumed that the 
aggregation is the result of the dimerisation of MDM2.  
 
This study showed that full length MDM2 was able to aggregate PSN-12.1, 
suggesting that FL MDM2 is dimeric in solution and maintains the biological activity 
of the hydrophobic pocket. It would be interesting to repeat this experiment with 
MDM2 ΔT and to see if the same level, diminished levels or no level of aggregation, 
when compared to MDM2 is seen. Repeating this experiment in this manner could 








Figure 6.2: SERS analysis of PSN aggregation. a) Calculated x-fold increase in SERS intensity 
following MDM2 addition to PSN-12.1 (red) and PSN-12.1WΔA (blue). b) Peak height at 1416 
cm
−1
 monitored every 60 seconds for 30 min following addition of varying amounts of MDM2 to PSN-
12.1 (red) and PSN-12.1WΔA (blue). X-value represents the excess of MDM2 monomers per PSN. 
Dotted line indicates PSN samples when MDM2 is absent. Error bars illustrate the SD. 
 
Figure from Robson AF, Hupp TR, Lickiss F, Ball KL, Faulds K, Graham D. Nanosensing protein 















Figure 6.3: Competitive inhibition of MDM2 binding to p53 derived BOX-1 peptides by ligand. a) 
and b) Biotinylated p53 BOX-1 peptide was adsorbed onto a streptavidin coasted ELISA well. Fixed 
levels of MDM2 were added into a buffer with increasing amounts of indicated ligand. Reaction 
solutions were added to the ELISA well and incubated from 1 hour at room temperature. MDM2 
binding was quantified using monoclonal antibody, 2A10 and secondary antibody coupled with 
horseradish peroxidase.  
 
Figure adapted from Robson AF, Hupp TR, Lickiss F, Ball KL, Faulds K, Graham D. Nanosensing 
protein allostery using a bivalent mouse double minute two (MDM2) assay. Proc Natl Acad 







6.1.3 Gel filtration chromatography 
 
Having established using SERS that FL MDM2 has a dimeric or oligomeric structure 
in solution I wanted to look in more detail at the structure of the RING domain. A size 
exclusion column contains hydrated beads made from cross-linked polymers such as 
dextran, agarose or polyacrylamide. The migration of a protein through the column is 
governed by its partitioning between the two solvent spaces, the solvent space 
surrounding the packed beads and the solvent within the packed beads, the smaller the 
proteins the more they interact with the solvent in the packed beads and they require a 
greater volume of buffer to pass through the column before they are eluted
250
. In 
principle therefore large proteins elute from the column first followed by proteins of 
decreasing size. 
 
Proteins fractions eluted from the column are collected and are examined by 
spectroscopic techniques such as ultraviolet (UV) or refractive index (RI). Aromatic 
amino acids absorb UV light at 280 nm. Tryptophan absorbs the greatest amount 
followed by tyrosine and to a lesser extent phenylalanine. Using the absorption trace 
of a protein with unknown size and a set of protein standards of a known size it is 
possible to calculate the size of the unknown protein.  
 
Advantages of size exclusion chromatography include the recovery of the protein, the 
ability to separate a protein from contaminants to obtain a clean sample and the ability 
to determine the oligomeric state of a protein. Disadvantages include the inability to 
separate proteins of similar sizes, the dilution of the protein sample and the need for a 
protein to contain aromatic residues. 
 
I wanted to use size exclusion chromatography to analyse the oligomeric state of my 
MDM2 RING protein with the tail (RING
322-491
) and without the tail (RING
322-479
). 
The theory was that I would be able to use this method to ascertain if the RING was a 
monomer or a homodimer in solution and, if the homodimer was the preferred 
species, if the tail was necessary for his dimer formation. I used a Superdex 200 




There were problems encountered with this method that we had not anticipated. The 
RING proteins did not provide a change in UV readout. RING
322-491
 contains one 
tryptophan, two tyrosines and three phenylalanines, RING
322-479 
contains one 
tryptophan, one tyrosine and two phenylalanines. From this limited number of 
aromatic amino acids I would perhaps expect to see a much smaller peak than for 
other proteins but I would expect a peak. However it appears that a property of RING 
structure is a lack of absorbance (similar results were obtained previously by the 
Walkinshaw biophysics unit). Any slight peak in the trace was negligible and could 
not be assigned with any degree of certainty to protein.  
 
In theory, even if a UV readout is not given, the protein should still travel through the 
column as expected, with larger complexes eluted from the column earlier than 
smaller ones. So I decided to see if I could still utilise size exclusion chromatography 
to analyse the oligomeric state of the RING. I collected fractions eluted from the 
column straight onto a microtitre plate, the idea being that I could detect the protein 
this way, using antibody detection instead of UV. 
 
Unfortunately this result is not easy to interpret, the antibody detected protein in the 
majority of the fractions indicating a broad elution, this result was seen for FL RING 







From these ELISAs I would predict that there are different oligomeric forms of the 
RING present in solution, i.e. monomer, dimer, tetramer etc. Interestingly although 
protein oligomeristaion state cannot be determined from the ELISAs when the ELISA 
for FL RING and RING ΔT are overlaid they appear to be behaving in a very similar 
way (figure 6.5a), this hints that perhaps the tail is not necessary for whatever 




 show different elution 
profiles to FL RING and RING ΔT, interestingly though their elution profiles are 
similar to each other (figure 6.5b). 
 
The RING proteins all elute in the included volume, there is no significant elution in 
the void volume. This suggests that although their elution ranges are broad and 
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multiple oligomeric states are likely, they are not forming aggregates as has been 
suggested previously in the literature
141
.    
 
Although this result did not provide oligomeric status for the RING, it did suggest that 
there are multiple states, this result was enough to warrant further investigation.        
   
 

































Figure 6.4: Elution profiles of RING proteins as detected by ELISA. a-d)  All protein fractions 
were eluted into a microtitre well and incubated overnight at 4 
o
C. Protein was detected using 

















Figure 6.5: Comparison of elution profiles of RING proteins as detected by ELISA a) A 
comparison of the elution profiles of FL RING and RING ΔT, the elution profiles for both the proteins 




, the elution 









6.1.4 Size exclusion chromatography with multi angle light scattering 
 
As the results from gel filtration were inconclusive a second, more specialised, 
method commonly used to determine the molecular weight of a protein was tried. Size 
exclusion chromatography coupled with multi angle light scattering (SECMALS) is 
widely used for determining the absolute molecular weight and average molecular 
weight of a protein
251
. However the instrumentation is expensive and therefore not 
widely available. The Edinburgh Protein Interaction Facility has recently been 
successful in obtaining this machine and so I was fortunate enough to run my 
samples.  
 
The main advantage of this technique is that it can provide an absolute measurement 
of molecular weight without requiring any calibration standards. Another advantage is 
multi angle light scattering is the determination of molecular dimensions of a protein, 
this combined with a molecular weight provides information on the size, shape and 
conformation of the protein in solution. An advantage for us using this technique, and 
the reason we tried it, is the fact that a visible UV absorbance is not strictly necessary 
for SECMALS, the RING will have a refractive index and this will allow us to detect 
its elution from the column. In theory SECMALS should produce a size and we can 
use this to determine oligomeric structure. 
 
RING ΔT gives a surprising and inconclusive result. Firstly there is a small UV peak 
which had not been seen previously, there was also a refractive index peak that 
aligned with the UV peak, therefore the peak we see on the UV trace is due to RING 
ΔT (figure 6.6a). These peaks however are extremely small, so much so that an 
absolute size of RING ΔT cannot be determined from this data. The data suggests that 
we are only recovering 30 % of the protein that was loaded onto the column, this 
would explain the small data peaks (figure 6.6b). This either means that the actual 
protein concentration was much lower than detected using the nanodrop or that the 




The small peak that can be seen correlates with RING ΔT being a monomer in 
solution. However this peak also has a shoulder (figure 6.6b), and this shoulder 
correlates with a size that would indicate that RING ΔT is also capable of forming a 
dimer in solution. If this result proves to be reproducible then it would suggest that 
RING ΔT prefers to be a monomer in solution yet is able to form a homodimer, this 
would further suggest that the tail is not necessary for dimer formation at least in 
some conformational sates. There is likely to be at last two distinct conformational 
states for the RING. This experiment would have to be repeated to test this 
hypothesis. 
 
FL RING did not provide a result for SECMALS. There was no visible UV or 
refractive index peak and the data retrieved suggested that we recovered less than 5 % 
of the protein. Like the RING ΔT either the actual protein concentration was much 
less than measured or the protein is sticking to the column.  
 
Based on the results that this technique could provide it would be worth repeating 


















Figure 6.6: SECMALS data for RING ΔT. a) Trace shows that the refractive index of the protein 
corresponds with the peak obtained by MALS. b) Traces show the UV peak of RING ΔT, a shoulder 







Data File: 2014-06-26_16;24;13_ring479_Sup200_01.vdt   Method: 
2 mg ml BSA stnd Sup200 260514-0001.vcm 
Peak RV - (ml) 46.721 
Mn - (Daltons) 24,332 
Mw - (Daltons) 24,455 
Mz - (Daltons) 24,599 
Mp - (Daltons) 24,559 
Mw / Mn 1.005 
Percent Above Mw:      
0 
100.000 
Percent Below Mw:      
0 
0.000 
IV - (dl/g) 0.0000 
Rh(w) - (nm) 0.000 
Rg(w) - (nm) No Calc 
Wt Fr  (Peak) 1.000 
Mark-Houwink a 0.000 
Mark-Houwink logK 0.000 
Branches 0.000 
Branch Freq. 0.000 
RI Area - (mvml) 2.31 
UV Area - (mvml) 0.00 
RALS Area - (mvml) 0.00 
LALS Area - (mvml) 0.00 
IVDP Area - (mvml) 0.00 
Sample Parameters Input Calculate
d 
Sample Conc - 
(mg/ml) 
0.500 0.159 
Sample Recovery (%) 0.000 31.785 
dn/dc - (ml/g) 0.1850 0.0000 
dA/dc - (ml/g) 0.8300 0.0000 
Annotation  
Method File Unsaved Method (2 mg ml 
BSA stnd Sup200 260514-
0001.vcm) 
Limits File  
Date Acquired Jun 26, 2014 - 16:24:13 
Solvent PBS 
Acquisition Operator admin : Administrator 
Calculation Operator admin : Administrator 
Column Set Superdex200 
System EPPF SEC MALS 
Flow Rate - (ml/min) 0.500 
Inj Volume - (ul) 100.0 
Volume Increment - (ml) 0.00498 
Detector Temp. - (deg C) 22.0 
Column Temp. - (deg C) 22.0 








As described in the introduction to this chapter, whether dimerization of MDM2 is 
absolutely required for its E3-ligase activity and precisely how the dimer facilitates 
the transfer of ubiquitin from the MDM2-E2-partner to its substrate remains unclear. 
There is agreement that MDM2 is able to form dimeric (and oligomeric) structures, 
either as homodimers or  heterodimers with MDM4
130
, what remains a point of 
contention is the type of dimer that MDM2 preferentially forms in vivo
139
 and the role 
of MDM2 homodimers verses MDM2:MDM4 heterodimers in the ubiquitination of 
p53. Structural studies have not shown significant differences between MDM2 
homodimers and MDM2:MDM4 heterodimers
130,137,139
.  However it is possible that 
the heterodimer is more thermodynamically stable than the homodimer and that this is 
important in cells. 
 
Another contentious point is whether MDM2 needs to be a dimer for E3 ligase 
activity in vivo as it has been shown to be active as both a monomer and dimer
141
, 
although some reports differ by claiming that the dimer is essential for its activity 
102
 . 
These studies are complicated by the fact that many of them are performed using cell 
based assays where it is difficult to determine whether monomers, dimers or 
oligomers are being studied and how additional cellular factors may be affecting the 
outcome
102,133,141
.  It is of course possible that MDM2 is active in both its monomeric 
and dimeric/oligomeric forms, though it seems likely that one form would be 
preferential in vivo, or that different  forms would perform distinct tasks, for example 
mono- vs polyubiquitination.  
 
Lastly, the available crystal structures for the RING of MDM2 as either a homodimer 
or heterodimer
137
 suggest that the tail is necessary for dimer formation
130
, as in these 
structures it sits at the dimer interface where it is buried. While it may certainly be 
important based on the residues implicated in dimer formation, NMR experiments 
from a former PhD student in the Walkinshaw group (‘Biochemical and Biophysical 
studies of MDM2-Ligand interactions.’) suggest that it may not be necessary for all 
forms of dimerization. Also unknown at the current time is the effect of E2 binding on 
the dimer interface and whether regions outside of the RING domain normally 
contribute to the formation of full-length MDM2 dimers.  For example studies on the 
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role of ATM dependent phosphorylation on the structure and function of MDM2 





The aim of the experiments in this chapter was therefore to further elucidate the role 
of the tail and investigate whether or not it was necessary for dimer formation 
 
6.1.5.1 Exploring the ability of full-length MDM2 and the RING domain to 
dimerize 
 
The theory behind using surface enhanced Raman scattering was that the N-terminal 
domain of MDM2 would bind a peptide 12.1 functionalised nanoparticle and if 
MDM2 dimerised this would bring more than one functionalised nanoparticle 





The results did show an aggregation of the nanoparticles and it was concluded that 
MDM2 was dimerising through its RING domain
249
. There is the possibility that 
MDM2 is dimerising through a different area but there is no evidence to support this. 
However, it can’t be ruled out as we know for example as stated above that regions 
out-with the RING, such as the tail and the linker region between the Zn finger and 
the RING
252
 can regulate dimerization.  
 
The study we performed in collaboration to develop a nanoparticle assay for MDM2 
oligomer formation supports the view that FL MDM2 can form a dimer in solution, 
however it does not provide information regarding the role of the tail of MDM2. 
There is the potential to repeat this experiment using MDM2 ΔT, as although missing 
the tail this protein can still bind peptide 12.1. Aggregation of the functionalised 
nanoparticles would imply that the tail is not necessary for dimer formation and no 
aggregation would imply that the tail was necessary. The process of conjugating the 
peptide to the nanoparticle is complicated, even though it is a one-step reaction and 




Size exclusion chromatography is commonly used to determine protein size. Our 
theory was that if we could examine the size of FL RING and RING ΔT in solution 
this would indicate whether the proteins were monomer or dimer. The size of RING 
ΔT compared to FL RING could indicate whether the tail was involved in dimer 
formation i.e. if RING ΔT was monomer sized and FL Ring was dimer sized this was 
indicate that the tail was necessary for dimer formation. 
 
Gel filtration did not provide a result for these two protein constructs as they do not 
give a UV absorption peak at 280 nm. Capturing and detecting the eluted fractions 
onto an ELISA plate hinted at different oligomeric forms of each protein in solution 
but they were not conclusive.  
 
This experiment could be repeated measuring UV absorbance at different wavelengths 
to see if the RING constructs give a peak. For example disulphide bonds that form 
between the two cysteines show an absorbance at 260 nm and peptide bonds show an 
absorbance at 230 nm. It is likely that this method is not suitable for the RING 
constructs and that investigation into other methods for sizing proteins may be 
beneficial. 
 
As size exclusion chromatography was not successful we decided to try SECMALS, 
which measures the absolute mass of a protein. Interestingly, RING ΔT did give a UV 
absorption peak at 280 nm, and this peak corresponded with the peak produced by the 
refractive index of the protein, however the two peaks were so small that no absolute 
mass could be calculated. However results hinted that RING ΔT was preferentially a 
monomer in solution though there was also the possibility of some dimer formation. 
 
The main issue that was highlighted when using this technique is that the 
concentration of protein recovered from the column was much less than the 
concentration of protein that was loaded. This may be due to the protein sticking to 
the column and if this is the case then this technique is not suitable for these RING 
constructs. However if it is due to the actual concentration of protein loaded being 
much lower than calculated then this need to be addressed for two reasons, firstly a 
higher concentration is need to measure the absolute mass and secondly the low 
concentration of the solution could impact on dimer formation and the ratio of 
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monomer and dimer in solution. Thus, SECMALS may be more suitable for sizing FL 
MDM2 and MDM2 ΔT, especially if the RING constructs are sticking to the column. 
 
The experiments in this chapter have not provided the information I was hoping for. 
However, in collaboration I have shown that the FL MDM2 forms a dimer/oligomer 
in solution and there are hints that the isolated RING can form a dimer even in the 
absence of the tail although this appears to be only a low percentage of total protein.  
 
6.1.5.2 Previous studies on the role of the tail in dimerization 
 
If we look at previous studies reported in the literature loss of E3-activity due to 
removal of the MDM2 tail, the introduction of point mutations in the tail and C-
terminal tail extensions, are almost always equated with the loss of dimer structure
102
. 
However, both in vitro assays and cell based studies exist that suggest that the MDM2 
monomer can have similar levels of E3-activity as dimers and homo-oligomers
141
. 
Further, E3-inactive MDM2 tail point mutant proteins can still form a dimer when 
mixed with MDM4 and the mixed dimer can be active as an E3-ligase even though 
MDM4 itself has no intrinsic E3-activity
133
. These studies suggest that, i) the 
monomer can be an active functional E3-ligase under some conditions, and, ii) that 
tail integrity is not a prerequisite for dimer formation. Some of this  confusion might 
be made more clear if we had more structural information on the position of the 
MDM2 tail and the role of the dimer in binding to the E2. For example, although the 
tail is burried in the homo- and hetrodimer structures
130
 does it remain burried once 
the RING is bound to the E2~Ub complex. My data (chapter 3 and 4) suggests that E2 
access to the tail is critical for MDM2 mediated allosteric activation of UbcH5 and 
therefore for transfer of Ub to a substrate. 
 
If we compare MDM2 to other RING domain E3-ligases where more detailed 
mechanistic information has been obtained the picture remains somewhat confused. 
The Hay lab have carried out studies on the mechanism of RNF4 and have published 
two papers on the RNF4 dimer in complex with the E2~Ub complex. The first of 
these
220
 puts forward a mechanism where the dimer is required for ubiquitin transfer 
by offering two distinct binding interfaces such that one RING would interact with the 
E2 and the second RING would interact with the ubiquitin. However this study relied 
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heavily on the introduction of multiple point mutations into the E2 which made 
interpretation of the data complex. Subsequently the same group published a second 
model
37
 where  both the E2 and ubiquitin could bind to a single RING domain. This is 
in good agreement with my studies showing that peptide 8 can bind to ubiquitin and 
UbcH5 simultaniously and with MD simulations carried out in collaboration with Dr 
Chandra Verma (see Chapter 3).   
 
However the second RNF4 study
37
 also argues that contact of ubiquitin with both 
RING domains  was essential  for ubiquitin transfer and that therefore a RING dimer 
is required. However, this contrasts with biochemical studies on the MDM2 RING 
showing an active monomer
141
. The difference could be in the tail structure of MDM2 
(that is not shared with RNF4)  and the role played by the tail in activating the E2 as 
demonstrated in this thesis.   
 
In my reading of the literature I have observed that the majority of studies on the 
MDM2 dimer and its role in the reaction mechanism of ubiquitination have been 
carried out using cell based assays and pulldowns which makes the claims about 
structure hard to validate. There are many inconsistencies  in the literature and many 
of the studies are contradictory. The structural studies that have been carried out on 
the mechanism of MDM2 mediated ubiquitination have concentrated on using the 
isolated RING domain, however these have been carried out in the absence of the E2 
or ubiquitin and therefore can not be used to inform us about the structure of the 
RING in relation to other ubiquitination pathway components or within the context of 
the full-length protein. As such it would add greatly to our understanding of MDM2 
mechansim if biochemical, biophysical and structural studies could be carried out that 










Chapter 7: FURTHER WORK 
 
7.1 Investigation of MDM2 and dimer formation 
 
My results show that MDM2 can form a dimer, specifically a homodimer, in solution. 
My results so far have not provided concrete evidence that the C-terminal tail of 
MDM2 is or is not absolutely required for dimer formation, however previous 
unpublished studies from the Walkinshaw group using NMR agree with my 
preliminary data (Figure 6.6) a portion of MDM2 ΔT in a dimer peak as determined 
by SECMALS. 
 
Surface-enhanced Raman scattering (SERS) data showed that full length MDM2 
oligomerised in solution (Chapter 4). The conclusion was that MDM2 was forming a 
homodimer through its RING domains as this is the mechanism that the current 
literature suggests. This experiment has the potential to be repeated with MDM2 ΔT. I 
predict that if the tail is not required for dimer formation aggregation of the 
functionalised nanoparticles should be seen, as was for FL MDM2 although this could 
give a reduced signal compared to FL MDM2 protein as SECMALS suggests that 
only a portion of MDM2 ΔT is in a dimer. If the tail is required then no aggregation 
should be seen. The only issue with repeating this experiment is that the process of 
conjugating the peptide to the nanoparticle is difficult and time intensive.  
 
Although I obtained some intriguing preliminary data by SECMALS (Chapter 4), 
suggesting as mentioned above that a portion of the MDM2 ΔT protein was dimeric 
the data was not of high enough quality for publication. The RING ΔT protein product 
appeared to be monomeric yet there was a shoulder present in the trace that suggested 
that dimer formation was still an option as a minor secondary product. I would like to 
retry SECMALS with more RING protein to see if a clearer answer can be obtained. 
There may be an intrinsic problem with the RING and SECMALS if the RING is 
sticking to the column (Chapter 4). If this is the case then I would like to try 
SECMALS with FL MDM2 and MDM2 ΔT, as the full length proteins are less prone 




I previously used HD exchange to analyse UbcH5α (Chapter 2), I would also like to 
use HD exchange to look at the RING proteins in solution. HD exchange could tell us 
more about the oligomeric state of the RINGS. Should a dimer be formed I would 
expect to see a lower rate, of or no exchange at the dimer interface.  
 
If answers can be found as to whether or not the RING is a dimer and whether or not 
the tail is necessary for dimer formation, then this could have implications for the 
mechanism of MDM2 E3 ligase activity. A study says that dimer formation is 
necessary for E3 ligase activity as when the tail is removed MDM2 is inactive as an 
E3 ligase because dimer formation can no longer occur
253
. My results also show that 
MDM2 ΔT is inactive as an E3 ligase (Chapter 1), however it is not clear whether this 
is because dimer formation is no longer an option. There are also studies showing 
MDM2 active as an E3 ligase when it is present as a monomer. It is possible that he 
tail may have another role in E3 ligase activity that is of yet unknown. Knowing the 
role of the tail in dimer formation could help probe the role of the tail in E3 ligase 
activity. 
 
7.2 MDM2 and the allosteric activation of UbcH5α 
 
My results show that UbcH5α binds with relatively high affinity to the RING of 
MDM2 and specifically somewhere in the region of the 20 most C-terminal amino 
acids (peptide 8) with a second lower affinity interaction between UbcH5α and 
peptide 2 of the RING, an area that maps to previous E2 binding sites (Chapter 1). I 
also found that when peptide 8 binds to UbcH5α, Ubch5α undergoes an allosteric 
change (Chapter 3). This is the first solid evidence that MDM2 allosterically activates 
its E2 partner. Good results were achieved using limited proteolysis linked with MS 
and promising results were achieved with the first round of HD exchange. 
 
I am going to repeat the HD exchange experiment using UbcH5α and a newly 
synthesised batch of peptide 8 in order to achieve publishable data. I would also like 
to repeat the HD exchange using the RING domain and UbcH5α, HD exchange on 
two proteins or protein domains is more tricky than using a protein and a peptide and 
less examples exist but successful application of this technique could provide 




I have written throughout my thesis about E2-ubiquitin conjugates (Chapter 1,2). 
Stable ubiquitin conjugates have not been successfully created and in order to increase 
the stability many mutations are being carried out on the UbcH5α
220
. These mutations 
may hide the true mechanism of E2 function and so another technique would be much 
better suited for my purpose. One such technique I would like to investigate further is 
‘Click’ chemistry. Click chemistry has already been used to stably link ubiquitin to 
PCNA. In this technique artificial amino acids that carried an azide or alkyne side 
chain were incorporated into ubiquitin and PCNA respectively. The two proteins were 
then linked site specifically by Cu (I)- catalysed azide-alkyne cycloaddition
226
. It 
should be possible incorporate an artificial amino acid into UbcH5α and ubiquitin in 
order to link them and form a stable conjugate with minimal mutation, and we have 
set up a collaboration with chemists to achieve this.   
 
If click chemistry is a viable option and it is possible to create the E2-ubiquitin 
conjugate I would like to use it to repeat some experiments already carried out with 
free UbcH5α Limited proteolysis suggested that the ubiquitin binding helix of 
UbcH5α increased in stability upon peptide 8 binding. I would like to see what 
happens when peptide 8 binds to the conjugate. I would investigate this using both 
limited proteolysis linked with MS and HD exchange.  
 
I carried out peptide phage display in order to confirm a conformational change of E2. 
As explained in Chapter 3 my peptide phage display assay has provided a wealth of 
information that I have not investigated. It would be worth using some of the 
programs outlined, such as MEME and BLAST, in order to investigate the difference 
in the interactome of  free UbcH5α and UbcH5α in complex with peptide 8/MDM2 
RING.                 
 
7.3 MDM2 and ubiquitin 
 
Throughout the course of my PhD I have focussed on the RING of MDM2 and its 
interaction with ubiquitin and UbcH5α and I have shown that the RING domain of 
MDM2 can bind both ubiquitin and UbcH5α. I then continued to focus on the 
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allosteric regulation of UbcH5α by MDM2, studying the activation of UbcH5α was 
the natural route to follow as the literature had already hinted that E2s had the 
potential to be allosterically activated by their partner E3s
35
. This led me to wonder 
about ubiquitin, could it too be undergoing some conformational change upon RING 
binding? The literature would perhaps suggest not as ubiquitin is unanimously 




During my time collaborating with the Masaryk Memorial Cancer Institute I was able 
to use electrochemistry to carry out preliminary investigations looking at free 
ubiquitin and ubiquitin in complex with peptide 8. 
 
For this work I used the Hanging Mercury Drop Electrode (HDME). The HDME 
produces a mercury drop, of a controlled, constant surface area, at the end of a 
capillary. An advantage of the HDME is that unlike solid electrodes it does not have 
to be cleaned and polished between each experiment, instead the HDME can release 
the contaminated drop and produce a new one between each experiment. 
 
Studies had already shown that using Constant Current Chronopotentiometric 
Stripping Analysis (CPSA) and a HDME that proteins and peptides, at negative 
potentials, gave distinctive peaks at nanomolar and subnanomolar concentrations. 
These peaks were denominated as peak H as they were due to catalytic hydrogen 
evolution.  
 





I decided to try this technique to look for potential differences in the structure of free 
and ligand (peptide 8) bound ubiquitin. Cysteine, along with the other basic residues, 
is important for this method in producing the peak, as these residues adsorb to the 
mercury electrode. Ubiquitin contains no cysteines and limited numbers of other basic 
residues however at the right conditions it does produce a small reproducible peak 
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(figure 7.1). Using the exact same conditions ubiquitin in complex with peptide 8 
produces a peak that was too great to measure.  
 
 
Figure 7.1: Electrochemistry data from free and ligand bound ubiquitin. a) Graph showing the 
peak of free ubiquitin, the peak is reproducible. b) Graph showing the peak of ligand bound ubiquitin, 
peptide 8 and free ubiquitin. Ligand bound ubiquitin produces a much greater signal than free ubiquitin 









Changing the stripping current, the current at which the protein is stripped from the 
electrode, meant that the peak from ubiquitin alone was too small to be seen but the 
peak produced by ubiquitin in complex with peptide 8 can be measured.  
 
The peptide by itself did not produce a peak under these conditions, even though it 
contains two cysteines; this indicates the change in peak intensity is due to the 
complex and not due to the mere presence of the peptide. 
 
A number of events could be taking place that account for this increased peak. Firstly, 
the cysteines within the peptide may be responsible for increased adsorption of 
ubiquitin onto the electrode, i.e. peptide 8 binds to ubiquitin, peptide 8 adsorbs to the 
electrode, facilitating greater ubiquitin adsorption onto the electrode resulting in an 
increased signal. Secondly, the peptide binding to ubiquitin could result in a 
conformational change within ubiquitin that exposes a greater number of basic 
residues, allowing for increased adsorption of ubiquitin onto the electrode and an 
increase in signal. The increase in signal could also be due to a combination of these 
two events. 
 
The electrochemistry data has indicated that there might be a change in the 
conformation of ubiquitin when it is in complex with peptide 8, unfortunately it 
cannot be used to confirm this change. To do this further biophysical assays would 
have to be carried out. 
 
One such biophysical approach I would like to use is NMR. The structure of ubiquitin 
has already been extensively mapped by NMR and so experiments would be relatively 
simple. I would like to compare the spectra of ubiquitin to that of ubiquitin in 
complex with peptide 8. This could provide information regarding the binding 
interface of peptide 8 and ubiquitin and also any conformational change in ubiquitin 
upon peptide 8 binding.  I have already tried preliminary NMR experiments, ubiquitin 
itself provided a good NMR spectra, however when I added peptide no change was 
seen. As previously described I realised the peptide was not the concentration I 
thought based on information provided by mimotopes, the company that synthesised 




7.4 MDM2 and gankyrin 
 
My PhD has focussed on the RING domain of MDM2 and its role in ubiquitination. 
Specifically I have focussed on the interaction of the RING with other ubiquitination 
cascade elements, UbcH5α and ubiquitin. The RING however can bind to other 
factors that are not part of the ubiquitination cascade, these other binding partners 
may or may not have an effect on the E3 activity of MDM2. One such binding partner 
is gankyrin. The Ball lab has begun a collaboration that is investigating the interaction 
of gankyrin with MDM2. This is of particular interest to me as gankyrin is one of the 




Gankyrin is a small oncoprotein, ~25kDa and 226 amino acids in length, made up of 
seven ankryin repeats. It is a subunit of the 26s proteasome that specifically interacts 
with the S6b ATPase of the 19s regulator. Gankyrin is highly conserved across 
eukaryotes and overexpressed in the majority of hepatocellular carcinomas
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. 
Gankyrin binds to retinoblastoma (pRb) protein and the 6s subunit of the 26s 
proteasome and increases the rate of degradation of pRb. Gankyrin also binds to 










A study has shown that gankyrin has an effect on the E3 activity of MDM2 towards 
p53. This study showed that gankyrin could bind to MDM2 and facilitate the binding 
of p53 to MDM2 as well as increasing the ubiquitination and degradation of p53
255
. 
The mechanism by which gankyrin facilitates p53 binding to MDM2 and increases 
the E3 activity of MDM2 is currently unknown. 
 
We are interested in investigating the interaction between gankyrin and MDM2 in an 
attempt to discover where on MDM2 Gankyrin makes contact and how the binding 
site(s) could have an effect on the E3 ligase activity of MDM2. I have already carried 






7.4.1 Gankyrin binds to MDM2 
 
I first tested two anti-gankyrin antibodies, a rabbit polyclonal and a mouse 
monoclonal, in order to identify reagents that can be used to study this protein. I 
designed an ELISA in which gankyrin (100 ng) was immobilised onto a microtitre 
well before detecting with the antibodies. The mouse monoclonal antibody had a 
higher binding capacity for gankyrin than the rabbit polyclonal (figure 7.2a), this is 
the antibody I therefore used routinely. 
 
In cell based assays MDM2 immunoprecipitated with gankyrin leading to the 
conclusion that gankyrin binds to MDM2
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. I carried out a protein binding assay to 
see if I was able to confirm the interaction and if the interaction was direct or required 
other cellular factors. In this particular protein biding assay MDM2 was immobilised 
on a microtitre well and gankyrin titrated in the mobile phase before being detected by 
the mouse anti-gankyrin MAb. Gankyrin bound to MDM2, confirming the interaction 
seen in the cell based assay. This assay does not work if it is performed in the 
opposite orientation i.e. gankyrin immobilised onto the well and MDM2 in solution, 
suggesting that the conformational flexibility of gankyrin may be an important 
determinant of MDM2 binding (figure 7.2b). 
 
Gankyrin is reported to increase the E3 ligase activity of MDM2 towards p53, I was 
curious therefore to see if gankyrins point(s) of contact with MDM2 were within the 
RING. I carried out a protein binding assay similar to that described above; though 
this time I used my FL RING instead of FL MDM2. In this assay gankyrin bound to 
MDM2, unlike in the assay with FL MDM2 gankyrin can bind to FL RING in either 
the immobile or solution phase (figure 7.3a and b). As the RING can bind to 
gankyrin in either phase it may not be as I thought, the flexibility of gankyrin may not 
be an important determinant of MDM2 binding instead it could be that the binding 
site of gankyrin is cryptic when FL MDM2 is in the mobile phase and by capturing it 
to the plate the site is exposed.  
 
Using a set of overlapping MDM2 peptides I carried out a peptide binding assay with 
gankyrin (figure 7.4). Having already shown that gankyrin binds to the RING of 
MDM2 it is of interest that gankyrin bound to several overlapping C-terminal MDM2 
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peptides. Strikingly gankyrin also bound to a number of N-terminal MDM2 peptides, 
suggesting that MDM2 and gankyrin have a complex extended interface involving 
both the N-terminal and C-terminal domains of MDM2. I would like to repeat this 
assay to test for consistent results and to confirm the peptide binding results using 
protein domains. In addition I plan to immobilise the MDM2 peptide library onto 
beads and use them to pull-down gankyrin from cell lysates to confirm and 
complement the in vitro peptide binding assay. As gankyrin binds to the RING 
domain of MDM2 and gankyrin has been shown to affect the ubiquitination activity 
of MDM2 I would like to carry out a peptide binding assay using the overlapping 
RING domain peptides. Ascertaining where in the RING gankyrin binds could help 
determine the mechanism of its activating effect on MDM2 E3 ligase activity. 
   
 
 













































Figure 7.2: Gankyrin binds to MDM2. a) Rabbit polyclonal and mouse monoclonal antibodies detect 
gankyrin. b) MDM2 was captured onto microtitre wells (100 ng/well), a titration of gankyrin was 
added in the mobile phase and incubated for 1 hour at room temperature. Unbound protein was 
removed by extensive washing and bound protein was detected using mouse monoclonal antibody. 












Figure 7.3: Gankyrin binds to the RING domain of MDM2. a) FL RING was captured onto 
microtitre wells (100 ng/well), a titration of gankyrin was added in the mobile phase and incubated for 
1 hour at room temperature. Unbound protein was removed by extensive washing and bound protein 
was detected using mouse monoclonal antibody. Graphs show gankyrin binding expressed as relative 
light units (R.L.U). b) Gankyrin was captured onto microtitre wells (100 ng/well), a titration of FL 
RING was added in the mobile phase and incubated for 1 hour at room temperature. Unbound protein 
was removed by extensive washing and bound protein was detected using monoclonal antibody 2A10. 
















Figure 7.4: Gankyrin binding to MDM2 peptides. a) A series of biotin labelled MDM2 
peptides (100 ng/well) were captured onto streptavidin coated microtitre wells, gankyrin (100 
ng/well) was added and incubated for 1 hour at room temperature. Unbound gankyrin was 
removed by extensive washing and bound protein was detected using mouse monoclonal 
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VLLSICSLLCDPNPDDPLVPDIAQIYK 10 1 1 119389044 2954.50559 High 5.34     High 2.97 
GSSHHHHHHSSGLVPR 183 1 1 119389044 1768.84966 High 4.90 High 5.02 High 4.87 
SAYQGGVFFLTVHFPTDYPFKPPK 6 1 1 119389044 2743.39469 High 3.75 High 2.77 High 3.34 
IYHPNINSNGSICLDILR 7 1 1 119389044 2042.04411 High 3.54 High 2.22 High 2.61 
SQWSPALTVSK 144 1 1 119389044 1203.63738 High 3.32 High 3.45 High 3.42 
HAREWTQK 16 1 1 119389044 1055.53850 High 2.51 High 2.52 High 2.47 
DPLVPDIAQIYK 18 1 1 119389044 1371.75151 High 2.45 Medium 1.25 High 2.59 
EWTQKYAM 4 1 1 119389044 1056.48235 High 2.23 High 2.34 High 2.53 
GSHMALKR 2 1 1 119389044 899.48827 Medium 1.99     High 2.30 
YNRHAR 34 1 1 119389044 816.42137 Medium 1.73 Medium 1.22 Medium 1.37 
ELSDLQR 12 1 1 119389044 860.44725 Medium 1.61 Medium 1.98 Medium 1.95 
YPFKPPK 4 1 1 119389044 876.49797 Medium 1.39 Medium 1.68 Medium 1.39 
IAQIYKSD 7 1 1 119389044 937.49895 Low 0.75 Medium 1.13 Low 0.52 
GSHMALKRIQK 4 1 1 119389044 1268.71379 Low 0.45 Low 0.52 Low 0.60 
SAYQGGVFFLTVHFPTDYPFKPPKIAFTTK 1 1 1 119389044 3404.74663 Low 0.27         
IYHPNINSNGSICLD 3 1 1 119389044 1659.76773 Low 0.23 Low 0.91 Low 0.63 
WTQKYAM 2 1 1 119389044 927.44341 Low 0.07     Low 0.39 
DPLVPDIAQIYKSD 2 1 1 119389044 1573.80559     Low 0.39 Low 0.57 
IAFTTKIYHPNINSNGSICLDILR 3 1 1 119389044 2703.40688     Low 0.03 Low 0.74 
SAYQGGVFFLTVHFPTD 1 1 1 119389044 1885.92754         Low 0.55 
IQKELSD 1 1 1 119389044 832.44103         Low 0.17 




































































































































VLLSICSLLCDPNPDDPLVPDIAQIYK 10 1 1 119389044 2954.52188 High 5.03 High 4.46 High 3.55 
GSSHHHHHHSSGLVPR 116 1 1 119389044 1768.85076 High 4.70 High 4.97 High 4.59 
SQWSPALTVSK 151 1 1 119389044 1203.63738 High 3.41 High 3.57 High 3.45 
SAYQGGVFFLTVHFPTDYPFKPPK 7 1 1 119389044 2743.39634 High 3.30 High 3.09 High 3.07 
EWTQKYAM 2 1 1 119389044 1056.48198 High 2.28     Medium 1.20 
ELSDLQR 25 1 1 119389044 860.44725 High 2.27 Medium 1.88 High 2.23 
IYHPNINSNGSICLDILR 4 1 1 119389044 2042.04819 High 2.19 High 3.51     
HAREWTQK 5 1 1 119389044 1055.53801 High 2.16 High 2.51     
VLLSICSLLCDPNPDDPLVPD 1 1 1 119389044 2238.09355 High 2.01         
GSHMALKR 5 1 1 119389044 899.48772 Medium 1.94 Medium 1.74     
DPLVPDIAQIYK 11 1 1 119389044 1371.75102 Medium 1.84 High 2.12 Low 0.56 
YPFKPPK 4 1 1 119389044 876.49767 Medium 1.69 Medium 1.42 Medium 1.53 
YNRHAR 9 1 1 119389044 816.42174 Medium 0.95 Low 0.49 Low 0.42 
IAQIYKSD 5 1 1 119389044 937.50408 Low 0.49 Low 0.76     
GSHMALKRIQK 6 1 1 119389044 1268.71379 Low 0.39 Low 0.79 Low 0.57 
DPLVPDIAQIYKSD 3 1 1 119389044 1573.82590 Low 0.27 Low 0.50     
SQWSPALTVSKVLLSICSLLCDPNPDDPLVPD 1 1 1 119389044 3422.74106 Low 0.21         
SQWSPALTVSKVLLSICSLLCDPNPD 1 1 1 119389044 2786.40508 Low 0.05         
IQKELSD 2 1 1 119389044 832.44121 Low 0.04 Low 0.20     
ILRSQWSPALTVSK 2 1 1 119389044 1585.90654         Medium 1.18 
SAYQGGVFFLTVHFPTD 1 1 1 119389044 1885.90557         Low 0.76 
VLLSICSLLCDPNPD 1 1 1 119389044 1601.79924         Low 0.64 
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VLLSICSLLCDPNPDDPLVPDIAQIYK 1 1 1 119389044 2954.51518 High 3.65         
IYHPNINSNGSICLDILR 4 1 1 119389044 2042.04892 High 3.52         
SAYQGGVFFLTVHFPTDYPFKPPK 3 1 1 119389044 2743.39139 High 3.37         
GSSHHHHHHSSGLVPR 97 1 1 119389044 1768.85002 High 3.21 High 4.32 High 4.58 
SQWSPALTVSK 36 1 1 119389044 1203.63701 High 3.01 High 2.33 High 2.61 
DPLVPDIAQIYK 2 1 1 119389044 1371.75188 High 2.09     High 2.53 
EWTQKYAM 2 1 1 119389044 1056.48235 High 2.06     Medium 1.88 
GSHMALKR 4 1 1 119389044 899.48796 Medium 1.92     Medium 1.63 
ELSDLQR 4 1 1 119389044 860.44768 Medium 1.58 Medium 1.63 Medium 1.58 
YPFKPPK 3 1 1 119389044 876.49736 Medium 1.52 Low 0.51 Medium 1.68 
LSDLQRDPPAHCSAGPVGD 1 1 1 119389044 1934.91556 Medium 1.41         
DPLVPDIAQIYKSD 3 1 1 119389044 1573.82256 Low 0.49     Low 0.17 
YNRHARE 1 1 1 119389044 945.46361 Low 0.29         
HAREWTQK 3 1 1 119389044 1055.54717 Low 0.15 Low 0.62     
IAQIYKSD 3 1 1 119389044 937.49944     Low 0.47 Low 0.31 
YNRHAR 5 1 1 119389044 816.42107     Low 0.23 Low 0.73 
LQRDPPAHCSAGPVGDD 1 1 1 119389044 1734.78728         Medium 1.13 
DLFHWQATIMGPPD 1 1 1 119389044 1627.74175         Low 0.70 
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The tumor suppressor protein, p53, is either mutated or absent in
>50% of cancers and is negatively regulated by the mouse double
minute (MDM2) protein. Understanding and inhibition of the
MDM2-p53 interaction are, therefore, critical for developing novel
chemotherapeutics, which are currently limited because of a lack of
appropriate study tools. We present a nanosensing approach to in-
vestigate full-length MDM2 interactions with p53, thus providing
an allosteric assay for identifyingbinding ligands. Surface-enhanced
Raman scattering (SERS)-active nanoparticles, functionalized with
a p53 peptide mimic (peptide 12.1), display biologically specific ag-
gregation following addition of MDM2. Nanoparticle assembly is
competitively inhibited by the N-terminal MDM2-binding ligands
peptide 12.1 and Nutlin-3. This study reports nanoparticle assembly
through specific protein–peptide interactions that can be followed
by SERS. We demonstrate solution-based MDM2 allosteric interac-
tion studies that use the full-length protein.
assay system | biosensing | nano-assembly | protein interaction studies |
Raman spectroscopy
The p53 tumor suppressor protein is often referred to as the“guardian of the genome” owing to its key role in cell-cycle
regulation and its activity in a number of different cancer pathways
(1–3). The antiproliferative action of p53 arises from the induction
of cell-cycle arrest and apoptosis in cells subjected to DNA dam-
age in response to stress. As such, p53 is central to protecting
cells from uncontrolled growth and malignant transformation with
inactivation or mutation of p53 found in over 50% of human
cancers (1–3). Under nonstressed conditions, mouse double min-
ute (MDM)2 negatively regulates p53, primarily through the
ubiquitin degradation pathway but also via transrepression (4, 5).
Studies have shown up-regulation of MDM2 in malignancies
where p53 is fully functional, making the MDM2-p53 feedback
loop of great interest in chemotherapeutic studies (6, 7).
MDM2 is a multidomain protein that exerts E3-ligase activity
on a number of proteins, including p53 (5, 8, 9). The ubiquiti-
nation activity of MDM2 is a multisubunit process whereby the
N-terminal hydrophobic pocket and central acidic domain of
MDM2 are used in p53 binding, to the N-terminal and central
domains of p53, respectively (10). The complexity of this multi-
subunit interaction makes it relatively difficult to investigate the
allosteric nature of MDM2. This is made more difficult by the
problems in acquiring a structure of full-length MDM2 because
of intrinsically disordered regions on the protein that reduce
likelihood of crystallization. Focus solely on the N-terminal do-
main of MDM2 has identified Nutlin-3-type molecules that ac-
tivate p53 in cells; however, these also act as allosteric agonists
that stimulate rather than inhibit p53 ubiquitination (10–15).
The putative dimerization of MDM2 through the C-terminal
really interesting new gene (RING) domain is reported to be
critical for E3-ligase activity; however, molecular reasoning for
this is not fully understood (8, 16–18). To date, studies on
MDM2 structure have been conducted with purified domain
constructs, which is not representative of full-length protein ac-
tivity in nature.
Using full-length MDM2, which has the capacity to exhibit
allosteric interactions (19, 20), would provide an assay for the
screening of MDM2 ligands. Domain construct studies have in-
vestigated the multiple binding interactions of MDM2, but few,
thus far, have used unlabeled full-length protein to simulta-
neously interrogate two binding events. The assay described in
this report monitors both N-terminal and C-terminal activities of
MDM2 simultaneously using full-length protein, which is critical
to understanding the biological action of the native protein. The
methodology provides a step forward in the capability for in-
vestigating such intricate interactions, and a unique insight is
provided into the allosteric nature of native MDM2 that cannot
be observed using other techniques.
Current methodologies used to probe interactions in biological
systems commonly use readout tools such as fluorescence (21–23).
This technique is subject to a high background from biological
media and is limited by broad emission bands and the inability to
probe interactions over distances of more than 10 nm. Surface-
enhanced Raman scattering (SERS) is a vibrational spectroscopy
that can provide similar sensitivity to fluorescence, but narrower
spectral peaks allow for simultaneous detection of multiple species
(24, 25). SERS interrogates an analyte, adsorbed onto a rough-
ened metal surface, from which further Raman signal enhance-
ment is achieved by coinciding the laser excitation wavelength with
the analyte absorbance maxima (26, 27). SERS can also be en-
hanced or “turned on” by aggregation of nanoparticles (NPs) in
solution because of “hot spots” of higher electromagnetic fields at
NP junctions (26–28). Cotton et al. pioneered the use of NP and
SERS for proteomic investigations and developed the first SERS-
based enzyme immunoassay in 1989 (29). Subsequently, a number
of SERS-based immunoassays have been documented (30–39).
Assembly of functionalized NPs via protein–ligand interactions
has been previously demonstrated using techniques such as ex-
tinction spectroscopy, transmission electron microscopy, and gel
electrophoresis, all of which lack the sensitivity of SERS (40–44).
Such interactions have been detected via SERS on metal surfaces,
where binding events are compromised by protein orientation and
conformation at the surface. Solution-based studies allow struc-
tural integrity of the full-length protein to be maintained, thus
providing accurate information about complex interactions: how-
ever, such investigations have yet to be reported (36).
In this report, we outline a method for NP assembly through
the interaction of full-length MDM2 with an N-terminal-domain
peptide ligand. By exploiting the sensitivity and selectivity of
SERS, we provide insight into the allosteric nature of MDM2 in
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solution, which is not achievable by current methodologies, which
only monitor one binding interaction, involve protein labeling, or
require surface immobilization.
Results
Protein–Peptide Nanoparticle Assembly. We propose a solution-
based approach to investigate the interaction of full-length MDM2
with a p53 peptide mimic exploiting the sensitivity and selectivity
of SERS. p53 is known to bind the N-terminal hydrophobic pocket
of MDM2 by forming an ampipathic helix containing the peptide
motif, FxxxWxxL (45). Peptide 12.1 (MPRFMDYWEGLN) orig-
inates from a library of p53 peptide mimics and demonstrates
high-affinity binding to the MDM2 hydrophobic cleft (46). Tryp-
tophan, a key residue involved in aromatic-aromatic interactions
with MDM2 (47, 48), was replaced with alanine to create the
mutant peptide 12.1WΔA, which provided a negative control to
ensure biological specificity of the interaction. In theory, putative
dimerization of full-length MDM2 (through its RING domain)
would present two N-terminal hydrophobic pockets free (per di-
mer) to interact with ligands such as peptide 12.1. N-terminal
interactions with peptide ligand, therefore, allow the MDM2 di-
mer to bring together two peptide 12.1 functionalized silver NP,
peptide silver nanoparticle (PSN)-12.1, in solution (Fig. 1A, i). An
alternative model for PSN-12.1 assembly, via a secondary peptide
12.1-binding site, is also illustrated (Fig. 1A, ii). The latter is un-
likely because there is no evidence for two different peptide 12.1-
binding sites on MDM2, and cell based studies suggest MDM2 is
oligomeric in solution (16). MDM2-induced aggregation can be
monitored over time by extinction spectroscopy and premodifying
peptide 12.1 with a benzotriazole Raman tag, BT, enables the
Fig. 1. (A) Schematic of the proposed assembly of PSN through specific interactions between MDM2 and peptide 12.1 (not to scale). Inset shows two
proposed models for MDM2 bivalency resulting in PSN aggregation from a MDM2 dimerization (e.g., “oligomeric”) conformation (i) and monomeric MDM2
(ii) have two distinct binding sites with the known and an alternative peptide 12.1 binding site (not to scale). (B and C) Extinction spectroscopy (B) and SERS
analysis (C) before (dashed) and after (solid line) addition of MDM2 to PSN-12.1.
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process to be explored using SERS. Both extinction and SERS
intensity can be monitored over time to investigate the biological
interactions driving this NP-assembly process.
Peptide Silver Nanoparticles. Reproducibility of spectra from
Raman reporters used in SERS-based immunoassays is extremely
important to obtain reliable results. Benzotriazole dyes adsorb
onto silver nanoparticle surfaces in the same orientation irre-
spective of concentration, resulting in reproducible Raman spec-
tral intensities (49). This is attributable to steric hindrance
presented by covalent interactions between N1 and N3 lone elec-
tron pairs with the silver surface (50, 51). BT has an absorbance
λmax of 487 nm and, as such, is close in resonance when using an
excitation wavelength of 514 nm. The most prominent peak in the
BT Raman spectrum occurs at a shift of 1,416 cm−1 (Fig. 1C) and
can be attributed to the azo stretch in the dye structure (Fig. S1).
Peptide 12.1 andmutant peptide 12.1WΔAweremodifiedwith BT
and directly conjugated to EDTA-reduced silver NP (AgEDTA)
in a one-step reaction. BT consists of a triazole moiety with an
affinity for silver surfaces, a Raman active chromophore, and a
stabilizing polyethylene glycol spacer (Fig. S1). Circular dichro-
ism (CD) analysis of peptide 12.1 and BT-modified peptide 12.1
showed the modification to have no inhibitory effect on the
peptide adopting a helical conformation (Fig. S2). BT-modified
peptide 12.1 and mutant peptide 12.1WΔA displayed high- and
low-level binding, respectively, to MDM2 in ELISA competition
assays (Fig. S3). Successful PSN formation was shown by an in-
crease in particle size through extinction spectroscopy, and ma-
trix-associated laser desorption ionization–mass spectroscopy
(MALDI-MS) analysis was used to identify BT-peptide molecules
anchored on the nanoparticle surface (Figs. S4 and S5).
MDM2-Induced PSN Aggregation. Unlabeled full-length MDM2
was added to PSN solutions at various concentrations based on
a molar excess of protein to PSN. This is in line with previously
published data using streptavidin for controlled assembly of bi-
otin-functionalized gold NP (40). Aggregation of 15 pM PSN-
12.1 in solution was observed following the addition of MDM2
in a concentration-dependent manner, as shown by the plasmon
band decrease monitored by extinction spectroscopy (Figs. 2 and
3). A dampening in the band at 419 nm and an increase at longer
wavelengths are indicative of aggregate formation, verified by
the change in NP size distribution shown by dynamic light scat-
tering (Fig. 2B). Biological specificity of the MDM2–peptide 12.1
interaction was confirmed by using mutant PSN-12.1WΔA sam-
ples in which aggregation was observed to a much lesser extent at
MDM2 concentrations up to a NP: protein ratio of 1:1,000 (15
pM PSN, 15 nM MDM2) (Figs. 2 and 4 and SI Text). This
confirms the importance of specific amino acid residues in the
binding event between MDM2 and NP-bound peptide. At pro-
tein concentrations higher than this, the extent of aggregation
between PSN-12.1 and PSN-12.1WΔA solutions cannot be dis-
tinguished by extinction spectroscopy or dynamic light scatter-
ing (Figs. 2 and 3). At these concentrations, MDM2 is present
in such excess that binding to the mutant peptide 12.1WΔA is
comparable to that of peptide 12.1, indicating a saturation point
to the assay. Extinction spectroscopic measurements of samples
taken 96 h after MDM2 addition show a much greater distinction
in aggregation extent between PSN-12.1 and the mutant PSN-
12.1WΔA up to the saturation concentration of 15 nM MDM2
(Fig. 2A); however, such a time duration for an immunoassay is
impractical. The PSN assembly process can be monitored over
time by measuring the extinction change at the λ-max, and ag-
gregation was seen to plateau within the first 30 min (Fig. 3A).
These data correlate with previous literature describing binding
of p53 BOX-I to the MDM2 hydrophobic cleft to be a stable,
high-affinity interaction. PSN-12.1 assembly can be interpreted
through either of the models proposed in Fig. 1A; however, be-
cause there is no evidence to support the latter, the most likely
explanation for the observed PSN aggregation is an active
MDM2-dimer (or “oligomer”).
MDM2-Induced Aggregation “Turns On” SERS. Initial SERS studies
involved analysis of PSN samples after completion of aggregate
assembly monitored by extinction spectroscopy. SERS enhance-
ment was measured by comparing the standardized peak height
at 1,416 cm−1 (Fig. 1B) for each sample in relation to unag-
gregated PSN solutions. Raman signal intensity increased in
a positive correlation with MDM2 concentration up to a molar
ratio of 1:1,000 PSN:MDM2 (15 pM PSN, 15 nM MDM2) (Fig.
4). This corresponds with previous extinction spectroscopy
investigations indicating assay saturation at this concentration.
When MDM2 was present at a larger molar excess than 1:1,000,
a decrease in SERS intensity was observed (Fig. 4A). At these
concentrations, protein can form almost monolayer coverage on
the PSN surface, thus dampening Raman signals associated with
BT but still allowing aggregation, as seen by extinction spec-
troscopy (Fig. 3B). Another possibility is that large aggregates
Fig. 2. Extinction spectroscopy and particle size analysis of PSN solutions before and after addition of MDM2. (A and B) Extinction profiles (A) and particle
size distributions (B) of PSN-12.1 (i) and PSN-12.1WΔA (ii) samples without MDM2 (black) and 96 h after addition of 300 (dotted gray), 500 (short dashed gray),
1,000 (long dashed gray), and 2,000 (solid gray) MDM2 monomers per PSN.








form that fall out of solution; however, this explanation is con-
tradicted by the partial aggregation observed in scanning electron
microscopy (SEM) (Fig. S6). At a molar ratio of 1:1,000 PSN:
MDM2 (15 pM PSN, 15 nM MDM2), an eightfold increase in
peak height was observed compared with samples where protein
was absent. No such signal enhancement was apparent for PSN-
12.1WΔA samples or when MDM2 was replaced with a control
protein, BSA (Fig. 4A and Fig. S7). This demonstrated the high
biological specificity of the interaction, further validated by addi-
tional MDM2 binding studies (Fig. S8). SERS analysis of MDM2-
induced PSN aggregation enables protein detection at a molar
excess of 100 MDM2 per PSN (15 pM PSN, 1.5 nMMDM2), dem-
onstrating a lower limit of detection than was achievable using
extinction spectroscopy (Figs. 3B and 4A). Comparable results for
PSN-12.1 and PSN-12.1WΔA samples were also more distinguish-
able when applying SERS rather than extinction spectroscopy
(Figs. 3 and 4). These data indicate that SERS presents a more
sensitive analysis technique than extinction spectroscopy for NP
assembly controlled by biological interactions.
Temporal SERS Analysis of Aggregation. Our findings show that the
assembly of PSN-12.1 with MDM2 is a time- and concentration-
dependent process (Fig. 3). To this end, SERS analysis was in-
vestigated to monitor the PSN assembly process over time. To
minimize SERS signal variations, PSN preparation and final so-
lution concentrations were optimized. Focus of the laser through
the bulk of the solution and continuous sample rotation ensured
consistent sampling of the components throughout the duration
of the experiment.
The rate at which SERS intensity reached saturation was seen
to increase with MDM2 concentration, and it can be interpreted
from the data that the formation of PSN assemblies approaches
completion within 11, 9, and 7 min for PSN:MDM2 ratios of
1:300, 1:500, and 1:1,000, respectively (15 pM PSN, 4.5–15 nM
MDM2) (Fig. 4B). This is quicker than observed in extinction
spectroscopy (Fig. 3A), demonstrating the higher sensitivity of
SERS as an analytical tool for monitoring NP aggregation. These
data demonstrate that SERS can be used as a viable tool for
monitoring time-dependent NP assembly, although it must be
realized that it does not represent the system found in nature
owing to PSN solution kinetics.
Inhibition of the MDM2-PSN Interaction. To test the potential for
development of the assay for investigating MDM2 interactions
with small molecules, we exposed MDM2 to N-terminal-binding
ligands to competitively inhibit the aforementioned PSN-12.1
assembly. MDM2 is likely to exhibit a higher binding affinity to
free peptide 12.1 (inhibitor 12.1) than to NP-bound peptide 12.1,
because of the solution kinetics. Nutlin-3 is a potent and well
studied small molecule inhibitor of the MDM2-p53 interaction
(15). For all inhibition experiments, a molar ratio of 1:1,000 PSN:
MDM2 (15 pM PSN, 15 nMMDM2) was used owing to the large
extent of the aggregation observed (Figs. 2–4). MDM2 was
preincubated with a 100-fold molar excess of inhibitor (0.96 mM
MDM2, 96 mM inhibitor) before mixing with PSN-12.1 solutions
(6.25 mL added to 400 mL of 15 pM PSN), and temporal analysis
was carried out using extinction spectroscopy. A lesser decrease in
the plasmon band was observed for PSN-12.1 solutions treated
with MDM2 preincubated with either inhibitor 12.1 or Nutlin-3
than was evident following the addition of native MDM2 (Fig. 5).
A much greater enhancement in Raman signal was also observed
in the presence of native MDM2 compared with MDM2 pre-
incubated with inhibitor (Fig. 5B). Inhibitor 12.1 and Nutlin-3
were able to bind the MDM2 hydrophobic cleft, thus blocking the
binding site for peptide 12.1 molecules on PSN-12.1 and dis-
allowing MDM2-mediated PSN assembly. Signal changes in
SERS and extinction spectroscopy associated with PSN aggre-
gation were, therefore, not observed to the same extent (Fig. 5B).
It was subsequently observed that lowering the excess of inhibitor
resulted in a decrease in inhibition efficiency by extinction spec-
troscopy and SERS (Fig. 5C). Varying the molar excess of in-
hibitor 12.1 prebound to MDM2 in this way demonstrates PSN-
assembly inhibition in a dose-dependent manner. The extinction
spectroscopy and SERS data, together, demonstrate a competi-
tive inhibition of MDM2–peptide 12.1-driven NP assembly by
inhibitor 12.1 and Nutlin-3. A 1.4× increase in SERS response
was detected at the highest concentration of inhibitor 12.1, sug-
gesting that some PSN assembly occurred (Fig. 5C). Depletion in
extinction plasmon band for the same sample in extinction
spectroscopy is negligible (Fig. 5C), thus identifying SERS as the
superior technique to investigate inhibitor potency. SERS anal-
ysis also provides a positive response for NP assembly that is
Fig. 3. Extinction spectroscopy analysis of PSN aggregation. (A) Extinction
spectroscopy monitored for a 30-min duration following MDM2 addition to
PSN-12.1 (red) and PSN-12.1WΔA (blue) at a PSN:MDM2 molar ratio of
1:1,000. Dotted line indicates the average plasmon band intensity before
MDM2 addition. (B) Change in the plasmon band monitored from the 1–30
min after MDM2 addition. Error bars illustrate the SD.
Fig. 4. SERS analysis of PSN aggregation. (A) Calculated x-fold increase in
SERS intensity following MDM2 addition to PSN-12.1 (red) and PSN-12.1WΔA
(blue). (B) Peak height at 1416 cm−1 monitored every 60 seconds for 30 min
following addition of varying amounts of MDM2 to PSN-12.1 (red) and
PSN-12.1WΔA (blue). X-value represents the excess of MDM2 monomers per
PSN. Dotted line indicates PSN samples when MDM2 is absent. Error bars
illustrate the SD.
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advantageous over extinction spectroscopy where a decrease in
signal is monitored.
Disruption of the Dimerization Interface. To further test the assay
capabilities for investigating MDM2 and verify the requirement
for MDM2 oligomerization in PSN assembly, MDM2 was pre-
mixed with self-peptides from one linear motif that stabilizes the
MDM2/MDMX heterodimer at the N-terminal junction of the
C-terminal RING domain (amino acids 430-LPLNAI-435) (8) at
a molar ratio of 1:100 MDM2:peptide (0.96 mM MDM2, 96 mM
peptide). SERS analysis of PSN solutions (15 pM) was carried
out following the addition of MDM2 preincubated with peptides
43 (DKEESVESSLPLNAI) and 44 (PLNAIEPCVICQGRP)
(6.25 mL added to 400 mL), which represent overlapping se-
quences from the dimerization interface (Fig. S9). Preincubation
of MDM2 with peptides 43 and 44 resulted in a decrease in PSN-
12.1 assembly, as monitored using SERS (Fig. 6). Despite both
dimerization-motif peptides demonstrating an inhibitory effect
on PSN-12.1 assembly, a 1.69-fold increase in SERS was observed
in the presence of peptide 43 compared with a 1.14-fold increase
with peptide 44. The difference in PSN-12.1 assembly inhibition
potency of these two ligands indicates a positional effect of pep-
tide-ligand binding to the MDM2 dimerization interface in pre-
venting dimerization. As a control, the binding of peptides 43 and
44 toMDM2 using ELISA demonstrated no affect onN-terminal-
binding activity (Fig. S9B). These data highlight the difference
between a standard ligand-binding assay that does not distinguish
between the oligomeric or monomeric nature of the target pro-
tein (Fig. S9) and a SERS-based ligand-binding assay that
requires target protein “oligomerization” (Fig. 6; PSN assembly
model illustrated in Fig. 1A, i and ii).
Discussion
A number of SERS-based immunoassays have been developed for
the detection of biological interactions; however, few NP–protein
aggregation studies have been published. This report presents the
use of protein–peptide interactions as a controlled NP-assembly
template capable of “turning on” SERS. Furthermore, the protein
interactions investigated are of particular biological interest owing
to the critical role of MDM2 in cancer progression. PSN assembly
and associated SERS enhancement were successfully inhibited by
preincubating MDM2 with small-molecule-binding ligands.
We have demonstrated that full-length MDM2 is able to suc-
cessfully aggregate PSN-12.1, suggesting that the MDM2 protein
is in dimeric (oligomeric) state in solution, while maintaining bi-
ological activity of the hydrophobic pocket. These studies present
an innovative method for interrogating the allosteric interactions
of full-length unlabeled MDM2 using biologically driven NP as-
sembly.We also demonstrate a proof-of-concept with which to use
SERS-based ligand-binding assays to investigate other allosteric
proteins that undergo complex conformational interactions.
Methods
Peptide–BT Conjugation. Peptides 12.1 (SGSG-MPRFMDYWEGLN-resin) and
12.1WΔA (SGSG-MPRFMDYAEGLN-resin) were obtained bound to Wang resin
via the C terminus (Almac Sciences), with the N terminus deprotected.
Modification with BT was carried out via amide coupling in the solid phase
and cleaved from the resin using 95% TFA (SI Methods).
Nanoparticle Bioconjugation. AgEDTA nanoparticles were synthesized with
a 40-nm diameter using the method described by Heard et al. in 1983 (52).
Nanoparticles were centrifuged at 1,900 × g for 20 min and resuspended in
buffer [25 mM Hepes and 20 mM KCl (pH 7.5)] before addition of BT or
peptide–BT at a final concentration of 10−6 M. After shaking for a minimum
of 1 h, the conjugation solutions were centrifuged at 5,000 rpm for 20 min
and resuspended in buffer (×3) to remove any excess analytes. Complete BT–
peptide conjugates were characterized using extinction spectroscopy, dy-
namic light scattering, and MALDI-MS.
Dynamic Light Scattering. One-milliliter samples were analyzed via dynamic
light scattering using a Malvern high-performance particle sizer (HPPS) using
standard disposable cuvettes.
Extinction Spectroscopy. Absorbance readings were taken from 250–650 nm
using a Cary Eclipse extinction spectrometer. All spectra were baseline cor-
rected using 25 mM Hepes buffer (pH 7.5), 20 mM KCl, as a blank. NP con-
centrations were calculated using the extinction coefficient for 40-nm silver
nanoparticles at λ-max (ε = 2.87 × 1010). Peptide–BT concentrations were
calculated using the extinction coefficient for BT at 487 nm (ε = 12017).
MALDI-MS. Peptide samples were analyzed using a 1:1 ratio of sample to
matrix, α-cyano-4-hydroxycinnamic acid (α-cyano). Ionization was conducted
in the positive reflectron mode. A linear three-point calibration was ach-
ieved using a preprepared peptide mixture: 379.1 m/z (α-cyano matrix),
757.4m/z (Bradykinin fragment), and 1,046.5 m/z (angiotensin II). To analyze
nanoparticle-bound peptide samples, conjugates were removed from the
nanoparticles and desalted. Nanoparticle samples were treated with DTT (10
mM) for a minimum of 30 min to displace BT from the metal surface. Fol-
lowing centrifugation at 5,000 rpm for 20 min, 150 μL of supernatant was
desalted using PepClean C-18 spin columns (Thermo Scientific) MALDI-MS
carried out on the recovered sample.
Fig. 5. Competitive inhibition of MDM2-induced PSN aggregation. Sche-
matic illustrates proposed MDM2-induced PSN aggregation inhibition with
inhibitor peptide 12.1 and Nutlin-3. (A and B) X-fold decrease in the plasmon
band monitored by extinction spectroscopy [light gray (A) and X (B)] and x-
fold SERS intensity change following 30 min incubation of MDM2 with
varying concentrations of inhibitor molecule [dark gray (A) and circle (B)].
Fig. 6. Competitive inhibition of MDM2-induced PSN aggregation. Sche-
matic illustrates proposed MDM2-induced PSN assembly inhibition with di-
merization-motif self-peptides 43 and 44. Data show SERS peak height
measurements, at 1,416 cm−1, recorded for PSN-12.1 samples after comple-
tion of temporal analysis. Dotted line indicates PSN samples when MDM2 is
absent. Error bars illustrate the SD.








Protein Preparation. MDM2 was purified as indicated in SI Methods. Purified
full-lengthMDM2was stored at−20 °C in storage buffer [25mMHepes (pH 7.5),
10% (vol/vol) glycerol, 1 mMbenzamidine, 5 mMDTT, 290 mMKCl], and buffer
exchange into assay buffer [25 mMHepes (pH 7.5), 20 mM KCl] was performed
using a concentrator with a 10-kDamolecular mass cutoff filter (Millipore). BSA
was obtained from Sigma and dissolved in assay buffer. MDM2 and BSA stocks
were prepared at a concentration of ∼8 × 10−7 M in assay buffer for use in NP
aggregation assays. MDM2 protein was validated in the dual-site-binding assay
that measures the ability of Nutlin to stimulate the interaction of MDM2 with
the Rb1 peptide (10). Rb1 peptide binds to the acidic domain of MDM2 and
mimics the interaction ofMDM2with the p53 central DNA-binding domain (10).
SERS Analysis. SERS spectra were collected using a Renishaw inViamicroscope
system. Excitation at 514.5 nm was achieved via an Ar+ laser attenuated
using neutral density filters. Spectra were obtained using 180° backscat-
tering with the grating centered at 1400 cm−1 using a 20× long-working
distance objective. Static scans with a 2-s collection time were obtained for
analysis of postassay samples in disposable cuvettes. Temporal SERS analysis
of samples was conducted using an NMR tube spinner microscope attach-
ment. A 1-s scan duration was used, and one spectrum was acquired every
60-s for 30 min.
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